Advisory Committees
FDA asks panels of outside experts to advise on hard approval decisions and safety questions. Their advice is not binding, but FDA usually follows it. This is every meeting since 2010 and what each one discussed.
938 FDA advisory committee meetings noticed in the Federal Register since 2010, with the applications and devices on each agenda and who submitted them.
- Upcoming: 1
- Meetings in 2026: 14
- Naming an application: 246
Meetings per Year
Meetings FDA noticed in the Federal Register, by meeting date; cancelled ones left out.
How to read this
A hatched bar is a year that is not over, so its count covers only part of the year.
Busiest Committees
Meetings in the last five years.
- Vaccines and Related Biological Products Advisory Committee26
- Oncologic Drugs Advisory Committee20
- Cellular, Tissue, and Gene Therapies Advisory Committee8
- Cardiovascular and Renal Drugs Advisory Committee8
- Antimicrobial Drugs Advisory Committee6
- Pediatric Advisory Committee5
- General and Plastic Surgery Devices Panel5
- Endocrinologic and Metabolic Drugs Advisory Committee5
- Peripheral and Central Nervous System Drugs Advisory Committee5
- Pharmacy Compounding Advisory Committee4
Upcoming
Noticed meetings that have not happened yet, soonest first| Meeting | Committee | On the agenda | Submitted by |
|---|---|---|---|
| Nov 19, 2026 | Microbiology Devices Panel | The Committee will discuss and make recommendations on information regarding the examination of scientific, clinical, and public health dimensions of the use of pathogen-agnostic sequencing as it relates to emergency… | — |
Every Meeting
Newest first; each committee opens its Federal Register notice| Oct 30, 2026 | Dermatologic and Ophthalmic Drugs Advisory Committee | NDA 219694The Committee will discuss new drug application (NDA) 219694, for atropine sulfate ophthalmic solution 0.01%, submitted by Sydnexis. Inc. The proposed indication (use) is for slowing of myopia progression in children 3… | Sydnexis. Inc |
| Oct 1, 2026 | Vaccines and Related Biological Products Advisory Committee | The Committee will convene in open session to discuss strain selection for influenza virus vaccines for the 2027 Southern Hemisphere influenza season and provide recommendations. | — |
| Sep 23, 2026 | Molecular and Clinical Genetics Panel | The Committee will meet in an open session to discuss, make recommendations, and vote on information regarding the premarket approval application (PMA) for the Galleri[supreg] test sponsored by GRAIL, Inc. The proposed… | — |
| Sep 16, 2026 | Pediatric Advisory Committee | The PAC will meet to discuss post- marketing pediatric-focused safety reviews of the following products: 1. Center for Biologics Evaluation and Research a. Epicel (cultured epidermal [[Page 47245]] autografts)… | — |
| Jul 30, 2026 | Cellular, Tissue, and Gene Therapies Advisory Committee | Agenda not stated in the notice. | — |
| Jul 30, 2026 | Cellular, Tissue, and Gene Therapies Advisory Committee | BLA 125827The Committee will meet in open session to discuss and make recommendations on Biologics License Application (BLA) 125827, from Replimune, Inc. for vusolimogene oderparepvec. The proposed indication (use) is in… | — |
| Jul 29, 2026 | Cellular, Tissue, and Gene Therapies Advisory Committee | BLA 125842The Committee will meet in open session to discuss and make recommendations on Biologics License Application (BLA) 125842 from Capricor, Inc. for deramiocel (human allogeneic cardiosphere-derived cells) the treatment of… | — |
| Jul 23, 2026 | Pharmacy Compounding Advisory Committee | FDA, invited attendees, and the public will be able to attend the meeting in-person at FDA's White Oak Campus (see ADDRESSES). The meeting presentations will also be heard, viewed, captioned, and recorded through an… | — |
| Jun 18, 2026 | Vaccines and Related Biological Products Advisory Committee | The Committee will meet in open session to discuss and make recommendations on the safety and effectiveness of MFLUSIVA (Influenza Vaccine, mRNA), manufactured by Moderna TX Inc., with a requested indication in… | — |
| May 28, 2026 | Vaccines and Related Biological Products Advisory Committee | The Committee will meet in open session to discuss and make recommendations on the selection of the 2026-2027 Formula for COVID-19 vaccines for use in the United States. | — |
| Apr 30, 2026 | Oncologic Drugs Advisory Committee | NDA 220359, NDA 218197The Committee will discuss new drug application (NDA) 220359, for camizestrant tablets, submitted by AstraZeneca Pharmaceuticals LP. The proposed indication (use) is in combination with a CDK4/6 inhibitor (palbociclib,… | AstraZeneca Pharmaceuticals LP |
| Mar 12, 2026 | Vaccines and Related Biological Products Advisory Committee | The Committee will meet in open session to discuss and make recommendations on the strain composition of influenza virus vaccines for use in United States during the 2026-2027 influenza season. | — |
| Jan 22, 2026 | Tobacco Products Scientific Advisory Committee | The Center for Tobacco Products' TPSAC will convene for one open session, during which the Committee will discuss modified risk tobacco product applications submitted by Swedish Match USA, Inc. for the following… | — |
| Dec 3, 2025 | Circulatory System Devices Panel | The meeting will be virtual. The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing and/or video conferencing platform. On December 3, 2025, the Committee will… | — |
| Nov 13, 2025 | Pediatric Advisory Committee | The PAC will meet to discuss post- marketing pediatric-focused safety reviews of the following products: 1. Center for Devices and Radiological Health a. ENTERRA THERAPY SYSTEM (Humanitarian Device Exemption (HDE)) b.… | — |
| Nov 6, 2025 | Digital Health Advisory Committee | The Committee will discuss and make recommendations on the topic of ``Generative Artificial Intelligence- Enabled Digital Mental Health Medical Devices.'' Many of these medical devices pose novel risks and, as mental… | — |
| Oct 9, 2025 | Vaccines and Related Biological Products Advisory Committee | The Committee will meet in open session to discuss and make recommendations on the following separate topics. Under Topic I, the Committee will discuss and make recommendations on the strain selection for the influenza… | — |
| Oct 8, 2025 | General Hospital and Personal Use Devices Panel | The Committee will deliberate and make recommendations on issues related to an emerging technology in the context of medical devices and germicidal ultraviolet (UV) light as a mode of disinfection. FDA is seeking to… | — |
| Oct 7, 2025 | Tobacco Products Scientific Advisory Committee | The Center for Tobacco Product's TPSAC will convene for one open session, during which the Committee will discuss the renewal of modified risk granted orders issued to Philip Morris Products S.A. for the following… | — |
| Aug 13, 2025 | General and Plastic Surgery Devices Panel | The Committee will discuss a new indication for use for dermal filler devices in the d[eacute]colletage area and will make recommendations regarding risks associated with new indications for use such as in the… | — |
| Jul 18, 2025 | Psychopharmacologic Drugs Advisory Committee | NDA 205422The Committee will discuss supplemental New Drug Application (sNDA) 205422/S-012, for REXULTI (brexpiprazole) tablets, submitted by Otsuka Pharmaceutical Company, Ltd., for the proposed indication of treatment of adults… | — |
| Jul 17, 2025 | Oncologic Drugs Advisory Committee | BLA 761440The Committee will discuss BLA 761440, belantamab mafodotin submitted by GlaxoSmithKline LLC, for the treatment of adults with multiple myeloma in combination with bortezomib and dexamethasone in patients who have… | — |
| Jul 9, 2025 | Pediatric Advisory Committee | The PAC will meet to discuss post- marketing pediatric-focused safety reviews of the following products: 1. Center for Devices and Radiological Health a. LIPOSORBER LA-15 SYSTEM (Humanitarian Device Exemption (HDE)) b.… | — |
| May 22, 2025 | Vaccines and Related Biological Products Advisory Committee | The Committee will meet in open session to discuss and make recommendations on the selection of the 2025-2026 Formula for COVID-19 vaccines for use in the United States. FDA regrets that it was unable to publish this… | — |
| May 20, 2025 | Oncologic Drugs Advisory Committee | BLA 761309, BLA 761145, NDA 215793, NDA 211651The Committee will discuss supplemental biologics license application (sBLA) 761309/S-001, for COLUMVI (glofitamab) injection, submitted by Genentech, Inc. The proposed indication (use) is in combination with… | Genentech, Inc |
| Feb 24, 2025 | Cardiovascular and Renal Drugs Advisory Committee | NDA 218276The Committee will discuss supplemental new drug application (sNDA) 218276 S-004, for FABHALTA (iptacopan) oral capsules, submitted by Novartis Pharmaceuticals Corporation, for the treatment of adults with complement 3… | — |
| Feb 20, 2025 | General and Plastic Surgery Devices Panel | The Committee will discuss and make recommendations regarding the benefits and risks of dermal fillers with new indications for use such as in the decolletage area. The discussion will include the following topics: (1)… | — |
| Feb 5, 2025 | Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee | The Committees will discuss the findings of the completed ER/LA OA PMRs 3033-1 and 3033-2 (link to Release and Reissue letter: <a… | — |
| Jan 10, 2025 | Anesthetic and Analgesic Drug Products Advisory Committee | BLA 761393The Committee will discuss BLA 761393, condoliase injection submitted by Seikagaku Corp., for the proposed indication of the treatment of radicular leg pain associated with lumbar disc herniation in adults. | — |
| Dec 12, 2024 | Vaccines and Related Biological Products Advisory Committee | Under Topic I, the Committee will meet in open session to discuss Considerations for RSV Vaccine Safety in Pediatric Populations. Under Topic II, the Committee will meet in open session to hear overviews of the LI and… | — |
| Dec 4, 2024 | Pharmacy Compounding Advisory Committee | FDA, invited attendees, and the public will be able to attend the meeting in-person at FDA's White Oak Campus (see ADDRESSES). The meeting presentations will also be heard, viewed, captioned, and recorded through an… | — |
| Nov 21, 2024 | Cellular, Tissue, and Gene Therapies Advisory Committee | The Committee will meet in open session to discuss and make [[Page 80252]] recommendations on supplemental biologics license application 125586/ 546 from AstraZeneca AB, submitted to confirm the clinical benefit of… | — |
| Nov 19, 2024 | Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Psychopharmacologic Drugs Advisory Committee | The Committees will discuss the reevaluation of the Clozapine Risk Evaluation and Mitigation Strategy (REMS) and possible changes to minimize burden on patients, [[Page 65366]] pharmacies, and prescribers while… | — |
| Nov 7, 2024 | General and Plastic Surgery Devices Panel | The Committee will discuss, make recommendations, and vote on clinical information related to a De Novo request for the ProSense Cryoablation System sponsored by IceCure Medical Ltd. The discussion will focus on the… | — |
| Oct 31, 2024 | Endocrinologic and Metabolic Drugs Advisory Committee | The Committee will discuss new drug application 210934, for sotagliflozin oral tablet, submitted by Lexicon Pharmaceuticals, Inc., for the proposed indication, as an adjunct to insulin therapy, to improve glycemic… | — |
| Oct 30, 2024 | Patient Engagement Advisory Committee | The Committee will discuss and make recommendations on ``Patient-Centered Informed Consent in Clinical Study of FDA-Regulated Medical Products.'' The individuals who volunteer to participate in clinical research play an… | — |
| Oct 29, 2024 | Pharmacy Compounding Advisory Committee | FDA, invited attendees, and the public will be able to attend the meeting in-person at FDA's White Oak Campus (see ADDRESSES). The meeting presentations will also be heard, viewed, captioned, and recorded through an… | — |
| Oct 10, 2024 | Vaccines and Related Biological Products Advisory Committee | The Committee will meet in open session to discuss the following three separate topics. Under Topic I, the Committee will discuss and make recommendations on the strain selection for the influenza virus vaccines for the… | — |
| Oct 10, 2024 | Cardiovascular and Renal Drugs Advisory Committee | NDA 215244The Committee will discuss new drug application (NDA) 215244, for elamipretide hydrochloride injection, submitted by Stealth BioTherapeutics Inc., for the treatment of Barth syndrome. | — |
| Oct 7, 2024 | Science Board to the Food and Drug Administration Advisory Committee | The Science Board to FDA will receive an update from the New Alternative Methods subcommittee and will hear details about FDA's reorganization scheduled for implementation on October 1, 2024, that includes significant… | — |
| Sep 26, 2024 | Oncologic Drugs Advisory Committee | BLA 125554, BLA 125514, BLA 761417, BLA 125377, BLA 761380During the morning session, the Committee will discuss the use of immune checkpoint inhibitors in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. The current labeling for… | Bristol Myers-Squibb Co.; and <bullet> sBLA 125514/S-143 |
| Sep 20, 2024 | Vaccines and Related Biological Products Advisory Committee | Under Topic I, the committee will meet in open session to discuss considerations related to the use of pertussis CHIMs in pivotal studies to demonstrate efficacy of pertussis vaccines for the purpose of licensure. Under… | — |
| Sep 18, 2024 | Pediatric Advisory Committee | The PAC will meet to discuss post- marketing pediatric-focused safety reviews of the following products: 1. Center for Biologics Evaluation and Research a. AGRIFLU (influenza virus vaccine) b. CUTAQUIG (immune globulin… | — |
| Sep 13, 2024 | Gastrointestinal Drugs Advisory Committee | NDA 207999The Committee will discuss supplemental new drug application (sNDA) 207999 S-011, for OCALIVA (obeticholic acid) 5 mg titrated to 10 mg oral tablets, administered once a day, submitted by Intercept Pharmaceuticals,… | Intercept Pharmaceuticals, Inc. |
| Sep 9, 2024 | Antimicrobial Drugs Advisory Committee | The Committee will discuss new drug application 213972, for oral sulopenem etzadroxil/probenecid tablets consisting of 500 milligrams (mg) sulopenem etzadroxil and 500 mg probenecid, submitted by Iterum Therapeutics US… | — |
| Aug 2, 2024 | Genetic Metabolic Diseases Advisory Committee | The Committee will discuss new drug application 214927, for arimoclomol, submitted by Zevra Denmark A/S, for the treatment of adults and pediatric patients 2 years of age and older with Niemann- Pick disease type C. | — |
| Jul 25, 2024 | Oncologic Drugs Advisory Committee | BLA 761069The Committee will discuss supplemental biologics license application (sBLA) 761069/S-043, for IMFINZI (durvalumab) injection, submitted by AstraZeneca UK Limited. The proposed indication (use) is IMFINZI in combination… | AstraZeneca UK Limited |
| Jun 26, 2024 | The Tobacco Products Scientific Advisory Committee | Agenda not stated in the notice. | — |
| Jun 26, 2024 | The Tobacco Products Scientific Advisory Committee | The Center for Tobacco Product's TPSAC will convene for one open session, during which the committee will discuss the renewal of a risk modification order, submitted by Swedish Match USA, Inc. for the following loose… | Swedish Match USA, Inc. |
| Jun 10, 2024 | Peripheral and Central Nervous System Drugs Advisory Committee | The Committee will discuss biologics license application 761248, for donanemab solution for intravenous infusion, submitted by Eli Lilly and Co., for the treatment of early symptomatic Alzheimer's disease. | — |
| Jun 4, 2024 | Psychopharmacologic Drugs Advisory Committee | The Committee will discuss new drug application 215455, for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the proposed indication of treatment of post- traumatic stress disorder. The Committee… | Lykos Therapeutics |
| May 24, 2024 | Endocrinologic and Metabolic Drugs Advisory Committee | The Committee will discuss the safety and efficacy of biologics license application 761326 for NNC0148-0287 injection (insulin icodec), a long-acting insulin analog product, submitted by Novo Nordisk. The proposed… | Novo Nordisk |
| May 23, 2024 | Molecular and Clinical Genetics Panel | The committee will discuss, make recommendations, and vote on information regarding the premarket approval application for the Shield test by Guardant Health, Inc. The proposed indication for use statement is as… | — |
| May 22, 2024 | Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee | Amendments made by section 504 of the 2017 FDA Reauthorization Act to section 505B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355c) required, for original applications submitted on or after August 18, 2020,… | — |
| May 16, 2024 | Vaccines and Related Biological Products Advisory Committee | The Committee will meet in open session to discuss and make recommendations on the selection of strain(s) to be included in the 2024-2025 Formula for COVID-19 vaccines. | — |
| May 9, 2024 | Blood Products Advisory Committee | The Committee will meet in open session to discuss strategies to reduce the risk of transfusion- transmitted malaria by testing blood donations from donors at risk of malaria exposure. | — |
| Apr 12, 2024 | Oncologic Drugs Advisory Committee | The Committee will discuss the use of minimal residual disease (MRD) as an endpoint in multiple myeloma clinical trials, including considerations regarding timing of assessment, patient populations, and trial design for… | — |
| Mar 21, 2024 | Ophthalmic Devices Panel | The committee will discuss and make recommendations on information related to the De Novo request by Balance Ophthalmics, Inc. for the safety and effectiveness of the FSYX Ocular Pressure Adjusting Pump (FSYX OPAP)… | — |
| Mar 15, 2024 | Oncologic Drugs Advisory Committee | BLA 125746, BLA 125736During the morning session, the Committee will discuss supplemental biologics license application (sBLA) 125746.74 for CARVYKTI (ciltacabtagene autoleucel), suspension for intravenous infusion, submitted by Janssen… | Janssen Biotech, Inc |
| Mar 14, 2024 | Oncologic Drugs Advisory Committee | NDA 217779The Committee will discuss new drug application (NDA) 217779 for imetelstat for injection, submitted by Geron Corporation. The proposed indication for this product is for the treatment of transfusion-dependent anemia in… | Geron Corporation |
| Mar 5, 2024 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2024 to 2025 influenza season. | — |
| Mar 5, 2024 | Medical Imaging Drugs Advisory Committee | NDA 214511The Committee will discuss efficacy and safety data submitted in support of a new drug application (NDA) 214511 for pegulicianine for injection, the optical imaging drug constituent of a drug/device combination product,… | Lumicell, Inc |
| Feb 13, 2024 | Circulatory System Devices Panel | The committee will discuss, make recommendations, and vote on information regarding the premarket approval application (PMA) for the TriClip G4 System by Abbott Medical. The proposed Indication for Use statement is as… | — |
| Feb 6, 2024 | General Hospital and Personal Use Devices Panel | The Committee will discuss and make recommendations on medical device supply chain resiliency and shortage issues, including the ``506J Device List'' which has been developed as a requirement of the Consolidated… | — |
| Feb 2, 2024 | Anesthesiology and Respiratory Therapy Devices Panel | The Committee will discuss ongoing concerns that pulse oximeters may be less accurate in individuals with darker skin pigmentation. The Committee will discuss an approach to improve the quality of premarket studies and… | — |
| Nov 29, 2023 | Molecular and Clinical Genetics Panel | The committee will discuss and make recommendations on the design of multi-cancer detection (MCD) in vitro diagnostic devices (tests) as well as potential study designs and study outcomes of interest that could inform… | — |
| Nov 17, 2023 | Pulmonary-Allergy Drugs Advisory Committee | The Committee will discuss new drug application 215010, for gefapixant oral tablets, submitted by Merck Sharp & Dohme Corp., for the proposed indication of treatment of adults with refractory or unexplained chronic… | — |
| Nov 16, 2023 | Oncologic Drugs Advisory Committee | NDA 22468, NDA 206256The Committee will receive updates on the accelerated approval program in oncology and two new drug applications (NDAs) approved under 21 CFR 314.500 (subpart H, accelerated approval regulations) that have not met their… | Acrotech Biopharma Inc |
| Nov 7, 2023 | Radiological Devices Panel | The committee will discuss and make recommendations on the classification of blood irradiator devices for the prevention of metastasis, which are currently unclassified pre-amendments devices, to class III (general… | — |
| Oct 31, 2023 | Cellular, Tissue, and Gene Therapies Advisory Committee | BLA 125787The Committee will discuss and make recommendations on BLA 125787 from Vertex Pharmaceuticals, Inc. for exagamglogene autotemcel (exa-cel). The applicant has requested an indication for the treatment of sickle cell… | — |
| Oct 5, 2023 | Vaccines and Related Biological Products Advisory Committee | The Committee will meet in open session to discuss the Strain Selection for the Influenza Virus Vaccines for the 2024 Southern Hemisphere Influenza Season. | — |
| Oct 5, 2023 | Oncologic Drugs Advisory Committee | NDA 214665The Committee will discuss supplemental new drug application (sNDA) 214665/S-005, for LUMAKRAS (sotorasib) tablets, submitted by Amgen Inc., for the proposed treatment of adult patients with KRAS G12C mutated locally… | Amgen Inc. |
| Oct 4, 2023 | Oncologic Drugs Advisory Committee | NDA 215500The Committee will discuss new drug application (NDA) 215500, for eflornithine tablets, submitted by USWM, LLC (doing business as U.S. WorldMeds). The proposed indication (use) for this product is to reduce the risk of… | USWM, LLC (doing business as U.S. WorldMeds) |
| Sep 27, 2023 | Cellular, Tissue, and Gene Therapies Advisory Committee | BLA 125782The committee will discuss and make recommendations on BLA 125782 from BrainStorm Therapeutics, Inc. for debamestrocel (autologous bone marrow-derived mesenchymal stromal cells induced to secrete neurotrophic factors).… | — |
| Sep 21, 2023 | Endocrinologic and Metabolic Drugs Advisory Committee | NDA 209053The Committee will discuss the safety and efficacy of ITCA 650 (exenatide in DUROS device), a drug-device combination product that is the subject of a new drug application (NDA) submitted by Intarcia Therapeutics, Inc.… | Intarcia Therapeutics, Inc. (Intarcia) (NDA 209053) |
| Sep 19, 2023 | Pediatric Advisory Committee | The purpose of this public advisory committee meeting is to discuss the appropriate development plans for establishing safety and effectiveness of artificial womb technology devices, including regulatory and ethical… | — |
| Sep 13, 2023 | Cardiovascular and Renal Drugs Advisory Committee | NDA 210922The committee will discuss supplemental new drug application (sNDA) 210922-s015, for ONPATTRO (patisiran) lipid complex for injection, submitted by Alnylam Pharmaceuticals, Inc., for the proposed treatment of the… | — |
| Sep 11, 2023 | Nonprescription Drugs Advisory Committee | The Committee will discuss new data regarding the `Generally Recognized as Safe and Effective' (GRASE) status of oral phenylephrine as a nasal decongestant that have become available since FDA last examined the issue. | — |
| Sep 7, 2023 | Microbiology Devices Panel | All meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing and/or video conferencing platform. FDA is seeking the Committee's preliminary input on potential future… | — |
| Sep 6, 2023 | Patient Engagement Advisory Committee | The Committee will discuss and make recommendations on the topic of ``Advancing Health Equity in Medical Devices.'' FDA CDRH is committed to working toward ensuring that all patients have access to high-quality, safe,… | — |
| Aug 22, 2023 | Circulatory System Devices Panel | On both days, the committee will discuss, make recommendations, and vote on devices indicated to reduce blood pressure in patients with hypertension. On August 22, 2023, the committee will discuss, make recommendations,… | — |
| Aug 1, 2023 | Medical Imaging Drugs Advisory Committee | The committee will discuss dosimetry data needed to support the initial clinical study in an original investigational new drug (IND) application for certain new positron emission tomography (PET) drugs. FDA would like… | — |
| Jun 28, 2023 | Endocrinologic and Metabolic Drugs Advisory Committee | NDA 215559The committee will discuss new drug application (NDA) 215559, for palovarotene capsules, submitted by Ipsen Biopharmaceuticals, Inc. The proposed indication is the prevention of heterotopic ossification in adults and… | Ipsen Biopharmaceuticals, Inc |
| Jun 16, 2023 | Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee | The subcommittee will discuss considerations related to dosage optimization of new drug and biological products for pediatric patients with cancer. Dosage optimization is an integral aspect of oncology drug development… | — |
| Jun 15, 2023 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to discuss and make recommendations on the selection of strain(s) to be included in the periodic updated COVID-19 vaccines for the 2023-2024 vaccination campaign. This discussion… | — |
| Jun 9, 2023 | Peripheral and Central Nervous System Drugs Advisory Committee | The committee will discuss supplemental biologics license application 761269/s-001, for LEQEMBI (lecanemab) solution for intravenous infusion, submitted by Eisai, Inc., for the treatment of early Alzheimer's disease.… | Eisai, Inc. |
| Jun 8, 2023 | Antimicrobial Drugs Advisory Committee | BLA 761328The committee will discuss biologics license application (BLA) 761328, for nirsevimab, a long-acting respiratory syncytial virus (RSV) F protein inhibitor monoclonal antibody for intramuscular use, submitted by… | AstraZeneca AB |
| May 19, 2023 | Gastrointestinal Drugs Advisory Committee | NDA 212833The committee will discuss new drug application (NDA) 212833, obeticholic acid (OCA) 25 mg oral tablets, submitted by Intercept Pharmaceuticals, Inc., for the treatment of pre-cirrhotic liver fibrosis due to… | — |
| May 18, 2023 | Vaccines and Related Biological Products Advisory Committee | BLA 125768The committee will meet in open session to discuss and make recommendations on the safety and effectiveness of ABRYSVO (Respiratory Syncytial Virus Vaccine), manufactured by Pfizer Inc., with a requested indication, in… | — |
| May 12, 2023 | Cellular, Tissue, and Gene Therapies Advisory Committee | BLA 125781The committee will discuss BLA 125781 from Sarepta Therapeutics, Inc. for delandistrogene moxeparvovec. The applicant has requested an indication for the treatment of ambulatory patients with DMD with a confirmed… | — |
| May 11, 2023 | Pulmonary-Allergy Drugs Advisory Committee | NDA 214697The committee will discuss new drug application (NDA) 214697, for epinephrine nasal spray, submitted by ARS Pharmaceuticals Inc., for the proposed indication of emergency treatment of allergic reactions (Type I)… | — |
| May 9, 2023 | Joint Meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee | NDA 17031The committees will discuss supplemental new drug application (sNDA) 017031/S-041, for OPILL (norgestrel) Tablet, 0.075 mg, submitted by Laboratoire HRA Pharma. OPILL is proposed for nonprescription use as a once daily… | — |
| Apr 28, 2023 | Oncologic Drugs Advisory Committee | NDA 208558The committee will discuss supplemental new drug application (sNDA) 208558/S-025, for LYNPARZA (olaparib) tablets, submitted by AstraZeneca Pharmaceuticals LP. The proposed indication (use) for this product is in… | AstraZeneca Pharmaceuticals LP |
| Apr 26, 2023 | Blood Products Advisory Committee | The committee will meet in open session to hear an overview of the research programs in the Division of Hemostasis, Office of Plasma Protein Therapeutics Chemistry, Manufacturing, and Controls, Office of Therapeutic… | — |
| Apr 20, 2023 | Orthopaedic and Rehabilitation Devices Panel | The committee will discuss, make recommendations, and vote on clinical information related to the De Novo request for the NUsurface Meniscus Implant sponsored by Active Implants, Inc. The device is a polymeric… | — |
| Apr 19, 2023 | Anesthetic and Analgesic Drug Products Advisory Committee | The committee will discuss postmarketing requirement 3033-11, issued to application holders of new drug applications (NDAs) for extended-release and long-acting opioid analgesics to evaluate long-term efficacy of opioid… | — |
| Apr 17, 2023 | Antimicrobial Drugs Advisory Committee | NDA 216974The committee will discuss new drug application (NDA) 216974, for sulbactam- durlobactam for injection, submitted by Entasis Therapeutics, Inc. The Applicant's proposed indication is for the treatment of infections due… | Entasis Therapeutics, Inc |
| Apr 14, 2023 | Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Peripheral and Central Nervous System Drugs Advisory Committee | NDA 205422The committees will discuss supplemental new drug application (sNDA) 205422 s009, efficacy supplement for REXULTI (brexpiprazole) tablets, submitted by Otsuka Pharmaceutical Company, Ltd., and Lundbeck, Inc., for the… | — |
| Apr 4, 2023 | Science Advisory Board to the National Center for Toxicological Research Advisory Committee | The Science Advisory Board Chair will welcome the participants, and the NCTR Director will provide a Center- wide update on scientific initiatives and accomplishments during the past year. The Science Advisory Board… | — |
| Mar 22, 2023 | Peripheral and Central Nervous System Drugs Advisory Committee | NDA 215887The committee will discuss new drug application (NDA) 215887, for tofersen (BIIB067) intrathecal injection, submitted by Biogen Inc., for the treatment of amyotrophic lateral sclerosis (ALS) associated with a mutation… | — |
| Mar 20, 2023 | Joint Meeting of the Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee | The committees will discuss new drug application 217722, for naloxone hydrochloride nasal spray, 3 mg/0.1 mL, submitted by Harm Reduction Therapeutics, Inc. The product is proposed for nonprescription use as an opioid… | Harm Reduction Therapeutics, Inc |
| Mar 16, 2023 | Antimicrobial Drugs Advisory Committee | NDA 217188The committee will discuss new drug application (NDA) 217188, for PAXLOVID (nirmatrelvir and ritonavir co-packaged tablets) for oral use, submitted by Pfizer, Inc. The proposed indication is treatment of mild-… | Pfizer, Inc |
| Mar 9, 2023 | Oncologic Drugs Advisory Committee | BLA 761121The committee will discuss supplemental biologics license application (BLA) 761121/S- 008, for POLIVY (polatuzumab vedotin-piiq) for injection, submitted by Genentech, Inc. The proposed indication (use) for this product… | Genentech, Inc |
| Mar 7, 2023 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2023-2024 influenza season. | — |
| Feb 28, 2023 | Vaccines and Related Biological Products Advisory Committee | BLA 125769, BLA 125775Under Topic 1, the committee will meet in open session to discuss and make recommendations on the safety and effectiveness of ABRYSVO (Respiratory Syncytial Virus Vaccine), manufactured by Pfizer Inc., with a requested… | — |
| Feb 15, 2023 | Joint Meeting of the Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee | The committees will discuss supplemental new drug application 208411/S-006, for NARCAN (naloxone hydrochloride) nasal spray, 4 mg/0.1 mL, submitted by Emergent BioSolutions Inc. NARCAN is proposed for nonprescription… | Emergent BioSolutions Inc. NARCAN is |
| Feb 9, 2023 | Oncologic Drugs Advisory Committee | The committee will discuss investigational new drug application (IND) 157775, for dostarlimab for injection, submitted by GlaxoSmithKline LLC. The proposed indication (use) for this product is for monotherapy in… | GlaxoSmithKline LLC |
| Jan 26, 2023 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to discuss the future vaccination regimens addressing COVID-19. This discussion will include consideration of the composition and schedule of the primary series and booster… | — |
| Jan 24, 2023 | Antimicrobial Drugs Advisory Committee | The committee will discuss new drug application 217417, for rezafungin lyophilized powder for injection, submitted by Cidara Therapeutics, Inc., for treatment of candidemia and invasive candidiasis in adults. | — |
| Jan 9, 2023 | Dermatologic and Ophthalmic Drugs Advisory Committee | BLA 125387The committee will discuss supplemental biologics license application (sBLA) 125387, aflibercept solution for intravitreal injection, submitted by Regeneron Pharmaceuticals, Inc. The supplement was submitted in response… | Regeneron Pharmaceuticals, Inc |
| Dec 14, 2022 | Cardiovascular and Renal Drugs Advisory Committee | The committee will discuss the available data for supplemental new drug application 021845-S025, REVATIO (sildenafil citrate tablets), submitted by Viatris Specialty, LLC, to support an indication for pediatric patients… | Viatris Specialty, LLC |
| Dec 13, 2022 | Cardiovascular and Renal Drugs Advisory Committee | The committee will discuss new drug application 216401, for omecamtiv mecarbil tablets, submitted by Cytokinetics, Inc. The proposed indication is to reduce the risk of cardiovascular death and heart failure events in… | Cytokinetics, Inc |
| Dec 8, 2022 | Science Board to the Food and Drug Administration Advisory Committee | The Science Board will consider research needs for the evaluation of potential adverse health effects in children associated with oral cadmium exposure. The Science Board will also hear about the Agency's cross- cutting… | — |
| Dec 8, 2022 | Blood Products Advisory Committee | The committee will meet in open session to hear an overview of the research programs of the Laboratory of Emerging Pathogens and the Laboratory of Molecular Virology, Division of Emerging and Transfusion Transmitted… | — |
| Nov 22, 2022 | Oncologic Drugs Advisory Committee | The committee will hear an update on supplemental new drug application 208447/S-025, for ZEJULA (niraparib) capsules, submitted by GlaxoSmithKline, LLC., for the maintenance treatment of adult patients with recurrent… | GlaxoSmithKline, LLC. |
| Nov 18, 2022 | Joint Meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee | The committees will discuss supplemental new drug application 017031/S-041 for OPILL (norgestrel) Tablet, 0.075 mg, submitted by Laboratoire HRA Pharma. OPILL is proposed for nonprescription use as a once-daily oral… | — |
| Nov 16, 2022 | Cardiovascular and Renal Drugs Advisory Committee | The committee will discuss new drug application 213931, for tenapanor hydrochloride tablets, submitted by Ardelyx, Inc., for the control of serum phosphorus levels in adults with chronic kidney disease on dialysis. The… | Ardelyx, Inc. |
| Nov 10, 2022 | Ophthalmic Devices Panel | The committee will discuss and make recommendations on the classification of ophthalmic dispensers, which are currently unclassified pre-amendment devices to class I (general controls). This will include a discussion of… | — |
| Nov 8, 2022 | Pulmonary-Allergy Drugs Advisory Committee | The committee will discuss the new drug application 214070, for a fixed dose combination of budesonide and albuterol sulfate metered dose inhaler, submitted by AstraZeneca and Bond Avillion 2 Development LP. The… | AstraZeneca and Bond Avillion 2 Development LP |
| Nov 2, 2022 | Pharmaceutical Science and Clinical Pharmacology Advisory Committee | The meeting will focus on two topics related to the Office of Pharmaceutical Quality's mission of promoting the availability of quality medicines for the American public. On November 2, 2022, the committee will discuss… | — |
| Nov 1, 2022 | Anesthesiology and Respiratory Therapy Devices Panel | The committee will discuss ongoing concerns that pulse oximeters may be less accurate in individuals with darker skin pigmentations. The committee will also discuss factors that may affect pulse oximeter accuracy and… | — |
| Oct 31, 2022 | Endocrinologic and Metabolic Drugs Advisory Committee | NDA 215559The committee will discuss new drug application (NDA) 215559, for palovarotene capsules, submitted by Ipsen Biopharmaceuticals, Inc. The proposed indication is the prevention of heterotopic ossification in adults and… | Ipsen Biopharmaceuticals, Inc |
| Oct 28, 2022 | Oncologic Drugs Advisory Committee | The committee will discuss biologics license application 761176, for \131\ I-omburtamab solution for injection, submitted by Y- mAbs Therapeutics, Inc. The proposed indication (use) for this product is for the treatment… | Y- mAbs Therapeutics, Inc |
| Oct 26, 2022 | General and Plastic Surgery Devices Panel | On day 1, October 26, 2022, in the morning, the committee will discuss and make recommendations on the classification proposal for tissue expanders and accessories, which are currently unclassified preamendments… | — |
| Oct 26, 2022 | Cardiovascular and Renal Drugs Advisory Committee | NDA 216951The committee will discuss new drug application (NDA) 216951, for the hypoxia inducible factor prolyl hydroxylase inhibitor, daprodustat tablets, submitted by GlaxoSmithKline, LLC, for the treatment of anemia due to… | — |
| Oct 20, 2022 | Clinical Chemistry and Clinical Toxicology Devices Panel | Agenda not stated in the notice. | — |
| Oct 20, 2022 | Clinical Chemistry and Clinical Toxicology Devices Panel | The committee will discuss, make recommendations, and vote on clinical information related to the De Novo request for the AvertD Test sponsored by SolvD, Inc. The AvertD is a prescription, qualitative genotyping test… | — |
| Oct 6, 2022 | Pulmonary-Allergy Drugs Advisory Committee | The committee will discuss the request for Emergency Use Authorization 113, for sabizabulin oral capsule, a tubulin polymerization inhibitor, submitted by Veru Inc., for the treatment of SARS-CoV-2 infection in moderate… | — |
| Oct 6, 2022 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to discuss the Strain Selection for the Influenza Virus Vaccines for the 2023 Southern Hemisphere Influenza Season. | — |
| Sep 22, 2022 | Vaccines and Related Biological Products Advisory Committee | BLA 125739The committee will meet in open session to discuss BLA 125739 from Rebiotix Inc., for a product REBYOTA (Fecal Microbiota, Live), with a requested indication to ``reduce the recurrence of Clostridioides difficile… | — |
| Sep 22, 2022 | Oncologic Drugs Advisory Committee | NDA 215643, NDA 214383, NDA 211155During the first session of September 22, 2022, the committee will discuss new drug application (NDA) 215643, for poziotinib tablets, submitted by Spectrum Pharmaceuticals, Inc. The proposed indication (use) for this… | Spectrum Pharmaceuticals, Inc |
| Sep 7, 2022 | Peripheral and Central Nervous System Drugs Advisory Committee | NDA 216660The committee will discuss new drug application (NDA) 216660, for sodium phenylbutyrate/taurursodiol (AMX0035) powder for oral suspension, submitted by Amylyx Pharmaceuticals Inc., for the treatment of amyotrophic… | — |
| Jul 28, 2022 | General and Plastic Surgery Devices Panel | P090012, P150046The committee will discuss the topic of skin lesion analyzer technology and its application to detecting skin cancers in various patient care settings. The skin lesion analyzer devices on which the discussion is focused… | — |
| Jul 12, 2022 | Patient Engagement Advisory Committee | On July 12 and 13, 2022, the committee will discuss and make recommendations on the topic of ``Augmented Reality (AR) and Virtual Reality (VR) Medical Devices.'' AR/VR devices are increasingly applied to healthcare… | — |
| Jun 29, 2022 | Cellular, Tissue, and Gene Therapies Advisory Committee | The Committee will meet in open session on both days to discuss the current regulatory expectations for xenotransplantation products. The discussion topics include human cells that have had ex vivo contact with animal… | — |
| Jun 28, 2022 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to discuss whether and how the SARS-CoV-2 strain composition of COVID-19 vaccines should be modified. | — |
| Jun 17, 2022 | Psychopharmacologic Drugs Advisory Committee | The committee will discuss supplemental new drug applications 210793-s008 and 207318- s011, efficacy supplement resubmission for NUPLAZID (pimavanserin) tablets, submitted by Acadia Pharmaceuticals Inc., for the… | — |
| Jun 15, 2022 | Vaccines and Related Biological Products Advisory Committee | Under Topic 1, the committee will meet in open session to discuss amending the EUA of the Moderna COVID-19 mRNA vaccine to include the administration of the primary series to children and adolescents 6 years through 17… | — |
| Jun 14, 2022 | Science Board to the Food and Drug Administration Advisory Committee | The Science Board to the Food and Drug Administration will consider challenges in evaluating the safety of dietary supplement and food ingredients with predicted pharmacological activity, utilizing cannabinoids as a… | — |
| Jun 9, 2022 | Cellular, Tissue and Gene Therapies Advisory Committee | BLA 125755, BLA 125717The committee will discuss two biologics license applications (BLAs) from bluebird bio, Inc.: (1) BLA 125755 for elivaldogene autotemcel (autologous CD34+ stem cells genetically modified with a lentiviral vector to… | — |
| Jun 8, 2022 | Pharmacy Compounding Advisory Committee | The committee will discuss the following four bulk drug substances nominated for inclusion on the 503A Bulks List: Ammonium tetrathiomolybdate, enclomiphene citrate, ferric subsulfate, and glutathione. The chart below… | — |
| Jun 7, 2022 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to discuss an EUA request by Novavax for a vaccine to prevent COVID-19 in individuals 18 years of age and older. | — |
| May 18, 2022 | Science Advisory Board to the National Center for Toxicological Research Advisory Committee | The Science Advisory Board Chair will welcome the participants, and the NCTR Director will provide a Center- wide update on scientific initiatives and accomplishments during the past year. The Science Advisory Board… | — |
| May 11, 2022 | Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee | The subcommittee will discuss the development of a conceptual framework that will inform the decision making of FDA on sponsor plans and requests for waivers of early pediatric investigations of molecularly targeted… | — |
| Apr 21, 2022 | Oncologic Drugs Advisory Committee | The committee will discuss the appropriate approach for phosphatidylinositol-3-kinase inhibitors currently under development in patients with hematologic malignancies and whether randomized data should be required to… | TG Therapeutics, Inc |
| Apr 6, 2022 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to discuss considerations for use of additional COVID-19 vaccine booster doses and the process for COVID-19 vaccine strain selection to address current and emerging variants. | — |
| Mar 30, 2022 | Peripheral and Central Nervous System Drugs Advisory Committee | NDA 216660The committee will discuss new drug application (NDA) 216660, for sodium phenylbutyrate/taurursodiol (AMX0035) powder for oral suspension, submitted by Amylyx Pharmaceuticals, Inc., for the treatment of amyotrophic… | Amylyx Pharmaceuticals, Inc. |
| Mar 10, 2022 | Cellular, Tissue and Gene Therapies Advisory Committee | On March 10, [[Page 8851]] 2022, for Topic I, the committee will meet in open session to hear an overview of the research programs in the Gene Transfer and Immunogencity Branch, Division of Cellular and Gene Therapies,… | — |
| Mar 3, 2022 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2022-2023 influenza season. | — |
| Mar 2, 2022 | Device Good Manufacturing Practice Advisory Committee | As required by section 520(f)(1)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360j(f)(1)(B)), on March 2, 2022, the committee will discuss and make recommendations on the current good… | — |
| Feb 15, 2022 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to discuss a request to amend the Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 mRNA vaccine for administration to children 6 months through 4 years of age. | — |
| Feb 15, 2022 | Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee | NDA 213231The committees will be asked to discuss new drug application (NDA) 213231, for tramadol hydrochloride injection, submitted by Avenue Therapeutics, Inc., for the management of moderate to moderately severe pain in adults… | Avenue Therapeutics, Inc. |
| Feb 10, 2022 | Oncologic Drugs Advisory Committee | The committee will discuss biologics license application 761222, for sintilimab injection, submitted by Innovent Biologics (Suzhou) Co., Ltd. The proposed indication (use) for this product is in combination with… | Innovent Biologics (Suzhou) Co., Ltd |
| Dec 10, 2021 | Neurological Devices Panel | The committee will discuss, make recommendations, and vote on information regarding the premarket approval application (PMA) for the BrainsGate Ischemic Stroke System (ISS500) by BrainsGate Ltd. The proposed indications… | — |
| Dec 8, 2021 | Cardiovascular and Renal Drugs Advisory Committee | NDA 215484The committee will discuss new drug application (NDA) 215484, for the Nrf2 activator, bardoxolone methyl capsules, submitted by Reata Pharmaceuticals, Inc. The proposed indication is to slow the progression of chronic… | Reata Pharmaceuticals, Inc |
| Dec 2, 2021 | Oncologic Drugs Advisory Committee | NDA 205353The committee will hear updates on new drug applications (NDAs) approved under 21 CFR 314.500 (subpart H, accelerated approval regulations) that have not verified clinical benefit. This update will provide information… | — |
| Nov 30, 2021 | Antimicrobial Drugs Advisory Committee | The committee will discuss Emergency Use Authorization (EUA) 000108, submitted by Merck & Co. Inc., for emergency use of molnupiravir oral capsules for treatment of mild to moderate COVID-19 in adults who are at risk… | — |
| Nov 4, 2021 | Blood Products Advisory Committee | For Topic I, the committee will meet in open session to hear an overview of the research programs of the Plasma Derivatives Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies,… | — |
| Nov 4, 2021 | Psychopharmacologic Drugs Advisory Committee | NDA 214812The committee will discuss new drug application (NDA) 214812, for carbetocin nasal spray, submitted by Levo Therapeutics, Inc., for the proposed treatment of hyperphagia, anxiety, and distress behaviors associated with… | — |
| Nov 2, 2021 | Circulatory System Devices Panel | The committee will discuss and make recommendations on information about the benefit-risk profile of the Endologix AFX endovascular graft system with regards to the risk of Type III endoleaks. FDA requests panel input… | — |
| Oct 28, 2021 | Allergenic Products Advisory Committee | The committee will meet in open session to hear an overview of the research programs in the Laboratory of Immunobiochemistry (LIB), Division of Bacterial, Parasitic and Allergenic Products (DBPAP), Office of Vaccines… | — |
| Oct 28, 2021 | Oncologic Drugs Advisory Committee | NDA 214383The committee will discuss new drug application (NDA) 214383, PEPAXTO (melphalan flufenamide) for injection submitted by Oncopeptides AB, approved under 21 CFR 314.500 (subpart H, accelerated approval regulations), in… | — |
| Oct 26, 2021 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to discuss a request to amend Pfizer-BioNTech's EUA for administration of their COVID-19 mRNA vaccine to children 5 through 11 years of age. | — |
| Oct 20, 2021 | General and Plastic Surgery Devices Panel | The committee will discuss, make recommendations, and vote on information regarding the premarket approval application (PMA) for the SurgiMend PRS Acellular Bovine Dermal Matrix (SurgiMend PRS ABDM) by Integra… | — |
| Oct 13, 2021 | Vaccines and Related Biological Products Advisory Committee | Under Topic 1, the committee will meet in open session to discuss the EUA of the Moderna COVID-19 mRNA vaccine for the administration of a booster dose, following completion of the primary series, to individuals 18… | — |
| Oct 7, 2021 | Antimicrobial Drugs Advisory Committee | NDA 215596The committee will discuss new drug application (NDA) 215596, for maribavir oral tablets, submitted by Takeda Pharmaceuticals USA, Inc., for the treatment of adults with post-transplant cytomegalovirus infection and/ or… | — |
| Oct 6, 2021 | Patient Engagement Advisory Committee | Agenda not stated in the notice. | — |
| Sep 30, 2021 | Vaccines and Related Biological Products Advisory Committee | Under Topic I, the committee will meet in open session to hear an overview of the research programs in the Laboratory of Bacterial Polysaccharides, Division of Bacterial, Parasitic, and Allergenic Products, Office of… | — |
| Sep 17, 2021 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to discuss the Pfizer-BioNTech supplemental Biologics License Application for COMIRNATY for administration of a third dose, or ``booster'' dose, of the COVID-19 vaccine, in… | — |
| Sep 17, 2021 | Pediatric Advisory Committee | Agenda not stated in the notice. | — |
| Sep 17, 2021 | Pediatric Advisory Committee | The Pediatric Advisory Committee (PAC) will discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act (Pub. L. 107- 109) and the Pediatric Research Equity Act of 2003 (Pub. L.… | — |
| Sep 2, 2021 | Cellular, Tissue and Gene Therapies Advisory Committee | The CTGTAC committee will meet in open session on both days to discuss the toxicity risks of AAV vector-based gene therapy products. The discussion topics include oncogenicity risks due to vector genome integration and… | — |
| Aug 3, 2021 | Circulatory System Devices Panel | The committee will discuss and make recommendations on information regarding the premarket notification (510(k)) submission for the TriGUARD 3 Cerebral Embolic Protection Device. The proposed indication for use for the… | — |
| Jul 15, 2021 | Cardiovascular and Renal Drugs Advisory Committee | The committee will discuss new drug application 213805, for the hypoxia inducible factor prolyl hydroxylase inhibitor, roxadustat tablets, submitted by FibroGen, Inc., for the treatment of anemia due to chronic kidney… | — |
| Jul 14, 2021 | Gastroenterology and Urology Devices Panel | The committee will discuss, make recommendations, and vote on information regarding the premarket approval application (PMA) for the Organ Care System (OCS) Liver System, by TransMedics, Inc. The proposed Indication for… | — |
| Jun 24, 2021 | Oncologic Drugs Advisory Committee | BLA 761209The committee will discuss biologics license application (BLA) 761209, for retifanlimab injection, submitted by Incyte Corporation. The proposed indication (use) for this product is for the treatment of adult patients… | Incyte Corporation |
| Jun 10, 2021 | Vaccines and Related Biological Products Advisory Committee | The Committee will meet in open session to discuss, in general, data needed to support authorization and/or licensure of COVID-19 vaccines for use in pediatric populations. | — |
| Jun 9, 2021 | Pharmacy Compounding Advisory Committee | The committee will discuss the following four bulk drug substances nominated for inclusion on the 503A Bulks List: Choline chloride, oxitriptan (also known as 5-hydroxytryptophan or 5-HTP), melatonin, and… | — |
| Jun 3, 2021 | Neurological Devices Panel | During session I, the committee will discuss and make recommendations regarding the classification of topical refrigerants (vapocoolants), which are currently unclassified preamendment devices, to class II (general and… | — |
| May 27, 2021 | Endocrinologic and Metabolic Drugs Advisory Committee | BLA 761183The committee will discuss the safety and efficacy of biologics license application (BLA) 761183, for teplizumab intravenous infusion, submitted by Provention Bio, Inc. The proposed indication is for the delay or… | Provention Bio, Inc |
| May 11, 2021 | Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee | The subcommittee will discuss the development and successful implementation of the Pediatric Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) as a tool for eliciting… | — |
| May 11, 2021 | Science Advisory Board to the National Center for Toxicological Research Advisory Committee | The Science Advisory Board Chair will welcome the participants, and the NCTR Director will provide a Center- wide update on scientific initiatives and accomplishments during the past year. The Science Advisory Board… | — |
| May 6, 2021 | Arthritis Advisory Committee | NDA 214487The committee will discuss new drug application (NDA) 214487, for avacopan oral capsules, submitted by ChemoCentryx, Inc., for the treatment of anti- neutrophil cytoplasmic antibody-associated vasculitis. FDA intends to… | ChemoCentryx, Inc. |
| Apr 27, 2021 | Oncologic Drugs Advisory Committee | BLA 761034, BLA 125514, BLA 125554The committee will hear updates on certain supplemental biologics license applications (sBLAs) approved under 21 CFR 601.40 (subpart E, accelerated approval regulations) with confirmatory trial(s) that have not verified… | Genentech, Inc. |
| Apr 6, 2021 | Circulatory System Devices Panel | The committee will discuss, make recommendations, and vote on information regarding the premarket approval application for the TransMedics Organ Care System (OCS) Heart, by TransMedics, Inc. The proposed Indication for… | — |
| Mar 24, 2021 | Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee | BLA 761130The committees will discuss biologics license application (BLA) 761130, tanezumab subcutaneous injection, submitted by Pfizer Inc., for the proposed indication of relief of signs and symptoms of moderate to severe… | — |
| Mar 23, 2021 | General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee, Notice of Meeting | The committee will discuss and make recommendations regarding the benefits and risks of dermal fillers concerning the following topics: (1) Risks associated with intravascular injection of dermal fillers and (2) patient… | — |
| Mar 5, 2021 | Vaccines and Related Biological Products Advisory Committee | The Committee will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2021 to 2022 influenza season. | — |
| Feb 26, 2021 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to discuss EUA of the Janssen Biotech Inc. COVID-19 Vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years and older. EUA authority… | — |
| Feb 17, 2021 | Circulatory System Devices Panel | The committee will discuss, make recommendations, and vote on information regarding the premarket approval application (PMA) for the Lutonix 014 Drug Coated Balloon Percutaneous Transluminal Angioplasty (PTA) catheter.… | — |
| Feb 9, 2021 | Oncologic Drugs Advisory Committee | BLA 125514The committee will discuss supplemental biologics license application (sBLA) 125514/ s-089, for KEYTRUDA (pembrolizumab), submitted by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. The proposed indication… | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc |
| Dec 17, 2020 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to discuss EUA of the Moderna, Inc., COVID-19 Vaccine for the prevention of COVID-19 in individuals 18 years and older. EUA authority allows FDA to help strengthen the nation's… | — |
| Dec 16, 2020 | Cardiovascular and Renal Drugs Advisory Committee | The committee will discuss spironolactone for the proposed treatment of heart failure with preserved ejection fraction, a serious and often fatal condition for which no drug is approved to improve outcomes. The data… | — |
| Dec 15, 2020 | Cardiovascular and Renal Drugs Advisory Committee | NDA 207620The committee will discuss supplemental new drug application (sNDA) 207620-S18, for the angiotensin receptor-neprilysin inhibitor, ENTRESTO (sacubitril and valsartan) tablets, submitted by Novartis Pharmaceuticals… | — |
| Dec 10, 2020 | Vaccines and Related Biological Products Advisory Committee | The Committee will meet in open session to discuss EUA of the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 in individuals 16 years of age and older. EUA authority allows FDA to help strengthen the… | — |
| Nov 9, 2020 | Ophthalmic Devices Panel | The committee will discuss, make recommendations and vote on information regarding the premarket application (PMA) for the VisAbility Micro Insert sponsored by Refocus Group, Inc. The proposed Indication for Use for the… | — |
| Nov 6, 2020 | Peripheral and Central Nervous System Drugs Advisory Committee | BLA 761178The committee will discuss biologics license application (BLA) 761178, for aducanumab solution for intravenous infusion, submitted by Biogen Inc., for the treatment of Alzheimer's disease. FDA intends to make the… | Biogen Inc. |
| Nov 2, 2020 | Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee | NDA 209257The committees will discuss new drug application (NDA) 209257, proposed tradename, HYDEXOR, a fixed-dose combination oral tablet, submitted by [Otilde]las Pharma, Inc., that contains hydrocodone, acetaminophen, and… | — |
| Oct 27, 2020 | Circulatory System Devices Panel | The committee will discuss, make recommendations, and vote on information regarding the premarket approval application for the Neovasc Reducer System sponsored by Neovasc, Inc. The proposed Indication for Use of the… | — |
| Oct 22, 2020 | Vaccines and Related Biological Products Advisory Committee | In open session, the committee will discuss, in general, the development, authorization and/or licensure of vaccines to prevent COVID-19. No specific application will be discussed at this meeting. FDA intends to make… | — |
| Oct 22, 2020 | Patient Engagement Advisory Committee | The committee will discuss and make recommendations on the topic ``Artificial Intelligence (AI) and Machine Learning (ML) in Medical Devices.'' Specifically, we will discuss the composition of the datasets on which the… | — |
| Oct 9, 2020 | Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee | NDA 213378The committees will discuss the efficacy, safety, and benefit-risk profile of new drug application (NDA) 213378, olanzapine and samidorphan oral tablets, submitted by Alkermes, Inc., for the proposed indications of… | — |
| Oct 8, 2020 | Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee | NDA 211179The committees will discuss new drug application (NDA) 211179, for amphetamine sulfate immediate-release oral capsules, submitted by Arbor Pharmaceuticals, LLC, for the proposed indication of treatment of attention… | Arbor Pharmaceuticals, LLC |
| Oct 7, 2020 | Circulatory System Devices Panel | The committee will discuss, make recommendations, and vote on information regarding the premarket approval application (PMA) for the TransMedics Organ Care System (OCS)--Heart, by TransMedics, Inc. The proposed… | — |
| Oct 2, 2020 | Vaccines and Related Biological Products Advisory Committee | In open session, the committee will discuss and make recommendations on the selection of strains to be included in an influenza virus vaccine for the 2021 southern hemisphere influenza season. | — |
| Sep 15, 2020 | Pediatric Advisory Committee | Agenda not stated in the notice. | — |
| Sep 15, 2020 | Pediatric Advisory Committee | The Pediatric Advisory Committee (PAC) will discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act (Pub. L. 107- 109) and the Pediatric Research Equity Act of 2003 (Pub. L.… | — |
| Sep 10, 2020 | Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee | NDA 22272The committees will discuss the results of required postmarketing studies (Postmarketing Requirements 3051-1, 3051-2, 3051-3, and 3051-4) that evaluated the effect of the reformulation of OXYCONTIN (oxycodone… | — |
| Sep 8, 2020 | Orthopaedic and Rehabilitation Devices Panel | During session 1, the committee will discuss and make recommendations regarding the classification of facet screws systems which are currently unclassified pre-amendment devices to Class II (general and special… | — |
| Aug 31, 2020 | Pulmonary-Allergy Drugs Advisory Committee | The meeting will be heard, viewed, captioned, and recorded through an online teleconferencing platform. On August 31, 2020, the committee will discuss supplemental new drug application 209482/S-008, for TRELEGY ELLIPTA,… | GlaxoSmithKline |
| Aug 18, 2020 | Science Advisory Board to the National Center for Toxicological Research Advisory Committee | The SAB Chair will welcome the participants, and the NCTR Director will provide a Center-wide update on scientific initiatives and accomplishments during the past year. The SAB will be presented with an overview of the… | — |
| Aug 13, 2020 | Oncologic Drugs Advisory Committee | BLA 125706The committee will discuss biologics license application (BLA) 125706, for remestemcel-L (ex-vivo culture-expanded adult human mesenchymal stromal cells suspension for intravenous infusion), submitted by Mesoblast, Inc.… | Mesoblast, Inc |
| Jul 15, 2020 | Cardiovascular and Renal Drugs Advisory Committee | The committee will discuss new drug application (NDA) 22231, terlipressin, lyophilized powder for solution for injection, submitted by Mallinckrodt Pharmaceuticals, for the proposed indication of treatment of… | Mallinckrodt Pharmaceuticals |
| Jul 14, 2020 | Oncologic Drugs Advisory Committee | BLA 761158The committee will discuss biologic license application (BLA) 761158, for belantamab mafodotin, submitted by GlaxoSmithKline Intellectual Property Development Ltd. England. The proposed indication (use) for this product… | GlaxoSmithKline Intellectual Property Development Ltd. England |
| Jun 17, 2020 | Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee | Information will be presented regarding pediatric development plans for two products that are in development for an adult oncology indication. The subcommittee will consider and discuss issues relating to the… | — |
| Jun 9, 2020 | Ophthalmic Devices Panel | The committee will discuss, make recommendations, and vote on information regarding the premarket approval application (PMA) for the VisAbility Micro Insert sponsored by Refocus Group, Inc. The proposed Indication for… | — |
| May 15, 2020 | Allergenic Products Advisory Committee | The Center for Biologics Evaluation and Research's (CBER) Allergenic Products Advisory Committee (APAC) will meet in open session to discuss and make recommendations on the safety and efficacy of Peanut (Arachis… | — |
| May 8, 2020 | Cellular, Tissue, and Gene Therapies Advisory Committee | The committee will meet by teleconference. In open session, the committee will hear an overview and updates of research programs in the Tumor Vaccines and Biotechnology Branch (TVBB) and Cellular and Tissue Therapy… | — |
| Apr 23, 2020 | Orthopaedic and Rehabilitation Devices Panel | During session I, the committee will discuss and make recommendations regarding the classification of facet screws systems, which are currently unclassified pre-amendment devices to class II (general and special… | — |
| Apr 23, 2020 | Medical Imaging Drugs Advisory Committee | The committee will discuss new drug application 212123, flortaucipir F18 intravenous injection, a radioactive diagnostic agent, submitted by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company,… | — |
| Apr 21, 2020 | Pulmonary-Allergy Drugs Advisory Committee | NDA 209482The committee will discuss supplemental new drug application (sNDA) 209482/S-008, for TRELEGY ELLIPTA, a fixed dose combination (fluticasone furoate, umeclidinium, and vilanterol inhalation powder (FF/UMEC/VI)) oral… | GlaxoSmithKline |
| Apr 16, 2020 | Circulatory System Devices Panel | The committee will discuss, make recommendations, and vote on information regarding the premarket approval application (PMA) for the TransMedics Organ Care System (OCS)--Heart, by TransMedics, Inc. The proposed… | — |
| Apr 2, 2020 | Blood Products Advisory Committee | In the morning, the BPAC will meet in open session to discuss and make recommendations on strategies to reduce the risk of ZIKV transmission by blood and blood components. The committee will discuss whether universal… | — |
| Mar 11, 2020 | Nonprescription Drugs Advisory Committee | In the Agency's document entitled ``Food Handler Antiseptic Drug Products for Over-the-Counter Human Use; Request for Data and Information'' (December 7, 2018, 83 FR 63168) (Docket No. FDA-2018-N- 3458), FDA sought… | — |
| Mar 4, 2020 | Vaccines and Related Biological Products Advisory Committee | Under Topic I, the Center for Biologics Evaluation and Research's (CBER) VRBPAC will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines… | — |
| Feb 26, 2020 | Oncologic Drugs Advisory Committee | During the morning session, the committee will discuss new drug application 212578 for padeliporfin di-potassium powder for solution for injection, submitted by STEBA Biotech, S.A. The proposed indication (use) for this… | STEBA Biotech, S.A |
| Feb 14, 2020 | The Tobacco Products Scientific Advisory Committee | The Center for Tobacco Product's TPSAC will convene for one open session, during which the Committee will discuss the modified risk tobacco product applications, submitted by 22nd Century Group Inc. for the following… | — |
| Jan 16, 2020 | Anesthetic and Analgesic Drug Products Advisory Committee | NDA 204803The committee will discuss new drug application (NDA) 204803, bupivacaine extended-release solution for instillation, submitted by DURECT Corp., for the proposed indication of post-surgical analgesia. The committee will… | DURECT Corp. |
| Jan 15, 2020 | Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee | NDA 213426, NDA 209653During the morning session, the committees will discuss new drug application (NDA) 213426, for tramadol 44 milligrams (mg) and celecoxib 56 mg tablet, which contains a fixed-dose combination of an opioid and a… | Esteve Pharmaceuticals, S.A. |
| Jan 14, 2020 | Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee | The committees will discuss new drug application 211802 for oxycodegol, a new molecular entity full mu-opioid receptor agonist, submitted by Nektar Therapeutics, for the management of chronic low back pain in adult… | Nektar Therapeutics |
| Dec 18, 2019 | Oncologic Drugs Advisory Committee | BLA 761136, NDA 211723During the morning session, the committee will discuss biologics license application (BLA) 761136/Original 2, for luspatercept for injection, application submitted by Celgene Corporation. The proposed indication (use)… | Celgene Corporation |
| Dec 17, 2019 | Oncologic Drugs Advisory Committee | NDA 208558, BLA 125514During the morning session, the committee will discuss supplemental new drug application (sNDA) 208558/010 for LYNPARZA (olaparib) tablets, submitted by AstraZeneca Pharmaceuticals LP. The proposed indication (use) for… | AstraZeneca Pharmaceuticals LP |
| Dec 13, 2019 | Dermatologic and Ophthalmic Drugs Advisory Committee | BLA 761143The committee will discuss biologics license application (BLA) 761143, teprotumumab solution for intravenous use, submitted by Horizon Pharma Ireland, Ltd., proposed for the treatment of active thyroid eye disease. | — |
| Dec 10, 2019 | Cardiovascular and Renal Drugs Advisory Committee | NDA 22034The committee will be asked to discuss new drug application (NDA) 022034, for vernakalant HCl solution, for intravenous injection, submitted by Correvio International S[agrave]rl, for the proposed indication of rapid… | — |
| Dec 3, 2019 | Science Advisory Board to the National Center for Toxicological Research Advisory Committee | The Science Advisory Board Chair will welcome the participants, and the NCTR Director will provide a Center-wide update on scientific initiatives and accomplishments during the past year. The Science Advisory Board will… | — |
| Nov 22, 2019 | Blood Products Advisory Committee | The BPAC will meet in open session to discuss scientific considerations for cold stored platelet products intended for transfusion, including product characterization, duration of storage and clinical indications for… | — |
| Nov 14, 2019 | Endocrinologic and Metabolic Drugs Advisory Committee | The committee will discuss supplemental new drug application 202057/S-035, for VASCEPA (icosapent ethyl) capsules for oral administration, sponsored by Amarin Pharma Inc., for the following proposed indication: To… | — |
| Nov 13, 2019 | Endocrinologic and Metabolic Drugs Advisory Committee | NDA 204629The committee will discuss supplemental new drug application (sNDA) 204629/S-020 for empagliflozin oral tablet, sponsored by Boehringer Ingelheim Pharmaceuticals, Inc., for the following proposed indication: As an… | — |
| Nov 8, 2019 | Vaccines and Related Biological Products Advisory Committee | The VRBPAC will meet in an open session to discuss and make recommendations on the development of chikungunya vaccines. | — |
| Oct 30, 2019 | Bone, Reproductive and Urologic Drugs Advisory Committee | NDA 204017The committee will discuss new drug application (NDA) 204017 (levonorgestrel and ethinyl estradiol) transdermal system, submitted by Agile Therapeutics, Inc., for the prevention of pregnancy in women of reproductive… | — |
| Oct 29, 2019 | Bone, Reproductive and Urologic Drugs Advisory Committee | NDA 21945The committee will discuss supplemental new drug application (sNDA 021945/S-023#) for MAKENA (hydroxyprogesterone caproate injection, 250 milligrams per milliliter) manufactured by AMAG Pharmaceuticals. In 2011, MAKENA… | — |
| Oct 16, 2019 | Antimicrobial Drugs Advisory Committee | NDA 209445The committee will discuss new drug application (NDA) 209445, cefiderocol lyophilized powder for intravenous administration, submitted by Shionogi Inc., for the treatment of complicated urinary tract infections (cUTI),… | — |
| Oct 9, 2019 | Vaccines and Related Biological Products Advisory Committee | Under topic I, the Center for Biologics Evaluation and Research's (CBER) VRBPAC will meet in open session to hear an overview of the research programs in the Laboratory of Hepatitis Viruses (LIR) and the Laboratory of… | — |
| Oct 7, 2019 | Science Board to the Food and Drug Administration Advisory Committee | The Science Board will hear a response from the Center for Biologics Evaluation and Research (CBER) to the recommendations made by the Science Board's review of CBER's research program. The Science Board will also… | — |
| Sep 27, 2019 | Joint Pediatric Advisory Committee and Drug Safety and Risk Management Advisory Committee | The Pediatric Advisory Committee and the Drug Safety and Risk Management Advisory Committee will meet to discuss a pediatric-focused safety review of neuropsychiatric events with use of Singulair (montelukast). | — |
| Sep 26, 2019 | Joint Pediatric Advisory Committee and Drug Safety and Risk Management Advisory Committee | The Pediatric Advisory Committee and the Drug Safety and Risk Management Advisory Committee will meet to discuss the pediatric-focused safety review for OxyContin (oxycodone hydrochloride) extended-release tablets, as… | — |
| Sep 18, 2019 | Nonprescription Drugs Advisory Committee | NDA 208425The committee will discuss data submitted by GlaxoSmithKline Consumer Healthcare Holdings (US) LLC, to support new drug application (NDA) 208425, for over-the-counter (OTC) marketing of nicotine oral spray (1 milligram… | GlaxoSmithKline Consumer Healthcare Holdings (US) LLC |
| Sep 13, 2019 | Allergenic Products Advisory Committee | The Center for Biologics Evaluation and Research's (CBER) Vaccines and Related Biological Products Advisory Committee (VRBPAC) will meet in open session to discuss and make recommendations on the safety and efficacy of… | — |
| Sep 10, 2019 | Patient Engagement Advisory Committee | The Committee will discuss and make recommendations on the topic ``Cybersecurity in Medical Devices: Communication That Empowers Patients.'' Medical devices are increasingly connected to the internet, hospital networks,… | — |
| Aug 7, 2019 | Antimicrobial Drugs Advisory Committee | NDA 208215The committee will discuss supplemental new drug application (sNDA) 208215, supplement 12, DESCOVY (emtricitabine 200 milligrams (mg) and tenofovir alafenamide 25 mg tablets), submitted by Gilead Sciences, Inc.,… | — |
| Jul 31, 2019 | Psychopharmacologic Drugs Advisory Committee | NDA 209500The committee will discuss new drug application (NDA) 209500, lumateperone tosylate capsules for oral administration, submitted by Intra-Cellular Therapies, Inc., for the treatment of schizophrenia. | — |
| Jul 25, 2019 | Arthritis Advisory Committee | NDA 205832The committee will discuss supplemental new drug application (sNDA) 205832 for nintedanib capsules (drug name OFEV), sponsored by Boehringer Ingelheim, for the treatment of systemic sclerosis-associated interstitial… | — |
| Jun 20, 2019 | Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee | During the morning session, the particular matter for this meeting will be review and discussion of the FDA Reauthorization Act of 2017 (FDARA) mandated Relevant Pediatric Molecular Target List now posted on the FDA… | — |
| Jun 19, 2019 | Circulatory System Devices Panel | On June 19 and 20, 2019, the committee will discuss and make recommendations on information related to recent observations of increased long-term mortality in peripheral arterial disease patients treated with… | — |
| Jun 11, 2019 | Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee | FDA is seeking public input on the clinical utility and safety concerns associated with the higher range of opioid analgesic dosing (both in terms of higher strength products and higher daily doses) in the outpatient… | — |
| Jun 6, 2019 | Antimicrobial Drugs Advisory Committee | NDA 212862The committee will discuss new drug application (NDA) 212862, pretomanid tablets for oral administration, submitted by The Global Alliance for TB Drug Development, Inc., proposed as part of a combination regimen with… | — |
| May 30, 2019 | General and Plastic Surgery Devices Panel | The committee will discuss and make recommendations regarding the reclassification of surgical stapler devices for internal use from Class I (general controls) to Class II (special controls). On May 31, 2019, the… | — |
| May 14, 2019 | Oncologic Drugs Advisory Committee | NDA 211810, NDA 212166During the morning session, the committee will discuss new drug application (NDA) 211810 for pexidartinib capsule, submitted by Daiichi Sankyo, Inc. The proposed indication (use) for this product is for the treatment of… | Daiichi Sankyo, Inc |
| May 8, 2019 | Pulmonary-Allergy Drugs Advisory Committee | NDA 202049The committee will discuss new drug application (NDA) 202049, for mannitol inhalation powder, for oral inhalation submitted by Chiesi USA, Inc., for the proposed indication of management of cystic fibrosis to improve… | — |
| May 7, 2019 | Pharmaceutical Science and Clinical Pharmacology Advisory Committee | The committee will discuss the following topics: (1) Approaches to evaluate the effect of renal impairment on drug exposure, and (2) best practice considerations for translating pharmacokinetic (PK) information into… | — |
| Apr 26, 2019 | Antimicrobial Drugs Advisory Committee | The committee will discuss the safety and effectiveness of bacitracin for intramuscular injection for the treatment of infants with pneumonia and empyema caused by staphylococci shown to be susceptible to the drug,… | — |
| Apr 25, 2019 | Antimicrobial Drugs Advisory Committee | The committee will discuss one or more possible pathways for approval of rabies virus monoclonal antibodies for use as the passive-immunization component of post-exposure prophylaxis. | — |
| Apr 8, 2019 | Pediatric Advisory Committee | The PAC will meet to discuss drug development for testosterone replacement therapy in male adolescents for conditions associated with a deficiency or absence of endogenous testosterone resulting from structural or… | — |
| Mar 27, 2019 | Pulmonary-Allergy Drugs Advisory Committee | NDA 208646The committee will discuss new drug application (NDA) 208646, submitted by AllerQuest, LLC, for a skin-test kit (proposed trade name PRE-PEN Plus) that combines the approved product PRE-PEN (benzylpenicilloyl polylysine… | AllerQuest, LLC |
| Mar 22, 2019 | Vaccines and Related Biological Products Advisory Committee | In followup to a delay by the World Health Organization (WHO) in recommending H3N2 strain for inclusion in the 2019-2020 seasonal influenza vaccines, the Center for Biologics Evaluation and Research will reconvene the… | — |
| Mar 21, 2019 | Neurological Devices Panel | The committee will discuss and make recommendations on clinical information related to the de novo request for the NeuroAD Therapy System by Neuronix, Ltd. The NeuroAD Therapy System is intended to provide concurrent… | — |
| Mar 20, 2019 | Blood Products Advisory Committee | In the morning, BPAC will meet in open session to discuss and make recommendations on strategies to reduce the risk of Zika virus (ZIKV) transmission by blood and blood components. The committee will discuss whether… | — |
| Mar 19, 2019 | Science Advisory Board to the National Center for Toxicological Research Advisory Committee | The SAB Chair will welcome the participants, and the NCTR Director will provide a Center-wide update on scientific initiatives and accomplishments during the past year. The SAB will be presented with an overview of the… | — |
| Mar 8, 2019 | Microbiology Devices Panel Advisory Committee | The committee will discuss and make recommendations regarding new or alternative approaches to the clinical study design and evaluation of devices detecting Human Papillomavirus (HPV) nucleic acid. These approaches will… | — |
| Mar 6, 2019 | Vaccines and Related Biological Products Advisory Committee | Under Topic I, the Center for Biologics Evaluation and Research's (CBER) VRBPAC will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines… | — |
| Feb 26, 2019 | Oncologic Drugs Advisory Committee | NDA 212306The committee will discuss new drug application (NDA) 212306 for selinexor tablets, application submitted by Karyopharm Therapeutics Inc. The proposed indication (use) for this product is in combination with… | Karyopharm Therapeutics Inc |
| Feb 12, 2019 | Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee | NDA 211243The committees will discuss the efficacy, safety, and risk- benefit profile of new drug application (NDA) 211243, esketamine 28 mg single-use nasal spray device, submitted by Janssen Pharmaceuticals, Inc., for the… | — |
| Feb 12, 2019 | Obstetrics and Gynecology Devices Panel | The Committee will discuss and make recommendations regarding the safety and effectiveness of surgical mesh placed transvaginally in the anterior vaginal compartment to treat pelvic organ prolapse. FDA is convening this… | — |
| Feb 6, 2019 | The Tobacco Products Scientific Advisory Committee | On February 6-7, 2019, the Committee will convene for two sessions. The first session will convene on February 6, 2019, during which the Committee will discuss an amendment to the modified risk tobacco product… | Swedish Match North America |
| Jan 17, 2019 | Endocrinologic and Metabolic Drugs Advisory Committee | The Committee will discuss new drug application 210934 for sotagliflozin oral tablet, sponsored by Sanofi-Aventis U.S. LLC, for the proposed indication: Adjunct to insulin therapy to improve glycemic control in adults… | — |
| Jan 16, 2019 | Bone, Reproductive and Urologic Drugs Advisory Committee | The committee will discuss biologics license application 761062, romosozumab injection, submitted by Amgen, for the proposed indication of treatment of osteoporosis in postmenopausal women at high risk for fracture,… | — |
| Jan 11, 2019 | Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee | The committees will discuss supplemental new drug application (sNDA) 021-856, ULORIC (febuxostat) tablets, sponsored by Takeda Pharmaceuticals, which includes the results from the postmarketing safety trial required by… | — |
| Dec 17, 2018 | Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee | The committees will provide input and advice on strategies to increase the availability of naloxone products intended for use in the community. The committees will be asked to consider various options for increasing… | — |
| Dec 4, 2018 | Science Advisory Board to the National Center for Toxicological Research Advisory Committee | The SAB Chairperson will welcome the participants, and the NCTR Director will provide a center-wide update on scientific initiatives and accomplishments during the past year. The SAB will be presented with an overview… | — |
| Dec 4, 2018 | Circulatory System Devices Panel | The committee will discuss, make recommendations, and vote on information regarding the premarket application (PMA) for the OPTIMIZER SMART Implantable Pulse Generator device, sponsored by Impulse Dynamics (USA), Inc.… | — |
| Nov 15, 2018 | Anesthetic and Analgesic Drug Products Advisory Committee | The committee will discuss the assessment of opioid analgesic sparing outcomes in clinical trials of acute pain. The committee will be asked to comment on the trial design and endpoints of these studies and how to… | — |
| Nov 15, 2018 | Patient Engagement Advisory Committee | The Committee will discuss and make recommendations on the topic ``Connected and Empowered Patients: E-Platforms Potentially Expanding the Definition of Scientific Evidence.'' The recommendations will address how FDA… | — |
| Nov 14, 2018 | Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee | NDA 209774The committees will discuss new drug application (NDA) 209774, for an immediate-release oral tablet formulation of oxycodone, which is intended to resist common methods of physical or chemical manipulation and to deter… | SpecGx Inc. |
| Nov 8, 2018 | Vaccines and Related Biological Products Advisory Committee | The Center for Biologics Evaluation and Research's (CBER) VRBPAC committee will meet in open session to hear an overview of the research program in the Laboratory of DNA Viruses (LDV), Division of Viral Products (DVP),… | — |
| Nov 7, 2018 | Allergenic Products Advisory Committee | The Center for Biologics Evaluation and Research's APAC will meet in open session to discuss the use of challenge studies in the clinical development of allergenic products for the diagnosis and treatment of allergy due… | — |
| Nov 2, 2018 | Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee | NDA 211371The committees will discuss the efficacy, safety, and benefit-risk profile of new drug application (NDA) 211371, brexanolone 5 mg/mL intravenous injection, submitted by Sage Therapeutics, for the proposed indication of… | — |
| Nov 1, 2018 | Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee | NDA 210417The committees will discuss the efficacy, safety, and risk- benefit profile of new drug application (NDA) 210417 for buprenorphine and samidorphan sublingual tablets, submitted by Alkermes, Inc., for adjunctive… | — |
| Oct 22, 2018 | Science Board to the Food and Drug Administration Advisory Committee | The Science Board will hear a response from the Center for Veterinary Medicine (CVM) to the recommendations made by the Science Board's 2017 review of CVM's National Antibiotic Resistance Monitoring System program. The… | — |
| Oct 18, 2018 | Gastrointestinal Drugs Advisory Committee | NDA 210166The committee will discuss new drug application (NDA) 210166 for prucalopride tablets for oral administration, submitted by Shire Development, LLC, proposed for the treatment of chronic idiopathic constipation in adults. | — |
| Oct 17, 2018 | Joint Meeting of the Gastrointestinal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee | NDA 21200The committees will discuss supplemental new drug application (sNDA) 021200, supplement 015, for ZELNORM (tegaserod maleate) tablets for oral administration, submitted by Sloan Pharma S.[agrave].r.l, Bertrange, Cham… | — |
| Oct 12, 2018 | Anesthetic and Analgesic Drug Products Advisory Committee | NDA 209128The committee will be asked to discuss new drug application (NDA) 209128, sufentanil sublingual tablets, submitted by AcelRx Pharmaceuticals, Inc., for the management of moderate-to-severe acute pain severe enough to… | AcelRx Pharmaceuticals, Inc. |
| Oct 11, 2018 | Anesthetic and Analgesic Drug Products Advisory Committee | NDA 210730The committee will be asked to discuss new drug application (NDA) 210730, for oliceridine 1 milligram/milliliter injection, submitted by Trevena, Inc., for the management of moderate-to-severe acute pain in adult… | Trevena, Inc. |
| Oct 10, 2018 | Oncologic Drugs Advisory Committee | The committee will discuss biologics license application 761088 for CT-P10, a proposed biosimilar to Genentech, Inc.'s RITUXAN (rituximab), submitted by Celltrion, Inc. The proposed indications (uses) for this product… | Celltrion, Inc |
| Oct 3, 2018 | Vaccines and Related Biological Products Advisory Committee | The VRBPAC will meet in an open session to discuss and make recommendations on the selection of strains to be included in an influenza virus vaccine for the 2019 southern hemisphere influenza season. | — |
| Sep 27, 2018 | Neurological Devices Panel Advisory Committee | The Committee will discuss, make recommendations, and vote on the premarket approval application sponsored by Sequent Medical, Inc. for the Woven Endobridge (WEB) Aneurysm Embolization System, which is intended to treat… | — |
| Sep 20, 2018 | Pediatric Advisory Committee | On Thursday, September 20, 2018, the PAC will meet to discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act (Pub. L. 107-109) and the Pediatric Research Equity Act of 2003… | — |
| Sep 20, 2018 | Pharmaceutical Science and Clinical Pharmacology Advisory Committee | The meeting will focus on two topics related to the Office of Pharmaceutical Quality's priority of promoting the availability of better medicine. During the morning session, the committee will discuss the modernization… | — |
| Sep 13, 2018 | Tobacco Products Scientific Advisory Committee | On September 13 and 14, 2018, the Committee will discuss modified risk tobacco product applications, submitted by R.J. Reynolds Tobacco Company for six products: <bullet> MR0000068: Camel Snus Frost <bullet> MR0000069:… | — |
| Sep 12, 2018 | Pharmacy Compounding Advisory Committee | The committee will receive information on the following two issues to follow up on discussions from previous PCAC meetings: Balancing the criteria for the 503A bulk drug substance evaluation and compounding as it… | — |
| Aug 8, 2018 | Antimicrobial Drugs Advisory Committee | The committee will discuss new drug applications 209816, for omadacycline tablets, and 209817, for omadacycline injection, sponsored by Paratek Pharmaceuticals, Inc., for the proposed indications for the treatment of… | — |
| Aug 7, 2018 | Antimicrobial Drugs Advisory Committee | NDA 207356The committee will discuss new drug application (NDA) 207356, amikacin liposome inhalation suspension, sponsored by Insmed, Inc., for the proposed indication of treatment of nontuberculous mycobacterial lung disease… | — |
| Aug 3, 2018 | Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee | The committees will discuss results from assessments of the transmucosal immediate-release fentanyl (TIRF) medicines' risk evaluation and mitigation strategy (REMS), approved in December 2011. The TIRF REMS requires… | — |
| Jul 26, 2018 | Antimicrobial Drugs Advisory Committee | NDA 210607The committee will discuss new drug application (NDA) 210607, tafenoquine tablet, 100 milligram (mg), sponsored by 60 Degrees Pharmaceuticals, LLC, for the proposed indication of prevention of malaria in adults for up… | — |
| Jul 25, 2018 | Pulmonary-Allergy Drugs Advisory Committee | BLA 125526The committee will discuss supplemental biologics license application (sBLA) 125526 for mepolizumab for injection, submitted by GlaxoSmithKline for add-on treatment to inhaled corticosteroid-based maintenance treatment… | — |
| Jul 18, 2018 | Blood Products Advisory Committee | The Blood Products Advisory Committee will meet in open session to discuss and provide advice regarding bacterial risk control strategies for blood collection establishments and transfusion services to enhance the… | — |
| Jul 12, 2018 | Antimicrobial Drugs Advisory Committee | NDA 210795The committee will discuss new drug application (NDA) 210795, tafenoquine tablet, 150 milligram, sponsored by GlaxoSmithKline Intellectual Property Development Ltd., England, for the proposed indication of the radical… | — |
| Jun 26, 2018 | Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee | The committees will discuss new drug application 022324, oxycodone extended-release capsules, submitted by Pain Therapeutics, with the proposed indication of the management of pain severe enough to require daily,… | Pain Therapeutics, with the |
| Jun 22, 2018 | Blood Products Advisory Committee | In the morning open session, under Topic 1, the Committee will hear presentations on the research programs in the Laboratory of Emerging Pathogens (LEP), Laboratory of bacterial and TSE Agents (LBTSE), and from the… | — |
| Jun 20, 2018 | Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee | The particular matter for this meeting will be review and discussion of a list of molecular targets for which evidence and/or biologic rationale exist to determine their potential relevance to the growth or progression… | — |
| Jun 14, 2018 | Anesthesiology and Respiratory Therapy Devices Panel | The committee will discuss, make recommendations and vote on information related to PneumRx, Inc.'s premarket approval application for the PNEUMRX ELEVAIR Endobronchial Coil System, which is a first of a kind… | — |
| Jun 12, 2018 | Circulatory System Devices Panel | The committee will discuss, make recommendations, and vote on the premarket approval application sponsored by Cordis, Inc. for the INCRAFT AAA Stent Graft System, which is intended for the endovascular treatment of… | — |
| May 22, 2018 | Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee | NDA 209588The committees will be asked to discuss new drug application (NDA) 209588, for buprenorphine sublingual spray, submitted by INSYS Development Company, Inc., for the treatment of moderate-to- severe acute pain where the… | INSYS Development Company, Inc. |
| May 17, 2018 | Vaccines and Related Biological Products Advisory Committee | Under Topic I, the Center for Biologics Evaluation and Research's (CBER) VRBPAC will meet in open session to discuss approaches for demonstrating effectiveness of group B streptococcus (GBS) vaccines intended for use in… | — |
| May 11, 2018 | Pediatric Advisory Committee and the Endocrinologic and Metabolic Drugs Advisory Committee | On Friday, May 11, 2018, the PAC and EMDAC will meet to discuss drug development for the treatment of children with achondroplasia. The following topics should be considered for discussion: Evidence required to… | — |
| May 10, 2018 | Endocrinologic and Metabolic Drugs Advisory Committee | NDA 210645The committee will discuss the safety and efficacy of new drug application (NDA) 210645, for volanesoren solution for subcutaneous injection, submitted by Akcea Therapeutics, Inc. The proposed indication is as an… | Akcea Therapeutics, Inc |
| May 3, 2018 | Gastrointestinal Drugs Advisory Committee and the Pediatric Advisory Committee | NDA 209904The committees will discuss new drug application (NDA) 209904 for stannsoporfin injection, for intramuscular use, submitted by InfaCare Pharmaceutical Corporation, proposed for the treatment of neonates greater than or… | — |
| May 2, 2018 | Antimicrobial Drugs Advisory Committee | NDA 210303The committee will discuss new drug application (NDA) 210303 for plazomicin, sponsored by Achaogen, Inc., for the proposed indications for the treatment of complicated urinary tract infections and blood stream… | — |
| May 1, 2018 | Antimicrobial Drugs Advisory Committee | NDA 208627The committee will discuss new drug application (NDA) 208627 for tecovirimat, sponsored by SIGA Technologies Inc., for the proposed indication of the treatment of smallpox disease caused by variola virus in adults and… | — |
| Apr 23, 2018 | Science Board to the Food and Drug Administration Advisory Committee | The Science Board will hear a report from the Center for Biologics Evaluation and Research Program Review Subcommittee; hear about FDA's Patient Affairs Initiative; and discuss how the Agency can leverage its existing… | — |
| Apr 23, 2018 | Arthritis Advisory Committee | NDA 207924The committee will discuss new drug application (NDA) 207924, for baricitinib tablets, submitted by Eli Lilly and Company, for the treatment of adult patients with moderately to severely active rheumatoid arthritis who… | Eli Lilly and Company |
| Apr 19, 2018 | Peripheral and Central Nervous System Drugs Advisory Committee | NDA 210365The committee will discuss new drug application (NDA) 210365, cannabidiol oral solution, sponsored by GW Pharmaceuticals, for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome or Dravet… | — |
| Mar 29, 2018 | Clinical Chemistry and Clinical Toxicology Devices Panel | The committee will discuss, make recommendations, and vote on information regarding a premarket approval application to market a novel continuous glucose monitoring (CGM) device system, the Senseonics, Inc. Eversense… | — |
| Mar 27, 2018 | Psychopharmacologic Drugs Advisory Committee | NDA 209229The committee will discuss new drug application (NDA) 209229, lofexidine hydrochloride, submitted by US WorldMeds, LLC, for mitigation of symptoms associated with opioid withdrawal and facilitation of completion of… | — |
| Mar 23, 2018 | Pediatric Advisory Committee | The PAC will meet to discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act (Pub. L. 107-109) and the Pediatric Research Equity Act of 2003 (Pub. L. 108- 155). Comments about… | — |
| Mar 22, 2018 | Pediatric Advisory Committee and the Endocrinologic and Metabolic Drugs Advisory Committee | The PAC and EMDAC will meet to discuss the major objectives of a phase 3 drug development program indicated for the treatment of children with achondroplasia (ACH). The following elements of a phase 3 program should be… | — |
| Mar 21, 2018 | Joint Meeting of the Blood Products Advisory Committee and the Microbiology Devices Panel | During the morning session on March 21, 2018, the Joint Committee [[Page 7745]] will discuss and make recommendations regarding the device reclassification from Class III to Class II of nucleic acid and serology-based… | — |
| Mar 8, 2018 | Gastrointestinal Drugs Advisory Committee | NDA 203214The committee will discuss supplemental new drug application (sNDA) 203214 supplement 18, XELJANZ (tofacitinib) tablets, submitted by Pfizer Inc., proposed for the treatment of adult patients with moderately to severely… | — |
| Mar 7, 2018 | Oncologic Drugs Advisory Committee | BLA 125557The committee will discuss supplemental biologic license application (sBLA) 125557/S-013, for BLINCYTO (blinatumomab) injection for intravenous use, application submitted by Amgen, Inc. The proposed indication (use) for… | Amgen, Inc |
| Mar 5, 2018 | Risk Communication Advisory Committee | On March 5 and 6, 2018, the committee will discuss the impact of pregnancy and lactation labeling information in prescription drug and biological products as modified under the Pregnancy and Lactation Labeling Rule. The… | — |
| Mar 1, 2018 | Vaccines and Related Biological Products Advisory Committee | Under Topic I, the Center for Biologics Evaluation and Research's (CBER) VRBPAC will meet in open session to hear an overview of the research program in the Laboratory of Mucosal Pathogens and Cellular Immunology… | — |
| Mar 1, 2018 | Neurological Devices Panel | The committee will discuss, make recommendations, and advise FDA regarding the evaluation of clinical study data to support the safety and effectiveness of intracranial aneurysm treatment devices and factors that can… | — |
| Feb 14, 2018 | Anesthetic and Analgesic Drug Products Advisory Committee | NDA 22496The committee will discuss supplemental new drug application (sNDA) 022496/S-009, for EXPAREL (bupivacaine liposomal injectable suspension), submitted by Pacira Pharmaceuticals, Inc., to produce local analgesia and as a… | — |
| Feb 14, 2018 | Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee | NDA 209257The committees will be asked to discuss new drug application (NDA) 209257, proposed tradename, HYDEXOR, a fixed-dose combination oral tablet, submitted by Charleston Laboratories, Inc., that contains hydrocodone,… | Charleston Laboratories, Inc., that contains hydrocodone, acetaminophen, and promethazine |
| Jan 24, 2018 | Tobacco Products Scientific Advisory Committee | On January 24 and 25, 2018, the committee will discuss modified risk tobacco product applications, submitted by Philip Morris Products S.A. for IQOS system with Marlboro Heatsticks, IQOS system with Marlboro Smooth… | — |
| Jan 11, 2018 | Antimicrobial Drugs Advisory Committee | NDA 210693The committee will discuss new drug application (NDA) 210693, ciprofloxacin dispersion for inhalation, sponsored by Aradigm Corp., for the proposed indication of treatment of non-cystic fibrosis bronchiectasis patients… | — |
| Jan 10, 2018 | Bone, Reproductive and Urologic Drugs Advisory Committee | NDA 208088The committee will discuss new drug application (NDA) 208088, oral testosterone undecanoate capsules, submitted by Lipocine Inc. for the proposed indication of testosterone replacement in males for conditions associated… | — |
| Jan 9, 2018 | Bone, Reproductive and Urologic Drugs Advisory Committee | NDA 206089The committee will discuss new drug application (NDA) 206089, oral testosterone undecanoate capsules, submitted by Clarus Therapeutics, for the proposed indication of testosterone replacement in males for conditions… | — |
| Dec 12, 2017 | Orthopaedic and Rehabilitation Devices Panel | The committee will discuss, make recommendations, and vote on information regarding the premarket approval application (PMA) for the Barricaid Anular Closure Device by Intrinsic Therapeutics. The proposed Indication for… | — |
| Dec 7, 2017 | Bone, Reproductive and Urologic Drugs Advisory Committee | The committee will discuss appropriate patient selection criteria and clinical trial design features, including acceptable endpoints, for demonstrating clinical benefit for drugs intended to treat interstitial cystitis… | — |
| Nov 30, 2017 | Blood Products Advisory Committee Advisory Committee | The Committee members will meet in open session to discuss bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for… | — |
| Nov 20, 2017 | Pharmacy Compounding Advisory Committee | The committee intends to discuss six bulk drug substances nominated for inclusion on the section 503A Bulks List. FDA will discuss the following nominated bulk drug substances: astragalus, L- citrulline, pregnenolone,… | — |
| Nov 16, 2017 | Antimicrobial Drugs Advisory Committee | NDA 209367The committee will discuss new drug application (NDA) 209367, ciprofloxacin inhalation powder, sponsored by Bayer HealthCare Pharmaceuticals, Inc., for the proposed indication of reduction of exacerbations in non-cystic… | — |
| Nov 7, 2017 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in an open session to discuss and make recommendations on the clinical development plan for Pfizer's investigational Staphylococcus aureus vaccine intended for pre-surgical prophylaxis in… | — |
| Nov 6, 2017 | Science Advisory Board to the National Center for Toxicological Research Advisory Committee | The SAB Chair will welcome the participants, and the NCTR Director will provide a Center-wide update on scientific initiatives and accomplishments during the past year. The SAB will be presented with an overview of the… | — |
| Nov 1, 2017 | Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee | NDA 210136The committee will discuss new drug application (NDA) 210136, buprenorphine subcutaneous injection, submitted by Braeburn Pharmaceuticals, Inc., for treatment of opioid dependence. | — |
| Oct 31, 2017 | Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee | NDA 209819The committees will discuss new drug application (NDA) 209819, buprenorphine subcutaneous injection, submitted by Indivior Pharmaceuticals, Inc., for treatment of opioid dependence. | — |
| Oct 18, 2017 | Endocrinologic and Metabolic Drugs Advisory Committee | NDA 209637The committee will discuss the safety and efficacy of new drug application (NDA) 209637 for semaglutide injection, submitted by Novo Nordisk, as an adjunct to diet and exercise to improve glycemic control in adults with… | — |
| Oct 13, 2017 | Dermatologic and Ophthalmic Drugs Advisory Committee | NDA 208254The committee will discuss the safety and efficacy of new drug application (NDA) 208254, for netarsudil ophthalmic solution 0.02%, submitted by Aerie Pharmaceuticals Inc., for the proposed indication to reduce elevated… | — |
| Oct 12, 2017 | Cellular, Tissue, and Gene Therapies Advisory Committee | BLA 125610The CTGTAC will meet in an open session to discuss and make recommendations on the safety and effectiveness of biologics license application (BLA) for voretigene neparvovec (BLA 125610), submitted by Spark Therapeutics,… | Spark Therapeutics, Inc |
| Oct 11, 2017 | Patient Engagement Advisory Committee | On October 11 and 12, 2017, the committee will discuss and make recommendations on the topic of patient input into medical device clinical trials. This meeting will provide the opportunity to bring patients, patient… | — |
| Oct 4, 2017 | Vaccines and Related Biological Products Advisory Committee | The VRBPAC will meet in an open session to discuss and make recommendations on the selection of strains to be included in an influenza virus vaccine for the 2018 southern hemisphere influenza season. | — |
| Sep 28, 2017 | Peripheral and Central Nervous System Drugs Advisory Committee | NDA 200896The committee will discuss new drug application (NDA) 200896, ataluren for oral suspension, sponsored by PTC Therapeutics, Inc., for the treatment of patients with dystrophinopathy due to a nonsense mutation in the… | — |
| Sep 19, 2017 | Oncologic Drugs Advisory Committee | NDA 21938The committee will discuss supplemental new drug application (sNDA) 021938/033 SUTENT (sunitinib malate) oral capsules, submitted by C.P. Pharmaceuticals International C.V., represented by Pfizer, Inc. (authorized U.S.… | — |
| Sep 14, 2017 | Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee | NDA 21306The committees will discuss supplemental new drug application (sNDA) 021306, for BUTRANS (buprenorphine) transdermal system submitted by Purdue Pharma L.P., evaluating BUTRANS in pediatric patients ages 7 through 16… | Purdue Pharma L.P., evaluating BUTRANS in pediatric patients ages 7 through 16 years |
| Sep 13, 2017 | Vaccines and Related Biological Products Advisory Committee | The VRBPAC will meet in an open session to discuss and make recommendations on the safety and effectiveness of Zoster Vaccine Recombinant, Adjuvanted, manufactured by GlaxoSmithKline Biologicals. | — |
| Sep 11, 2017 | Pediatric Advisory Committee | The PAC will meet to discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act (Pub. L. 107-109) and the Pediatric Research Equity Act (Pub. L. 108-155). Comments about the… | — |
| Sep 8, 2017 | Medical Imaging Drugs Advisory Committee | The committee will discuss the potential risk of gadolinium retention in the brain and other body organs in patients receiving gadolinium-based contrast agents for magnetic resonance clinical imaging procedures. | — |
| Aug 3, 2017 | Arthritis Advisory Committee | The committee will discuss supplemental new drug applications (sNDAs) 203214 supplement 17, for XELJANZ (tofacitinib) tablets and 208246 supplement 3, for XELJANZ XR (tofacitinib) extended release tablets submitted by… | Pfizer Inc. |
| Aug 2, 2017 | Arthritis Advisory Committee | BLA 761057The committee will discuss biologics license application (BLA) 761057, for sirukumab injection (proposed trade name PLIVENSIA), submitted by Janssen Biotech, Inc., for the treatment of adult patients with moderately to… | Janssen Biotech, Inc. |
| Jul 28, 2017 | Vaccines and Related Biological Products Advisory Committee | The VRBPAC will meet in an open session to discuss and make recommendations on the safety and efficacy of a Hepatitis B Vaccine manufactured by Dynavax. | — |
| Jul 26, 2017 | Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee | NDA 209653The committees will discuss new drug application (NDA) 209653, for oxycodone hydrochloride extended-release oral tablets, submitted by Intellipharmaceutics Corp., with the proposed indication of management of… | — |
| Jul 13, 2017 | Oncologic Drugs Advisory Committee | BLA 761028, BLA 761074During the morning session, the committee will discuss biologics license application (BLA) 761028 for ABP 215, a proposed biosimilar to Genentech/Roche's AVASTIN (bevacizumab), submitted by Amgen Inc. The proposed… | Amgen Inc |
| Jul 12, 2017 | Oncologic Drugs Advisory Committee | BLA 125646The committee will discuss biologics license application (BLA) 125646, for tisagenlecleucel-T suspension for intravenous use. The application was submitted by Novartis Pharmaceuticals Corp. The proposed indication (use)… | Novartis Pharmaceuticals Corp |
| Jul 11, 2017 | Oncologic Drugs Advisory Committee | BLA 761060The committee will discuss biologics license application (BLA) 761060, MYLOTARG (gemtuzumab ozogamicin) for intravenous use, submitted by Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. The proposed indication… | Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc |
| Jun 26, 2017 | Science Board to the Food and Drug Administration Advisory Committee | The Science Board will hear an update on FDA's biotechnology activities related to plant-derived food and animals and will hear a report from the National Antibiotic Resistance Monitoring System Review Subcommittee. | — |
| Jun 21, 2017 | Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee | Information will be presented to gauge investigator interest in exploring potential pediatric development plans for three products in various stages of development for adult cancer indications. The subcommittee will… | — |
| Jun 20, 2017 | Endocrinologic and Metabolic Drugs Advisory Committee | NDA 22341The committee will discuss a supplemental new drug application for VICTOZA (liraglutide) injection (sNDA 022341), sponsored by Novo Nordisk, for the proposed additional indication of: As an adjunct to standard treatment… | — |
| May 25, 2017 | Oncologic Drugs Advisory Committee | BLA 125545The committee will discuss biologics license application (BLA) 125545, for a proposed biosimilar to Amgen Inc.'s Epogen/Procrit (epoetin alfa), submitted by Hospira Inc., a Pfizer company. The proposed indications/uses… | Hospira Inc., a Pfizer company |
| May 24, 2017 | Oncologic Drugs Advisory Committee | NDA 208051, NDA 208587During the morning session, the committee will discuss new drug application (NDA) 208051, for neratinib maleate, an application submitted by Puma Biotechnology. The proposed indication (use) for this product is as a… | Puma Biotechnology |
| May 18, 2017 | Joint Meeting of the Pediatric Advisory Committee and the Pediatric Ethics Subcommittee | The PAC and the PES will meet to discuss a referral by an Institutional Review Board (IRB) of a clinical investigation that involves children and FDA regulated products. The clinical investigation is entitled ``A… | — |
| May 17, 2017 | Gastroenterology and Urology Devices Panel | The committee will discuss, make recommendations, and vote on information regarding the premarket approval application (PMA) for the TRANSMEDICS ORGAN CARE SYSTEM (OCS)--Lung System, by TransMedics, Inc. The proposed… | — |
| May 17, 2017 | Vaccines and Related Biological Products Advisory Committee | The VRBPAC will meet in an open session to discuss considerations for evaluation of Respiratory Syncytial Virus vaccine candidates in seronegative infants. | — |
| May 10, 2017 | Medical Imaging Drugs Advisory Committee | The committee will discuss new drug application (NDA) 208- 630 for 5-Aminolevulinic Acid Hydrochloride [5-ALA HCl], Powder, for oral solution, submitted by NX Development Corp., for the proposed indication as an imaging… | — |
| May 9, 2017 | Science Board to the Food and Drug Administration Advisory Committee | The Science Board will provide recommendations on the Agency's Innovation Funds work plan as prescribed in section 1002 of the 21st Century Cures Act (Pub. L. 114-255). | — |
| May 8, 2017 | Pharmacy Compounding Advisory Committee | The committee will receive updates on certain issues to follow up on discussions from previous meetings, including quality standards and conditions at certain compounding facilities. In addition, the committee intends… | — |
| Apr 13, 2017 | Antimicrobial Drugs Advisory Committee | The committee will discuss the development of antibacterial drugs that treat a single species of bacteria when the target species infrequently causes infections; examples of such drugs include those that are only active… | — |
| Apr 6, 2017 | Tobacco Products Scientific Advisory Committee | Under section 910(b)(2) (21 U.S.C. 387j(b)(2)) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), FDA may refer applications for premarket review of new tobacco products (PMTA) to the Tobacco Products… | — |
| Apr 5, 2017 | Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee | NDA 209777The committees will discuss new drug application (NDA) 209777, for oxycodone hydrochloride immediate-release oral tablets, submitted by Inspirion Delivery Sciences, LLC., with the proposed indication of management of… | Inspirion Delivery Sciences, LLC., with the |
| Apr 4, 2017 | Joint Meeting of the Nonprescription Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee | The committees will discuss safety issues associated with over-the-counter analgesic combination products used for upset stomach (i.e., heartburn, nausea, fullness, belching, gas, acid indigestion, and/or sour stomach)… | — |
| Apr 4, 2017 | Blood Products Advisory Committee | In open session, the Committee will discuss Recombinant Human Coagulation Factor IX, GlycoPEGylated. In the afternoon, in open session, the Committee will hear an update presentation on a summary of responses to Docket… | — |
| Mar 29, 2017 | Oncologic Drugs Advisory Committee | BLA 761064, NDA 209099During the morning session of March 29, 2017, the committee will discuss biologics license application (BLA) 761064, rituximab/ hyaluronidase injection for subcutaneous use, submitted by Genentech, Inc. The proposed… | Genentech, Inc |
| Mar 17, 2017 | Joint Meeting of the Ophthalmic Devices Panel of the Medical Devices Advisory Committee and the Risk Communication Advisory Committee | The committee will discuss and make recommendations regarding the potential risks of misuse of peroxide- based contact lens products. Specific issues to be discussed include adequate labeling and packaging of these… | — |
| Mar 15, 2017 | Pharmaceutical Science and Clinical Pharmacology Advisory Committee | The use of model-informed drug development (MIDD) for new and generic drugs has significantly increased over the past several years. The committee will discuss strategies, approaches, and challenges in MIDD with… | — |
| Mar 13, 2017 | Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee | NDA 201655The committees will be asked to discuss safety issues for new drug application (NDA) 201655, OPANA ER (oxymorphone hydrochloride) Extended-release Tablets, by Endo Pharmaceuticals Inc., with the indication of management… | — |
| Mar 9, 2017 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2017-2018 influenza season. | — |
| Mar 6, 2017 | [Pediatric Advisory Committee | The PAC will meet to discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act (Pub. L. 107-109) and the Pediatric Research Equity Act (Pub. L. 108-155). Comments about the… | — |
| Feb 23, 2017 | Circulatory System Devices Panel | The committee will discuss and make recommendations on clinical information related to the de novo request for the Sentinel[supreg] Cerebral Protection System, a first of a kind embolic protection device to be used with… | — |
| Feb 16, 2017 | Psychopharmacologic Drugs Advisory Committee | NDA 209241The committee will discuss new drug application (NDA) 209241, Valbenazine 40 milligram (mg) capsules, for the proposed treatment of Tardive Dyskinesia, submitted by Neurocrine Biosciences, Inc. | — |
| Dec 6, 2016 | Bone, Reproductive and Urologic Drugs Advisory Committee | The committee will discuss appropriate clinical trial design features, including acceptable endpoints for demonstrating clinical benefit, for drugs intended to treat secondary hypogonadism while preserving or improving… | — |
| Nov 17, 2016 | Blood Products Advisory Committee Advisory Committee | The Committee will meet in open session to discuss strategies to manage iron deficiency associated with blood donation. The Committee will also discuss proposed procedures for assuring donor safety for collections of… | — |
| Nov 16, 2016 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to discuss and make recommendations on the safety and efficacy of a Hepatitis B Vaccine manufactured by Dynavax. | — |
| Nov 15, 2016 | Science Board to the Food and Drug Administration Advisory Committee | The Science Board will hear about: (1) The Center for Biologics Evaluation and Research's strategic goals for regulatory science; (2) a progress update on FDA's Opioid Action Plan and the Bovine Heparin Initiative; (3)… | — |
| Nov 9, 2016 | Microbiology Devices Panel | During session one, the committee will [[Page 68433]] discuss and make recommendations regarding the reclassification of quantitative Cytomegalovirus (CMV) viral load devices from class III (Premarket approval) to class… | — |
| Nov 7, 2016 | Risk Communication Advisory Committee | The committee will discuss and make recommendations on FDA's draft Strategic Plan for Risk Communication and Health Literacy. The purpose of the Strategic Plan for Risk Communication and Health Literacy is to clarify… | — |
| Nov 4, 2016 | Antimicrobial Drugs Advisory Committee | The committee will discuss new drug applications 209006 and 209007, solithromycin capsules and solithromycin for injection, sponsored by Cempra Pharmaceuticals, Inc., respectively, for the proposed indication of… | — |
| Nov 3, 2016 | Pharmacy Compounding Advisory Committee | The committee intends to discuss five bulk drug substances nominated for inclusion on the section 503A Bulks List. FDA will discuss the following nominated bulk drug substances: Glycolic acid, trichloroacetic acid,… | — |
| Nov 1, 2016 | Science Advisory Board to the National Center for Toxicological Research Advisory Committee | The SAB Chair will welcome the participants, and the NCTR Director will provide a Center-wide update on scientific initiatives and accomplishments during the past year. The SAB will be presented with an overview of the… | — |
| Oct 27, 2016 | Allergenic Products Advisory Committee | The committee will meet by teleconference. In open session, the committee will hear updates of research programs in the Laboratory of Immunobiochemistry of the Division of Bacterial, Parasitic and Allergenic Products… | — |
| Oct 19, 2016 | Bone, Reproductive and Urologic Drugs Advisory Committee | NDA 201656The committee will discuss the efficacy and safety of new drug [[Page 39931]] application (NDA) 201656 (desmopressin), 0.75 mcg/0.1 mL and 1.5 mcg/ 0.1 mL nasal spray, submitted by Serenity Pharmaceuticals, LLC, for the… | — |
| Oct 13, 2016 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to discuss and make recommendations on the selection of strains to be included in an influenza virus vaccine for the 2017 southern hemisphere influenza season. | — |
| Oct 5, 2016 | Microbiology Devices Panel | During session I, the topic to be addressed will be reclassification of quantitative Cytomegalovirus (CMV) viral load devices from class III (Premarket approval) to class II (510(k)). A nucleic acid-based in vitro… | — |
| Oct 5, 2016 | Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee | The committees will be asked to discuss naloxone products intended for use in the community, specifically the most appropriate dose or doses of naloxone to reverse the effects of life-threatening opioid overdose in all… | — |
| Sep 15, 2016 | National Mammography Quality Assurance Advisory Committee | The Committee will discuss and make recommendations on: <bullet> Compliance Analysis. This presentation will be focused on Mammography Quality Standards Act (MQSA) current compliance trends, such as how most compliance… | — |
| Sep 15, 2016 | Anesthetic and Analgesic Drug Products Advisory Committee, the Drug Safety and Risk Management Advisory Committee, and the Pediatric Advisory Committee | The purpose of this public advisory committee meeting is to discuss the appropriate development plans for establishing the safety and efficacy of prescription opioid analgesics for pediatric patients, including… | — |
| Sep 14, 2016 | Pediatric Advisory Committee | The Pediatric Advisory Committee (PAC) will meet to discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act (Pub. L. 107-109) and the Pediatric Research Equity Act (Pub. L.… | — |
| Sep 14, 2016 | Oncologic Drugs Advisory Committee | The committee will discuss new drug application 208714, apaziquone for intravesical instillation, application submitted by Spectrum Pharmaceuticals, Inc. The proposed indication (use) for this product is for immediate… | Spectrum Pharmaceuticals, Inc |
| Sep 14, 2016 | Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee | The committees will discuss a completed postmarketing- requirement randomized, placebo controlled trial of the neuropsychiatric effects of CHANTIX (varenicline), ZYBAN (bupropion), and nicotine replacement therapy,… | — |
| Sep 7, 2016 | Cellular, Tissue, and Gene Therapies Advisory Committee | The committee will meet by teleconference. In open session, the committee will hear updates of research programs in the Gene Transfer and Immunogenicity Branch, Division of Cellular and Gene Therapies, Office of… | — |
| Aug 16, 2016 | Microbiology Devices Panel | The committee will discuss and make recommendations regarding the appropriateness of clearing or approving of over-the-counter (OTC) diagnostic tests for the detection of pathogens causing infectious diseases, focusing… | — |
| Aug 10, 2016 | Clinical Chemistry and Clinical Toxicology Devices Panel | The committee will discuss, make recommendations, and [[Page 34355]] vote on information regarding a de novo request for the SEEKER Newborn Screening System (SEEKER System), by Baebies, Inc. The SEEKER System consists… | — |
| Aug 4, 2016 | Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee | NDA 208630The committees will discuss new drug application (NDA) 208630, morphine sulfate extended-release tablets, submitted by Egalet U.S., Inc., with the proposed indication of the management of pain severe enough to require… | Egalet U.S., Inc., with the |
| Jul 26, 2016 | Cellular, Tissue and Gene Therapies Advisory Committee | The committee will meet by teleconference. In open session, the committee will hear updates of research programs in the Laboratory of Biological Chemistry and Laboratory of Molecular Oncology, Division of Biotechnology… | — |
| Jul 22, 2016 | Clinical Chemistry and Clinical Toxicology Devices Panel | The committee will discuss, make recommendations, and vote on information regarding a premarket approval application (PMA) panel-track supplement for a proposed change in intended use of Dexcom, Inc.'s, Dexcom… | — |
| Jul 19, 2016 | Dermatologic and Ophthalmic Drugs Advisory Committee | BLA 761032The committee will discuss biologics license application (BLA) 761032, brodalumab injection, a human monoclonal antibody, submitted by Valeant Pharmaceuticals Luxembourg S.[agrave].r.l, proposed for the treatment of… | — |
| Jul 13, 2016 | Arthritis Advisory Committee | The committee will discuss biologics license application 761042, for GP2015, a proposed biosimilar to Amgen Inc.'s ENBREL (etanercept) submitted by Sandoz, Inc. The proposed indications (uses) for this product are: (1)… | Sandoz, Inc |
| Jul 12, 2016 | Arthritis Advisory Committee | The committee will discuss biologics license application 761024, for ABP 501, a proposed biosimilar to AbbVie Inc.'s HUMIRA (adalimumab), submitted by Amgen, Inc. The proposed indications (uses) for this product are:… | Amgen, Inc |
| Jun 28, 2016 | Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee | Information will be presented to gauge investigator interest in exploring potential pediatric development plans for four products in various stages of development for adult cancer indications. The subcommittee will… | — |
| Jun 28, 2016 | Endocrinologic and Metabolic Drugs Advisory Committee | NDA 204629, NDA 206111The committee will discuss supplemental new drug application (sNDA) 204629, empagliflozin (JARDIANCE) tablets, and sNDA 206111, empagliflozin and metformin hydrochloride (SYNJARDY) tablets. Both sNDAs are sponsored by… | — |
| Jun 23, 2016 | Pharmacy Compounding Advisory Committee | The committee intends to discuss six bulk drug substances nominated for inclusion on the section 503A bulk drug substances list. FDA intends to discuss the following nominated bulk drug substances: Chrysin, cesium… | — |
| Jun 20, 2016 | Blood Products Advisory Committee | The Committee members will participate in the meeting via teleconference. In open session, the Committee will discuss the research programs in the Laboratory of Plasma Derivatives in the Division of Hematology Research… | — |
| Jun 9, 2016 | Antimicrobial Drugs Advisory Committee | BLA 761046The committee will discuss biologics license application (BLA) 761046, bezlotoxumab (MK-6072) injection, submitted by Merck Sharpe & Dohme Corp., for the proposed indication of prevention of Clostridium difficile… | — |
| Jun 8, 2016 | Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee | NDA 207621The committees will be asked to discuss new drug application (NDA) 207621, oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules, submitted by Pfizer, Inc., with the proposed indication of… | Pfizer, Inc., with the |
| Jun 7, 2016 | Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee | NDA 207975The committees will be asked to discuss new drug application (NDA) 207975, hydrocodone bitartrate extended-release tablets, submitted by Teva Branded Pharmaceutical Products R&D, Inc., with the proposed indication of… | — |
| May 25, 2016 | Endocrinologic and Metabolic Drugs Advisory Committee | NDA 208583The committee will discuss the safety and efficacy of new drug application (NDA) 208583 for insulin degludec and liraglutide injection, submitted by Novo Nordisk Inc., for the proposed indication: Adjunct to diet and… | — |
| May 24, 2016 | Circulatory System Devices Panel | The committee will discuss, make recommendations and vote on information related to the premarket approval application regarding St. Jude Medical's AMPLATZER Patent Foramen Ovale (PFO) Occluder. The AMPLATZER PFO… | — |
| May 24, 2016 | Endocrinologic and Metabolic Drugs Advisory Committee | The committee will discuss the safety and efficacy of new drug applications (NDAs) 208673 for insulin glargine and lixisenatide injection, a fixed ratio drug product consisting of insulin and a GLP-1 receptor agonist,… | — |
| May 11, 2016 | Vaccines and Related Biological Products Advisory Committee | The committee will participate via teleconference. In open session, the committee will hear updates of the research program in the Laboratory of Bacterial Polysaccharides, Division of Bacterial, Parasitic, and… | — |
| May 5, 2016 | Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee | NDA 208653The committees will be asked to discuss new drug application (NDA) 208653, benzhydrocodone/acetaminophen oral tablets, submitted by KemPharm, Inc., with the proposed indication of short-term (up to 14 days) [[Page… | KemPharm, Inc., with the |
| May 3, 2016 | Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee | The Food and Drug Administration Amendments Act of 2007 (Pub. L. 110-85) requires FDA to bring, at least annually, one or more drugs with Risk Evaluation and Mitigation Strategies (REMS) with Elements to Assure Safe Use… | — |
| Apr 25, 2016 | Peripheral and Central Nervous System Drugs Advisory Committee | NDA 206488The committee will discuss new drug application (NDA) 206488, [[Page 13377]] eteplirsen injection for intravenous infusion, sponsored by Sarepta Therapeutics, Inc., for the treatment of Duchenne muscular dystrophy (DMD)… | — |
| Apr 20, 2016 | Orthopaedic and Rehabilitation Devices Panel | The Committee will discuss, make recommendations, and vote on the premarket approval application for the Cartiva Synthetic Cartilage Implant (SCI), sponsored by Cartiva, Inc. The Cartiva Synthetic Cartilage Implant… | — |
| Apr 15, 2016 | Nonprescription Drugs Advisory Committee | The committee will discuss data submitted by Galderma Laboratories, L.P. to support supplemental new drug application (sNDA) 20-380, for over-the-counter (OTC) marketing of adapalene gel 0.1%. The proposed OTC use is… | Galderma Laboratories, L.P. |
| Apr 12, 2016 | Pediatric Advisory Committee | The Pediatric Advisory Committee (PAC) will meet to discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act (Pub. L. 107-109) and the Pediatric Research Equity Act (Pub. L.… | — |
| Apr 12, 2016 | Oncologic Drugs Advisory Committee | NDA 208542The committee will discuss new drug application (NDA) 208542, rociletinib tablets, application submitted by Clovis Oncology, Inc. The proposed indication (use) for this product is for the treatment of patients with… | Clovis Oncology, Inc |
| Apr 7, 2016 | Gastrointestinal Drugs Advisory Committee | NDA 207999The committee will discuss new drug application (NDA) 207999, obeticholic acid oral tablets, submitted by Intercept Pharmaceuticals, Inc., proposed for the treatment of primary biliary cirrhosis in combination with… | — |
| Mar 29, 2016 | Psychopharmacologic Drugs Advisory Committee | NDA 207318The committee will discuss the specific risk-benefit profile for new drug application (NDA) 207318, NUPLAZID (pimavanserin) 17 milligram (mg) immediate-release, film-coated oral tablets, submitted by Acadia… | — |
| Mar 15, 2016 | Circulatory System Devices Panel | The committee will discuss, make recommendations, and vote on information related to the premarket approval application for the Absorb GT1 Bioresorbable Vascular Scaffold (BVS) System sponsored by Abbott Vascular. The… | — |
| Mar 8, 2016 | Pharmacy Compounding Advisory Committee | The committee will discuss six bulk drug substances nominated for inclusion on the section 503A bulk drug substances list. FDA will discuss the following nominated bulk drug substances: Quinacrine hydrochloride,… | — |
| Mar 4, 2016 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2016-2017 influenza season. | — |
| Mar 1, 2016 | Science Board to the Food and Drug Administration Advisory Committee | The Science Board will hear about and discuss: (1) The role of opioids in pain management; (2) scientific challenges facing FDA in supporting the development of pain medications, including opioids, that have reduced… | — |
| Feb 25, 2016 | Gastroenterology and Urology Devices Panel | The committee will discuss, make recommendations, and vote on information regarding the premarket approval application (PMA) for ``TOPAS Treatment for Fecal Incontinence,'' by ASTORA Women's Health, LLC. The ``TOPAS… | — |
| Feb 19, 2016 | Orthopaedic and Rehabilitation Devices Panel | The Committee will discuss the premarket application for the DIAM Spinal Stabilization System. The DIAM Spinal Stabilization System is indicated for skeletally mature patients that have low back pain (with or without… | — |
| Feb 18, 2016 | Circulatory System Devices Panel | The Committee will discuss and make recommendations on clinical trial, postapproval study design, and physician training requirements for leadless cardiac pacemaker device technology. Specifically, the Committee will be… | — |
| Feb 16, 2016 | Cellular, Tissue and Gene Therapies Advisory Committee | The committee will meet by teleconference. In open session, the committee will hear updates of research programs in the Tumor Vaccines and Biotechnology Branch and the Cellular and Tissue Therapy Branch of the Division… | — |
| Feb 16, 2016 | Risk Communication Advisory Committee | On February 16 and 17, 2016, the Committee will discuss recent developments in risk communications and related sciences, and possible approaches and applications in the context of FDA communications. | — |
| Feb 9, 2016 | Arthritis Advisory Committee | BLA 125544The committee will discuss biologics license application (BLA) 125544, for CT-P13, a proposed biosimilar to Janssen Biotech Inc.'s REMICADE (infliximab), submitted by Celltrion, Inc. The proposed indications (uses) for… | Celltrion, Inc |
| Feb 3, 2016 | Psychopharmacologic Drugs Advisory Committee | During the morning session, the committee will discuss cognitive dysfunction in major depressive disorder (MDD). This is an evolving concept and experts in the field have not yet reached consensus as to whether… | — |
| Jan 22, 2016 | Peripheral and Central Nervous System Drugs Advisory Committee | The committee will discuss new drug application 206488, eteplirsen injection for intravenous infusion, sponsored by Sarepta Therapeutics, Inc., for the treatment of Duchenne muscular dystrophy (DMD) in patients who have… | — |
| Jan 21, 2016 | Allergenic Products Advisory Committee | The Committee will meet in an open session to discuss safety and effectiveness data, including challenge study endpoints, for licensure of food allergy immunotherapy products, and the clinical development of… | — |
| Jan 14, 2016 | Vaccines and Related Biological Products Advisory Committee | The committee will meet by teleconference. In open session, the committee will hear updates of the research program in the Laboratory of Method Development, Division of Viral Products, Center for Biologics Evaluation… | — |
| Jan 12, 2016 | Psychopharmacologic Drugs Advisory Committee | NDA 204442The committee will discuss new drug application (NDA) 204442, PROBUPHINE (buprenorphine hydrochloride and ethylene vinyl acetate) subdermal implant, submitted by Braeburn Pharmaceuticals, Inc., on behalf of Titan… | — |
| Dec 14, 2015 | Endocrinologic and Metabolic Drugs Advisory Committee | The committee will discuss the results of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE- IT). IMPROVE-IT was a clinical trial that studied the effect of ezetimibe/simvastatin compared… | — |
| Dec 10, 2015 | Joint Meeting of the Pulmonary-Allergy Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee | The committees will discuss the safety of codeine in children 18 years of age and younger. Codeine (most often in combination with acetaminophen) is used for the treatment of pain in children; however, it is… | — |
| Dec 9, 2015 | Pulmonary-Allergy Drugs Advisory Committee | The committee will discuss biologics license application 761033, reslizumab for injection, submitted by Teva Pharmaceutical Industries, Ltd., for the proposed indication to reduce exacerbations, relieve symptoms, and… | — |
| Dec 1, 2015 | Psychopharmacologic Drugs Advisory Committee | The committee will discuss the efficacy and safety data for new drug application (NDA) 21164, gepirone hydrochloride extended- release tablets, submitted by Fabre-Kramer Pharmaceuticals, Inc., for the proposed… | — |
| Nov 24, 2015 | Peripheral and Central Nervous System Drugs Advisory Committee | NDA 206031The committee will discuss new drug application (NDA) 206031, drisapersen solution for injection, sponsored by BioMarin Pharmaceutical Inc., for the treatment of patients with Duchenne muscular dystrophy with mutations… | — |
| Nov 19, 2015 | Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee | Information will be presented to gauge investigator interest in exploring potential pediatric development plans for two products in various stages of development for adult cancer indications. The subcommittee will… | — |
| Nov 18, 2015 | Science Board to the Food and Drug Administration Advisory Committee | The Science Board will be provided with updates from the Center for Food Safety and Applied Nutrition, Centers for Excellence in Regulatory Science and Innovation, Evaluation Subcommittee and the ORA Food Emergency… | — |
| Nov 18, 2015 | Gastroenterology and Urology Devices Panel | The committee will discuss, make recommendations and vote on information regarding the premarket approval application (PMA) for the TransMedics[supreg] Organ Care System<SUP>TM</SUP> (OCS)--Heart, by TransMedics, Inc.… | — |
| Nov 18, 2015 | Joint Meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee and the Oncologic Drugs Advisory Committee | BLA 125593The committees will discuss the safety and efficacy of Biologics License Application (BLA) 125593, Mycobacterium phlei Cell wall-Nucleic Acid complex (MCNA), submitted by Telesta Therapeutics, Inc. The proposed… | Telesta Therapeutics, Inc |
| Nov 13, 2015 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to discuss considerations for evaluation of the safety and effectiveness of vaccines administered to pregnant women to protect the infant. | — |
| Nov 6, 2015 | Anesthetic and Analgesic Drug Products Advisory Committee | NDA 22225The committee will discuss new drug application (NDA) 022225, sugammadex sodium injection, submitted by Organon USA Inc., a subsidiary of Merck & Co., Inc., for the proposed indication of reversal of moderate or deep… | — |
| Nov 5, 2015 | Joint Meeting of the Antimicrobial Drugs Advisory Committee (Formerly Known as the Anti-Infective Drugs Advisory Committee) and the Drug Safety and Risk Management Advisory Committee | The committees will discuss the risks and benefits of the systemic fluoroquinolone antibacterial drugs for the treatment of acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis in patients who… | — |
| Nov 3, 2015 | Bone, Reproductive, and Urologic Drugs Advisory Committee | NDA 207959The committee will discuss new drug application (NDA) 207959, enclomiphene citrate 12.5 milligram (mg) and 25 mg capsules, submitted by Repros Therapeutics, Inc., for the proposed treatment of secondary hypogonadism in… | — |
| Nov 3, 2015 | Science Advisory Board to the National Center for Toxicological Research Advisory Committee | The SAB Chair will welcome the participants, and the NCTR Director will provide a Center-wide update on scientific initiatives and accomplishments during the past year. The SAB will be presented with an overview of the… | — |
| Oct 27, 2015 | Pharmacy Compounding Advisory Committee | During the morning session, the committee will discuss a revision FDA is considering to the list of drug products that may not be compounded under the exemptions provided by the FD&C Act because the drug product has… | — |
| Oct 23, 2015 | Arthritis Advisory Committee | NDA 207988The committee will discuss new drug application (NDA) 207988, lesinurad oral tablets, submitted by Ardea Biosciences, Inc., for the treatment of hyperuricemia associated with gout, in combination with a xanthine oxidase… | — |
| Sep 24, 2015 | Obstetrics and Gynecology Devices Panel | P020014The committee will discuss the risks and benefits of Bayer HealthCare's Essure System for permanent female sterilization. The system, originally approved in November 2002, under P020014, consists of a delivery system… | — |
| Sep 16, 2015 | Pediatric Advisory Committee | The Pediatric Advisory Committee (PAC) will meet to discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act (Pub. L. 107-109) and the Pediatric Research Equity Act (Pub. L.… | — |
| Sep 15, 2015 | Vaccines and Related Biological Products Advisory Committee | From 8:30 a.m. to 2:30 p.m., the committee will meet in open session to discuss and make recommendations on the safety and immunogenicity of Seasonal Trivalent Influenza Vaccine, Surface Antigen, Inactivated, Adjuvanted… | — |
| Sep 11, 2015 | Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee | NDA 208090The committees will discuss new drug application (NDA) 208090, oxycodone extended-release capsules for oral use, submitted by Collegium Pharmaceuticals, proposed for the management of pain severe enough to require… | Collegium Pharmaceuticals |
| Sep 10, 2015 | Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee | NDA 206830The committees will be asked to discuss new drug application (NDA) 206830, oxycodone immediate-release tablets, submitted by Purdue Pharma, with the proposed indication of the management of moderate to severe pain where… | Purdue Pharma, with the |
| Jul 9, 2015 | Oncologic Drugs Advisory Committee | The committee will discuss biologics license application 125547, necitumumab injection, application submitted by Eli Lilly and Company. The proposed indication (use) for this product is in combination with gemcitabine… | Eli Lilly and Company |
| Jul 7, 2015 | Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee | NDA 22272The committees will discuss the results of post-marketing studies evaluating the misuse and/or abuse of reformulated OXYCONTIN (oxycodone hydrochloride) extended-release tablets, supplemental new drug application (sNDA)… | — |
| Jun 17, 2015 | Pharmacy Compounding Advisory Committee | During the morning session, the committee will receive updates on certain issues to follow up on discussions from the last meeting including the options for obtaining access to investigational new drugs and the… | — |
| Jun 11, 2015 | Pulmonary-Allergy Drugs Advisory Committee | BLA 125526The committee will discuss biologics license application (BLA) 125526, for mepolizumab for injection, submitted by GlaxoSmithKline for the proposed indication of add-on maintenance treatment in patients 12 years and… | — |
| Jun 10, 2015 | Endocrinologic and Metabolic Drugs Advisory Committee | BLA 125522The committee will discuss the safety and efficacy of biologics license application (BLA) 125522, proposed trade name REPATHA (established name: Evolocumab) for injection, submitted by Amgen Inc., as adjunct to diet to… | Amgen Inc., as adjunct |
| Jun 9, 2015 | Endocrinologic and Metabolic Drugs Advisory Committee | The committee will discuss the safety and efficacy of biologics license application 125559, proposed trade name PRALUENT (established name: Alirocumab) for injection, submitted by Sanofi Aventis, U.S., as an adjunct to… | — |
| Jun 8, 2015 | Risk Communications Advisory Committee | On June 8 and 9, 2015, the Committee will discuss approaches to communicating information about fetal effects in product labeling for methadone or buprenorphine maintenance therapy for opioid addiction, and about the… | — |
| Jun 4, 2015 | Joint Meeting of the Bone, Reproductive, and Urologic Drugs Advisory Committee, and the Drug Safety and Risk Management Advisory Committee | NDA 22526The committees will discuss new drug application (NDA) 022526, flibanserin 100 milligram (mg) tablets, submitted by Sprout Pharmaceuticals Inc., proposed for the treatment of hypoactive sexual desire disorder (HSDD) in… | — |
| Jun 1, 2015 | Transmissible Spongiform Encephalopathies Advisory Committee | The Transmissible Spongiform Encephalopathies Advisory Committee will meet in open session to hear update presentations on the following topics: (1) The variant Creutzfeldt-Jakob Disease (vCJD) situation worldwide and… | — |
| May 13, 2015 | Blood Products Advisory Committee | The Blood Products Advisory Committee will meet in open session to discuss strategies for implementation of serological and nucleic acid testing for Babesia microti in blood donors. In the afternoon, the committee will… | — |
| May 12, 2015 | Pulmonary-Allergy Drugs Advisory Committee | NDA 206038The committee will discuss new drug application (NDA) 206038, lumacaftor/ivacaftor combination tablets for oral use, submitted by Vertex Pharmaceuticals, proposed for the treatment of cystic fibrosis (CF) in patients… | — |
| May 12, 2015 | Vaccines and Related Biological Products Advisory Committee | From 8:30 a.m. to 5 p.m., the committee will meet in open session to discuss the development and licensure of Ebola vaccines. | — |
| May 1, 2015 | Ear, Nose, and Throat Devices Panel | The committee will discuss and make recommendations regarding the classification of Hearing Protectors, Circumaural Hearing Protectors, Middle Ear Inflation Devices, Tactile Hearing Aid Devices, and Vestibular Analysis… | — |
| Apr 29, 2015 | Joint Meeting of the Cellular, Tissue and Gene Therapies Advisory Committee and the Oncologic Drug Advisory Committee | BLA 125518The committees will discuss talimogene laherparepvec, Amgen, Inc., biologics license application (BLA) 125518, an oncolytic immunotherapy for the treatment of patients with injectable regionally or distantly metastatic… | — |
| Apr 17, 2015 | Neurological Devices Panel | The committee will discuss the current knowledge regarding the conduct of clinical studies and evaluation of clinical study data for flow diverter technology. FDA is convening this committee to seek expert opinion on… | — |
| Apr 15, 2015 | Cardiovascular and Renal Drugs Advisory Committee | The committee will discuss new drug application New Drug Application 204958, cangrelor injection, submitted by The Medicines Company, for the proposed indication of reduction of thrombotic cardiovascular events… | — |
| Apr 14, 2015 | Endocrinologic and Metabolic Drugs Advisory Committee | NDA 200678, NDA 22426, NDA 203414During the morning session, the committee will discuss the results of the cardiovascular outcomes trial (CVOT), Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus, for new drug… | — |
| Apr 9, 2015 | The Tobacco Products Scientific Advisory Committee | On April 9 and 10, 2015, the Committee will discuss modified risk tobacco product applications submitted by Swedish Match North America Inc. for 10 tobacco products: <bullet> MR0000020: General Loose, smokeless tobacco,… | — |
| Mar 24, 2015 | Pediatric Advisory Committee | The Pediatric Advisory Committee (PAC) will meet to discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act (Pub. L. 107-109) and the Pediatric Research Equity Act (Pub. L.… | — |
| Mar 23, 2015 | Pediatric Ethics Subcommittee of the Pediatric Advisory Committee | The Pediatric Ethics Subcommittee of the Pediatric Advisory Committee will meet to discuss the general topic of how procedural sedation for nontherapeutic (research) interventions or procedures in the pediatric… | — |
| Mar 19, 2015 | Joint Meeting of the Pulmonary-Allergy Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee | The committees will discuss supplemental new drug application 204275-S001, for fluticasone furoate and vilanterol inhalation powder (tradename Breo Ellipta) submitted by GlaxoSmithKline for the once daily maintenance… | GlaxoSmithKline |
| Mar 18, 2015 | Anesthetic and Analgesic Drug Products Advisory Committee | NDA 22225The committee will discuss new drug application (NDA) 022225, sugammadex sodium injection, submitted by Organon USA Inc., for the proposed indication of reversal of moderate or deep neuromuscular blockade induced by… | — |
| Mar 17, 2015 | Arthritis Advisory Committee | BLA 125544The committee will discuss biologics license application (BLA) 125544 for CT-P13, a proposed biosimilar to Janssen Biotech Inc.'s REMICADE (infliximab), submitted by Celltrion, Inc. The proposed indications (uses) for… | Celltrion, Inc |
| Mar 9, 2015 | Dermatologic and Ophthalmic Drugs Advisory Committee | NDA 206333During the morning session, the committee will discuss new drug application (NDA) 206333, deoxycholic acid injection, a cytolytic drug, submitted by Kythera Biopharmaceuticals, proposed for the improvement in the… | Kythera Biopharmaceuticals |
| Mar 4, 2015 | Vaccines and Related Biological Products Advisory Committee | From 8:30 a.m. to 3 p.m., the committee will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2015-2016 influenza season. | — |
| Feb 27, 2015 | General and Plastic Surgery Devices Panel | The committee will discuss, make recommendations and vote on information regarding the premarket approval application (PMA) panel-track supplement to expand the indication for use for the Radiesse Injectable Implant… | — |
| Feb 24, 2015 | Joint Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee and Ophthalmic Devices Panel | NDA 203324The committees will discuss new drug application (NDA) 203324, for riboflavin ophthalmic solutions with UV-A irradiation, submitted by Avedro, Inc. The combination products are used in corneal collagen cross-linking and… | Avedro, Inc |
| Feb 23, 2015 | Pharmacy Compounding Advisory Committee | During the morning session, the committee will discuss proposed revisions to the list of drug products that may not be compounded under the exemptions provided by the FD&C Act because the drug products have been… | — |
| Feb 20, 2015 | Orthopaedic and Rehabilitation Panel | The committee will discuss, make recommendations, and vote on information regarding the premarket approval application (PMA) for the Superion InterSpinous Spacer device sponsored by Vertiflex Inc. The proposed… | — |
| Jan 22, 2015 | Anti-Infective Drugs Advisory Committee | The committee will discuss new drug applications (NDAs) 207-500 and 207-501, isavuconazonium sulfate capsules and isavuconazonium sulfate for injection, sponsored by Astellas Pharma Global Development, Inc.,… | — |
| Jan 12, 2015 | Endocrinologic and Metabolic Drugs Advisory Committee | NDA 22517The committee will discuss the safety and efficacy of new drug application (NDA) 022517, proposed trade name NOCDURNA (established name: desmopressin), orally disintegrating sublingual tablets submitted by Ferring… | Ferring Pharmaceuticals, Inc |
| Jan 7, 2015 | Oncologic Drugs Advisory Committee | BLA 125553The committee will discuss biologics license application (BLA) 125553 for EP2006, a proposed biosimilar to Amgen Inc.'s NEUPOGEN (filgrastim), submitted by Sandoz, Inc. The proposed indications (uses) for this product… | Sandoz, Inc |
| Dec 18, 2014 | Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee | The meeting will be closed to permit discussion of whether FDA should permit further clinical development of an existing investigational drug product, which will include the review of trade secret and/or confidential… | — |
| Dec 12, 2014 | Orthopaedic and Rehabilitation Devices Panel | The committee will discuss, make recommendations, and vote on information regarding the premarket approval application for the Superion InterSpinous Spacer device sponsored by Vertiflex Incorporated. The proposed… | — |
| Dec 11, 2014 | Oncologic Drugs Advisory Committee | Information will be presented to gauge investigator interest in exploring potential pediatric development plans for three products in various stages of development for adult cancer indications. The subcommittee will… | — |
| Dec 5, 2014 | Anti-Infective Drugs Advisory Committee | The committee will discuss new drug application 206494 for ceftazidime-avibactam for injection, submitted by Cerexa Inc., for the proposed indications of: Complicated Intra-abdominal Infections, Complicated Urinary… | — |
| Dec 4, 2014 | Anti-Infective Drugs Advisory Committee | The committee will discuss issues related to clinical development programs and clinical trial designs for antibacterial products for the treatment of patients with serious bacterial infections for which there are… | — |
| Dec 2, 2014 | Blood Products Advisory Committee | The Committee will meet in open session to hear scientific data related to reconsideration of the current blood donor deferral policy for men who have had sex with another man (MSM) even one time since 1977. The… | — |
| Nov 24, 2014 | Anesthetic and Analgesic Drug Products Advisory Committee | The committee will discuss the risk of serious neurologic adverse reactions associated with epidural steroid injections (ESI) administered to reduce inflammation for pain management. The committee will also consider the… | — |
| Nov 19, 2014 | Science Board to the Food and Drug Administration Advisory Committee | The Science Board will review the existing nonclinical and clinical data related to the use and potential toxicity of anesthetics and sedation drugs in the pediatric population. The Science Board will be asked to make… | — |
| Nov 18, 2014 | Drug Safety and Risk Management Advisory Committee | The committee will discuss the Food and Drug Administration Amendments Act of 2007 which requires FDA to bring, at least annually, one or more drugs with Risk Evaluation and Mitigation Strategies (REMS) with elements to… | — |
| Nov 7, 2014 | Food Advisory Committee | The committee will discuss how risk assessments should account for the susceptibility to the effects of a particular chemical exposure because of factors such as genetics, age, sex, and health status and the… | — |
| Nov 6, 2014 | Oncologic Drugs Advisory Committee | NDA 205353, NDA 206317During the morning session, the committee will discuss new drug application (NDA) 205353, panobinostat capsules, application submitted by Novartis Pharmaceuticals Corporation. The proposed indication (use) for this… | Novartis Pharmaceuticals Corporation |
| Nov 6, 2014 | Cellular, Tissue and Gene Therapies Advisory Committee | The committee will discuss the draft guidance for industry entitled ``Design and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy and Oncolytic Products'' and the Dear Gene Therapy IND or Master… | — |
| Oct 30, 2014 | Cardiovascular and Renal Drugs Advisory Committee | NDA 206316The committee will discuss new drug application (NDA) 206316, edoxaban tablets, submitted by Daiichi Sankyo, Inc., for the prevention of stroke and systemic embolism (blood clots other than in the head) in patients with… | — |
| Oct 21, 2014 | Pulmonary-Allergy Drugs Advisory Committee | NDA 203188The committee will discuss supplemental new drug application (sNDA) 203188, ivacaftor oral tablets, submitted by Vertex Pharmaceuticals Inc., for the treatment of cystic fibrosis in patients with an R117H mutation in… | — |
| Oct 16, 2014 | Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee | The committees will discuss the risk of serious neuropsychiatric adverse events with CHANTIX (varenicline tartrate) tablets, NDA 21928, Pfizer, Inc., and discuss options for addressing this risk. | — |
| Oct 8, 2014 | Circulatory System Devices Panel | On October 8, the committee will discuss, make recommendations and vote on information related to the premarket approval application regarding the Boston Scientific Corporation's WATCHMAN Left Atrial Appendage (LAA)… | — |
| Oct 1, 2014 | Gastroenterology and Urology Devices Panel | The committee will discuss, make recommendations, and vote on information regarding the premarket approval application (PMA) for the SONABLATE 450 device sponsored by SonaCare Medical, LLC. The proposed Indication for… | — |
| Sep 30, 2014 | Science Advisory Board to the National Center for Toxicological Research Advisory Committee | The NCTR Director will welcome the participants and provide a Center-wide update on scientific initiatives and accomplishments during the past year. The SAB will be presented with an overview of the Division of… | — |
| Sep 23, 2014 | Pediatric Advisory Committee | The Pediatric Advisory Committee will meet to discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act for: AFINITOR DISPERZ (everolimus);… | — |
| Sep 22, 2014 | Ophthalmic Devices Panel | The committee will discuss, make recommendations, and vote on information related to the premarket approval application for the AcrySof[supreg] IQ ReSTOR[supreg] Multifocal Toric Posterior Chamber Intraocular Lens… | applicant Alcon Laboratories, Inc |
| Sep 18, 2014 | Cellular, Tissue and Gene Therapies Advisory Committee | The committee will meet by teleconference. In open session, the committee will hear updates of research programs in the Laboratory of Biochemistry, Division of Therapeutic Proteins, the Laboratory of Molecular Oncology… | — |
| Sep 18, 2014 | Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee | NDA 206089The committees will discuss new drug application (NDA) 206089 (oral testosterone undecanoate tablets), submitted by Clarus Therapeutics, for the proposed indication of testosterone replacement therapy in males for… | — |
| Sep 12, 2014 | Endocrinologic and Metabolic Drug Products Advisory Committee | BLA 125511The committee will discuss biologics license application (BLA) 125511, proposed trade name NATPARA (established name: Recombinant Human Parathyroid Hormone (rDNA) or (rhPTH[1-84]), submitted by NPS Pharmaceuticals,… | — |
| Sep 11, 2014 | Endocrinologic and Metabolic Drugs Advisory Committee | NDA 206321The committee will discuss the safety and efficacy of new drug application (NDA) 206321, liraglutide for injection, sponsored by Novo Nordisk, Inc. The proposed indication for liraglutide is as an adjunct to a… | — |
| Sep 10, 2014 | Cardiovascular and Renal Drugs Advisory Committee | The committee will be asked to discuss the potential clinical utility of fixed-combination prescription drugs composed of an anti-hypertensive drug, aspirin, and a statin administered to reduce the risk of… | — |
| Sep 9, 2014 | Cardiovascular and Renal Drugs Advisory Committee | NDA 206302The committee will discuss new drug application (NDA) 206302, nebivolol/valsartan fixed-dose combination tablets (5/80 milligrams (mg), 5/160 mg, 10/160 mg, 10/320 mg and 20/320 mg), submitted by Forrest Laboratories,… | — |
| Sep 4, 2014 | Nonprescription Drugs Advisory Committee | The committee will discuss the scope of safety testing that should be required for sunscreen active ingredients to be marketed in U.S. over-the-counter (OTC) sunscreen products. This discussion will take into… | — |
| Sep 3, 2014 | Nonprescription Drugs Advisory Committee | The committee will discuss the standards used to demonstrate that over-the-counter (OTC) topical antiseptics used in healthcare settings are generally recognized as safe and effective. The discussion will focus on… | — |
| Aug 14, 2014 | Pulmonary-Allergy Drugs Advisory Committee | The committee will discuss new drug application (NDA) 21936, for tiotropium bromide inhalation spray, submitted by Boehringer Ingelheim Pharmaceuticals, Inc., for the long-term, once-daily maintenance treatment of… | Boehringer Ingelheim Pharmaceuticals, Inc. |
| Aug 1, 2014 | General and Plastic Surgery Devices Panel | The committee will discuss, make recommendations and vote on information regarding the premarket application (PMA) for the TissuGlu Surgical Adhesive device sponsored by Cohera Medical, Inc. The proposed indication for… | — |
| Jul 31, 2014 | Blood Products Advisory Committee | The committee will meet in open session to discuss Baxter Healthcare Corporation's biologics license application for HyQvia, Immune Globulin Infusion 10 percent (human) combined with Recombinant Human Hyaluronidase for… | — |
| Jul 30, 2014 | Gastroenterology and Urology Devices Panel | The committee will discuss, make recommendations, and vote on information regarding the premarket approval application (PMA) for the Ablatherm Integrated Imaging device sponsored by EDAP Technomed, Inc. The proposed… | — |
| Jul 11, 2014 | Obstetrics and Gynecology Devices Panel | On July 10 and 11, 2014, the committee will discuss the safety of laparoscopic power morcellator devices as it pertains to their potential to disseminate and upstage a confined, but undetected (occult) uterine… | — |
| Jun 25, 2014 | Oncologic Drugs Advisory Committee | NDA 206162The committee will discuss new drug application (NDA) 206162, olaparib capsules, application submitted by AstraZeneca Pharmaceuticals LP. The proposed indication (use) for this product is as monotherapy for the… | AstraZeneca Pharmaceuticals LP |
| Jun 17, 2014 | Gastroenterology and Urology Devices Panel | The committee will discuss, make recommendations, and vote on information regarding the premarket application (PMA) for the Maestro[supreg] Rechargeable System sponsored by Enteromedics, Inc. The Maestro[supreg]… | — |
| Jun 12, 2014 | Circulatory System Devices Panel | The committee will discuss, make recommendations, and vote on information related to the premarket approval application for the LUTONIX 035 Drug Coated Balloon PTA Catheter sponsored by Lutonix, Inc. The LUTONIX 035… | — |
| Jun 11, 2014 | Anesthetic and Analgesic Drug Products Advisory Committee | The committee will discuss the potential cardiovascular risk associated with products in the class of peripherally acting opioid receptor antagonists and the necessity, timing, design, and size of cardiovascular… | — |
| Jun 6, 2014 | Ophthalmic Devices Panel | The committee will discuss, make recommendations, and vote on information related to the premarket approval application for the KAMRA Inlay (Model ACI 7000) (KAMRA Inlay) submitted by applicant AcuFocus, Inc. The KAMRA… | applicant AcuFocus, Inc |
| May 13, 2014 | Ophthalmic Devices Panel | The committee will discuss and make recommendations regarding the guidance documents for contact lenses and contact lens accessories. The guidance for contact lenses entitled ``Premarket Notification [510(k)] Guidance… | — |
| May 6, 2014 | Circulatory System Devices Panel | The committee will discuss, make recommendations, and vote on information related to the premarket approval application for the RESQCPR System sponsored by Advanced Circulatory Systems, Inc. The RESQCPR System is… | — |
| May 2, 2014 | Nonprescription Drugs Advisory Committee | NDA 204804The committee will discuss data submitted by MSD Consumer Care, Inc., to support new drug application (NDA) 204804, for over-the- counter (OTC) marketing of montelukast 10 milligram (mg) tablets (proposed trade name… | MSD Consumer Care, Inc. |
| Apr 24, 2014 | Neurological Devices Panel | The committee will discuss the current knowledge about the safety and effectiveness of aversive conditioning devices that are intended to deliver a noxious electrical stimulus to a patient to modify undesirable… | — |
| Apr 22, 2014 | Anesthetic and Analgesic Drug Products Advisory Committee | The committee will discuss the safety and efficacy for new drug application 203077, MOXDUO (morphine sulfate and oxycodone hydrochloride) capsules, QRxPharma Inc., for the proposed indication of management of moderate… | — |
| Apr 21, 2014 | Pediatric Advisory Committee | The Pediatric Advisory Committee (PAC) will meet to discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act (Pub. L. 107-109) and the Pediatric Research Equity Act (Pub. L.… | — |
| Apr 16, 2014 | The Tobacco Products Scientific Advisory Committee | The committee will consider scientific issues pertaining to dependence and addiction, including the development of addiction, measurement of dependence and addiction, and concepts concerning the assessment of addiction… | — |
| Apr 1, 2014 | Endocrinologic and Metabolic Drugs Advisory Committee | The committee will discuss new drug application (NDA) 22- 472, proposed trade name AFREZZA (TECHNOSPHERE Insulin Inhalation System), 3 unit and 6 unit cartridges for oral inhalation, manufactured by MannKind… | — |
| Mar 31, 2014 | Anti-Infective Drugs Advisory Committee | During the morning session, the committee will discuss new drug applications (NDAs) 205-435 and 205-436, tedizolid phosphate tablets and tedizolid phosphate injection, submitted by Trius Therapeutics, respectively, for… | Trius Therapeutics, respectively |
| Mar 27, 2014 | Cardiovascular and Renal Drugs Advisory Committee | BLA 125468The committee will discuss biologics license application (BLA) 125468, serelaxin injection, submitted by Novartis Pharmaceuticals Corp., as a treatment to improve the symptoms of acute heart failure through reduction of… | — |
| Mar 26, 2014 | Molecular and Clinical Genetics Panel | The committee will discuss, make recommendations and vote on information related to the premarket approval application sponsored by Epigenomics, Inc. for the Epi proColon. The Epi proColon test is a qualitative in vitro… | — |
| Mar 20, 2014 | Gastroenterology and Urology Devices Panel | The committee will discuss, make recommendations, and vote on information regarding the humanitarian device exemption (HDE) application for the XVIVO Perfusion System (XPS\TM\) sponsored by XVIVO Perfusion, Inc. The… | — |
| Mar 20, 2014 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to hear updates of the research programs in the Laboratory of Respiratory and Special Pathogens, Division of Bacterial, Parasitic and Allergenic Products, and in the Laboratory of… | — |
| Mar 18, 2014 | Blood Products Advisory Committee | The committee will meet in open session to discuss the evaluation of the safety and effectiveness of the Immucor PreciseType<SUP>TM</SUP> HEA Molecular BeadChip Assay, manufactured by BioArray Solutions Limited. In the… | — |
| Mar 14, 2014 | Ophthalmic Devices Panel | The committee will discuss, make recommendations, and vote on information regarding the premarket approval application for the Visian Toric Implantable Collamer Lens (TICL) sponsored by STAAR Surgical Company. ``Visian… | — |
| Mar 12, 2014 | Microbiology Devices Panel | The committee will discuss, make recommendations, and vote on a premarket approval application for a new indication for the cobas Human Papillomavirus (HPV) Test, sponsored by Roche Molecular Systems, Inc. The cobas HPV… | — |
| Mar 3, 2014 | Pediatric Advisory Committee | The Pediatric Advisory Committee (PAC) will meet to discuss pediatric focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act (Pub. L. 107-109) and the Pediatric Research Equity Act (Pub. L.… | — |
| Feb 28, 2014 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to hear an overview of the research program in the Laboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for… | — |
| Feb 26, 2014 | Nonprescription Drugs Advisory Committee | The committee will meet to discuss whether over-the-counter (OTC) bronchodilators administered by hand- held rubber bulb nebulizers for the temporary relief of mild symptoms of intermittent asthma (shortness of breath,… | — |
| Feb 25, 2014 | Joint Meeting of the Nonprescription Drugs Advisory Committee and the Pulmonary-Allergy Drugs Advisory Committee | NDA 205920The committees will discuss data submitted by Armstrong Pharmaceuticals, Inc., to support a new drug application (NDA) 205920, for over-the-counter (OTC) marketing of epinephrine inhalation aerosol 125 microgram… | Armstrong Pharmaceuticals, Inc. |
| Feb 25, 2014 | Cellular, Tissue, and Gene Therapies Advisory Committee | From 8 a.m. to 5:30 p.m. and on February 26, 2014, from 8 a.m. to approximately 11:15 a.m., the committee will discuss oocyte modification in assisted reproduction for the prevention of transmission of mitochondrial… | — |
| Feb 21, 2014 | Orthopaedic and Rehabilitation Devices Panel | The committee will discuss and make recommendations regarding the 515(i) order issued by FDA on April 9, 2009 [Docket No. FDA-2009-M-0101], relating to the regulatory classification of iontophoresis devices, one of the… | — |
| Feb 20, 2014 | Anesthesiology and Respiratory Therapy Devices Panel | The committee will discuss, make recommendations, and vote on information related to the premarket approval application regarding the Inspire II Upper Airway Stimulator, sponsored by Inspire Medical Systems, Inc. The… | — |
| Feb 14, 2014 | Ophthalmic Devices Panel | The committee will discuss, make recommendations, and vote on information regarding the premarket approval application for the Visian Toric Implantable Collamer Lens (TICL) sponsored by STAAR Surgical Company. ``Visian… | — |
| Feb 13, 2014 | Cardiovascular and Renal Drugs Advisory Committee | The committee will discuss biologics license application 125468, serelaxin injection, submitted by Novartis, as a treatment to improve the symptoms of acute heart failure through reduction of the rate of worsening of… | — |
| Feb 12, 2014 | Cardiovascular and Renal Drugs Advisory Committee | NDA 204958The committee will discuss new drug application (NDA) 204958, cangrelor injection, submitted by The Medicines Company, for the proposed indication of reduction of thrombotic cardiovascular events including stent… | Medicines Company |
| Jan 28, 2014 | Allergenic Products Advisory Committee | The committee will meet in open session to discuss and make recommendations on the safety and efficacy of RAGWITEK, a short ragweed pollen allergen extract tablet for sublingual use, manufactured by Merck, indicated for… | — |
| Jan 16, 2014 | Cardiovascular and Renal Drugs Advisory Committee | NDA 202439The committee will discuss supplemental new drug application (sNDA) 202439/S-002, rivaroxaban, trade name XARELTO 2.5 milligram tablets, submitted by Janssen Pharmaceuticals, Inc., for the proposed indication to reduce… | — |
| Jan 15, 2014 | Cardiovascular and Renal Drugs Advisory Committee | NDA 204886The committee will discuss new drug application (NDA) 204886, vorapaxar sulfate, proposed trade name ZONTIVITY, 2.5 milligram tablets, submitted by Merck Sharp & Dohme Corp., Inc., for the proposed indication of… | Merck Sharp & Dohme Corp., Inc. |
| Jan 14, 2014 | Cardiovascular and Renal Drugs Advisory Committee | NDA 203202The committee will discuss new drug application (NDA) 203202, NORTHERA (droxidopa capsules), submitted by Chelsea Therapeutics, Inc., for the treatment of symptomatic neurogenic orthostatic hypotension in patients with… | — |
| Dec 17, 2013 | Risk Communications Advisory Committee | The Committee will meet to identify and discuss new methods for communicating risk information as part of Risk Evaluation and Mitigation Strategies (REMS) to health care providers. The discussion will also address how… | — |
| Dec 12, 2013 | Endocrinologic and Metabolic Drugs Advisory Committee | NDA 202293The committee will discuss the efficacy and safety of new drug application (NDA) 202293, dapagliflozin tablet, submitted by Bristol-Myers Squibb. Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor developed as… | — |
| Dec 12, 2013 | Orthopaedic and Rehabilitation Devices Panel | P020033During Session I, the committee will discuss and make recommendations regarding the classification of spinal sphere devices. These devices are spheres manufactured from metallic (e.g., cobalt chromium molybdenum) or… | — |
| Dec 11, 2013 | Circulatory System Devices Panel | The committee will discuss, make recommendations, and vote on information related to the premarket approval application regarding the Boston Scientific WATCHMAN Left Atrial Appendage (LAA) Closure Technology. The… | — |
| Dec 11, 2013 | Allergenic Products Advisory Committee | The committee will meet in open session to discuss and make recommendations on the safety and efficacy of Oralair; a sweet vernal, orchard, perennial rye, Timothy, and Kentucky bluegrass mixed pollens allergen extract… | — |
| Dec 11, 2013 | Endocrinologic and Metabolic Drugs Advisory Committee | BLA 125390The committee will discuss the safety and efficacy of biologic license application (BLA) 125390, metreleptin for injection, sponsored by Amylin Pharmaceuticals, LLC, a wholly owned subsidiary of Bristol-Myers Squibb.… | — |
| Nov 19, 2013 | Endocrinologic and Metabolic Drugs Advisory Committee | BLA 125460The committee will discuss biologics license application (BLA) 125460, for Vimizim (elosulfase alfa), manufactured by BioMarin Pharmaceutical, Inc., for the treatment of Mucopolysaccharidosis Type IVA (Morquio A… | — |
| Nov 14, 2013 | Peripheral and Central Nervous System Drugs Advisory Committee | NDA 205677The committee will discuss new drug application (NDA) 205677, tasimelteon capsules, proposed trade name HETLIOZ, submitted by Vanda Pharmaceuticals, Inc. The proposed indication is for the treatment of Non-24 hour… | Vanda Pharmaceuticals, Inc |
| Nov 13, 2013 | Peripheral and Central Nervous System Drugs Advisory Committee | BLA 103948The committee will discuss supplemental biologics license application (sBLA) 103948-5139, alemtuzumab injection, proposed trade name LEMTRADA, submitted by Genzyme Corporation, a Sanofi Company. The proposed indication… | Genzyme Corporation, a Sanofi Company |
| Nov 13, 2013 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to hear an overview of the research programs in the Laboratory of Retroviruses and Laboratory of Immunoregulation, Division of Viral Products, Office of Vaccines Research and… | — |
| Nov 8, 2013 | Ear, Nose and Throat Devices Panel | The committee will discuss, make recommendations, and vote on information regarding the premarket approval (PMA) application for the Nucleus[supreg] Hybrid<SUP>TM</SUP> L24 Implant System sponsored by Cochlear Americas.… | — |
| Nov 5, 2013 | Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee | During the morning session, there will be a presentation and general discussion of the potential applicability of pharmacological and cellular manipulation of the immune system, as a potential therapeutic intervention… | Bristol-Myers Squibb Co. and (2) MK-3475, application submitted by Merck Sharp & Dohme |
| Nov 5, 2013 | Allergenic Products Advisory Committee | The committee will meet in open session to discuss and make recommendations on the safety and efficacy of Oralair, a Sweet Vernal Grass, Perennial Ryegrass, Timothy Grass, Orchard Grass, and Kentucky Bluegrass Mixed… | — |
| Nov 4, 2013 | Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee | The recent permanent reauthorization of the Pediatric Research Equity Act (Pub. L. 108-155) and the Best Pharmaceuticals for Children Act (Pub. L. 107-109) and their associated amendments require earlier consideration… | — |
| Nov 1, 2013 | Blood Products Advisory Committee | The committee will meet in open session to discuss MP Biomedicals' biologic license application for the MP Diagnostics HTLV Blot 2.4, a Western Blot intended for use as a confirmatory test for blood donors. In the… | — |
| Oct 31, 2013 | Advisory Committee for Pharmaceutical Science and Clinical Pharmacology | There will be two topics presented to the committee for their discussion and consideration. During the first session, the Office of New Drug Quality Assessment will lead a discussion on the challenges and opportunities… | — |
| Oct 30, 2013 | Advisory Committee for Pharmaceutical Science and Clinical Pharmacology | There will be two topics presented to the committee for their [[Page 58315]] discussion and consideration. During the first session, the Office of Pharmaceutical Science and the Office of Compliance will discuss with… | — |
| Oct 25, 2013 | Antiviral Drugs Advisory Committee | NDA 204671The committee will discuss new drug application (NDA) 204671, sofosbuvir (an NS5B polymerase inhibitor), manufactured by Gilead Sciences, Inc., with a proposed indication for the treatment of chronic hepatitis C… | — |
| Oct 24, 2013 | Antiviral Drugs Advisory Committee | NDA 205123The committee will discuss new drug application (NDA) 205123, simeprevir (a hepatitis C virus protease inhibitor), manufactured by Janssen Pharmaceutical Co., with a proposed indication for the treatment of chronic… | — |
| Oct 22, 2013 | Cellular, Tissue and Gene Therapies Advisory Committee | From 8 a.m. to 5:30 p.m., and on October 23, 2013, from 8 a.m. to approximately 11:15 a.m., the Committee will discuss oocyte modification in assisted reproduction for the prevention of transmission of mitochondrial… | — |
| Oct 18, 2013 | Anti-Infective Drugs Advisory Committee | NDA 204684The committee will discuss the safety and effectiveness of new drug application (NDA) 204684, miltefosine capsules, submitted by Paladin Therapeutics, Inc., for the proposed indication of treatment of patients with… | — |
| Oct 17, 2013 | Anti-Infective Drugs Advisory Committee | The purpose of the meeting on October 17, 2013, is to discuss susceptibility interpretive criteria for systemic antibacterial drugs and for dosing recommendations in product labeling. We will seek input on the role of… | — |
| Oct 16, 2013 | Endocrinologic and Metabolic Drugs Advisory Committee | The committee will discuss the supplemental new drug application 202057/S-005, VASCEPA (icosapent ethyl) capsules, submitted by Amarin Pharmaceuticals Ireland Ltd. VASCEPA is currently approved as monotherapy for the… | Amarin Pharmaceuticals Ireland Ltd. VASCEPA is currently approved as monotherapy |
| Oct 8, 2013 | Circulatory System Devices Panel | On both days the committee will discuss, make recommendations, and vote on devices indicated for use in patients with heart failure (HF). On October 8, 2013, the committee will discuss, make recommendations, and vote on… | — |
| Sep 25, 2013 | Advisory Committee for Pharmaceutical Science and Clinical Pharmacology | The committee will discuss optimal strategies for the evaluation, interpretation, and communication of drug-drug interaction (DDI) information. FDA will seek input on: (1) Best practices in DDI communication through… | — |
| Sep 19, 2013 | Pediatric Advisory Committee | And September 20, 2013, the Pediatric Advisory Committee (PAC) will meet to discuss pediatric- focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act (Pub. L. 107-109) and the for Pediatric… | — |
| Sep 19, 2013 | Ophthalmic Devices Panel | The committee will discuss, make recommendations, and vote on information regarding the premarket approval application for the ReSure Sealant sponsored by Ocular Therapeutix, Inc. The ReSure Sealant is an in situ formed… | — |
| Sep 12, 2013 | Oncologic Drugs Advisory Committee | The committee will discuss supplemental biologics license application 125409/51, with the trade name PERJETA (pertuzumab) injection, application submitted by Genentech, Inc. The proposed indication (use) for this… | Genentech, Inc |
| Sep 11, 2013 | Circulatory System Devices Panel | During session I, the committee will discuss and make recommendations regarding the proposed classification of external cardiac compressor (ECC) devices, one of the remaining preamendments class III devices regulated… | — |
| Sep 10, 2013 | Pulmonary-Allergy Drugs Advisory Committee | NDA 203975The committee will discuss the new molecular entity new drug application (NDA) 203975, for umeclidinium and vilanterol powder for inhalation (proposed trade name Anoro Ellipta), sponsored by Glaxo Group (d/b/a/GSK) for… | — |
| Sep 9, 2013 | Pediatric Ethics Subcommittee of the Pediatric Advisory Committee | On September 9 and 10, 2013, the Pediatric Ethics Subcommittee of the Pediatric Advisory Committee will meet to discuss ethical issues in pediatric product development, including medical counter measures, focusing on… | — |
| Sep 9, 2013 | Joint Meeting of the Gastroenterology-Urology Panel and the Radiological Devices Panel | The joint committee, convened by the Office of the Commissioner, will discuss current evidence on the risks and benefits of computed tomography colonography for screening of asymptomatic patients for colorectal cancer.… | — |
| Aug 16, 2013 | Risk Communications Advisory Committee | The Committee will discuss how FDA can communicate more effectively with [[Page 42088]] health care professionals and other stakeholders about the public health risks posed by counterfeit and unapproved drugs, in… | — |
| Aug 16, 2013 | Tobacco Products Scientific Advisory Committee | The Committee will discuss possible approaches for evaluating information on the risks and potential benefits of a proposed modified risk tobacco product (MRTP) to the population as a whole. MRTPs are tobacco products… | — |
| Aug 6, 2013 | Cardiovascular and Renal Drugs Advisory Committee | NDA 204819The committee will discuss new drug application (NDA) 204819, proposed trade name ADEMPAS (riociguat coated tablet), submitted by Bayer HealthCare Pharmaceuticals Inc., for the treatment of: (1) Chronic thromboembolic… | — |
| Aug 5, 2013 | Cardiovascular and Renal Drugs Advisory Committee | NDA 204441The committee will discuss new drug application (NDA) 204441, tolvaptan tablets, submitted by Otsuka Pharmaceutical Company, Ltd., for the proposed indication of slowing kidney disease in adults at risk of rapidly… | — |
| Aug 2, 2013 | Blood Products Advisory Committee | The Committee will meet in open session to hear updates on the research programs of the Laboratory of Molecular Virology, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review,… | — |
| Jul 31, 2013 | Nonprescription Drugs Advisory Committee | The committee will discuss data submitted by sanofi-aventis U.S., LLC to support a supplemental new drug application (sNDA) 20468/ S-035, for the switch from prescription to over-the-counter (OTC) of triamcinolone… | sanofi-aventis U.S., LLC |
| Jul 24, 2013 | Orthopaedic and Rehabilitation Devices Panel | The committee will discuss, make recommendations, and vote on information related to the premarket approval application for the Kineflex/C Cervical Artificial Disc sponsored by SpinalMotion. The Kineflex/C is a… | — |
| Jul 23, 2013 | Arthritis Advisory Committee | BLA 125057, BLA 125160During the morning session, the committee will discuss supplemental biologics license application (sBLA) 125057, HUMIRA (adalimumab) injection, by AbbVie Inc., for the proposed indication of reducing signs and symptoms… | — |
| Jul 22, 2013 | Arthritis Advisory Committee | The committee will discuss the Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis and the implications of using these criteria for drug approval. | — |
| Jul 18, 2013 | Dental Products Panel | The committee will discuss and make recommendations on the proposed regulatory classification for dental devices known as Endosseous Dental Implants (Blade-form), one of the remaining preamendments Class III devices.… | — |
| Jul 18, 2013 | Anesthetic and Analgesic Drug Products Advisory Committee | NDA 22225The committee will discuss new drug application (NDA) 022225, sugammadex sodium injection, submitted by Organon USA Inc., for the proposed indications of routine reversal of moderate and deep neuromuscular blockade… | — |
| Jul 17, 2013 | Anesthetic and Analgesic Drug Products Advisory Committee | NDA 203077The committee will discuss the safety and efficacy for the new drug application (NDA) 203077, proposed trade name MOXDUO (morphine sulfate and oxycodone hydrochloride) capsules, submitted by QRxPharma Inc., for the… | QRxPharma Inc. |
| Jul 10, 2013 | Drug Safety and Risk Management Advisory Committee | The Food and Drug Administration Amendments Act of 2007 requires FDA to bring, at least annually, one or more drugs with Risk Evaluation and Mitigation Strategies (REMS) with elements to assure safe use (ETASU) before… | — |
| Jun 27, 2013 | Gastroenterology and Urology Devices Panel | During session I, the committee will discuss and make recommendations regarding the proposed classification of sorbent hemoperfusion systems, one of the remaining preamendments class III devices. The class III sorbent… | — |
| Jun 26, 2013 | General and Plastic Surgery Devices Panel | The committee will discuss and make recommendations regarding the possible reclassification of blood lancet devices. The committee will discuss whether new scientific data are sufficient to support the reasonable… | — |
| Jun 13, 2013 | Microbiology Devices Panel | The committee will discuss and make recommendations regarding the possible reclassification of influenza detection devices, currently regulated as class I. The committee's discussion will involve making recommendations… | — |
| May 22, 2013 | Peripheral and Central Nervous System Drugs Advisory Committee | NDA 204569The committee will discuss new drug application (NDA) 204569, for suvorexant tablets, submitted by Merck Sharp and Dohme Corp., Worldwide Regulatory Group. The proposed indication is for insomnia characterized by… | Merck Sharp and Dohme Corp., Worldwide Regulatory Group |
| May 21, 2013 | Orthopaedic and Rehabilitation Devices Panel | The committee will discuss and make recommendations regarding the classification of one of the remaining preamendments class III devices, shortwave diathermy for all other uses except for the treatment of malignancies.… | — |
| May 8, 2013 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to hear updates of the research programs in the Laboratory of DNA Viruses, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and… | — |
| May 3, 2013 | Joint Meeting of the Medical Imaging Drugs Advisory Committee and the Oncologic Drugs Advisory Committee | The committees will discuss the safety and efficacy of currently approved leukocyte growth factors (LGFs) as potential treatments for radiation-induced myelosuppression associated with a radiological/nuclear incident.… | — |
| May 2, 2013 | General and Plastic Surgery Devices Panel | The committee will discuss, make recommendations and vote on information related to the premarket approval application for the Juv[eacute]derm Voluma XC sponsored by Allergan, Inc. Juv[eacute]derm Voluma XC is a dermal… | — |
| May 2, 2013 | Oncologic Drugs Advisory Committee | NDA 204408, NDA 201848During the morning session, the committee will discuss new drug application (NDA) 204408, with the established name tivozanib capsules, submitted by AVEO Pharmaceuticals, Inc. The proposed indication (use) for this… | AVEO Pharmaceuticals, Inc |
| Apr 30, 2013 | Tobacco Products Scientific Advisory Committee | Modified risk tobacco products (MRTPs) are tobacco products that are sold or distributed for use to reduce harm or the risk of tobacco-related disease associated with commercially marketed tobacco products. Before an… | — |
| Apr 29, 2013 | Risk Communications Advisory Committee | On April 29 and 30, 2013, the Committee will discuss general factors in risk communication about FDA-regulated products, including how to communicate effectively about FDA's adverse event reporting systems, and… | — |
| Apr 25, 2013 | Clinical Chemistry and Clinical Toxicology Devices Panel | During session I, the committee will discuss and make recommendations on the appropriate regulatory classification for diagnostic devices known as methotrexate enzyme immunoassays. Methotrexate enzyme immunoassays are… | — |
| Apr 18, 2013 | Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee | The committee will discuss the efficacy and safety of new drug application (NDA) 22219, AVEED (testosterone undecanoate) intramuscular injection, submitted by Endo Pharmaceutical Solutions, Inc., for the proposed… | Endo Pharmaceutical Solutions, Inc. |
| Apr 17, 2013 | Pulmonary-Allergy Drugs Advisory Committee | NDA 204275The committee will discuss the new drug application (NDA) 204275, for fluticasone furoate and vilanterol dry powder inhaler (proposed trade name BREO ELLIPTA), sponsored by GlaxoSmithKline, for the long-term maintenance… | — |
| Apr 17, 2013 | Cellular, Tissue and Gene Therapies Advisory Committee | The committee will meet by teleconference. In open session, the committee will hear updates of research programs in the Laboratory of Chemistry, Division of Therapeutic Proteins, Office of Biotechnology Products, Center… | — |
| Apr 11, 2013 | Device Good Manufacturing Practice Advisory Committee | The committee will discuss the potential effects of extreme weather and natural disasters on medical device manufacturing chain processes and marketed medical device safety and quality. The committee will further… | — |
| Apr 8, 2013 | Ophthalmic Devices Panel | The committee will discuss, make recommendations, and vote on information regarding the premarket approval application for the Trulign Toric posterior chamber intraocular lens sponsored by Bausch and Lomb. The Trulign… | — |
| Apr 5, 2013 | Orthopaedic and Rehabilitation Devices Panel | The committee will discuss and make recommendations regarding the possible reclassification of Shortwave Diathermy devices. On July 6, 2012 (77 FR 39953), FDA issued a proposed rule which, if made final, would make… | — |
| Mar 21, 2013 | Psychopharmacologic Drugs Advisory Committee | NDA 204442The committee will discuss new drug application (NDA) 204442, PROBUPHINE (buprenorphine hydrochloride and ethylene vinyl acetate) subdermal implant, submitted by Titan Pharmaceuticals, Inc., and its safety and efficacy… | — |
| Mar 20, 2013 | Circulatory System Devices Panel | The committee will discuss, make recommendations, and vote on information related to the premarket approval application for the MitraClip Delivery System sponsored by Abbott Vascular. The system consists of three major… | — |
| Mar 15, 2013 | Neonatal Subcommittee of the Pediatric Advisory Committee | The Food and Drug Administration Safety and Innovation Act identified the need to expand current pediatric science to include the neonatal population. On March 15, 2013, FDA's Neonatal Subcommittee of the Pediatric… | — |
| Mar 14, 2013 | Pediatric Advisory Committee | On Thursday, March 14, 2013, the Pediatric Advisory Committee will meet to discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act (Public Law 107- 109) and the for Pediatric… | — |
| Mar 14, 2013 | Transmissible Spongiform Encephalopathies Advisory Committee | The Committee will meet in open session to discuss FDA's draft risk assessment model for potential exposure to the variant Creutzfeldt-Jakob disease (vCJD) agent in Red Blood Cells for transfusion in the United States. | — |
| Mar 7, 2013 | Pulmonary-Allergy Drugs Advisory Committee | NDA 204275The committee will discuss the new drug application (NDA) 204275, for fluticasone furoate and vilanterol dry powder inhaler (proposed tradename BREO ELLIPTA), sponsored by GlaxoSmithKline, for the long-term maintenance… | — |
| Mar 5, 2013 | Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee | The committees will discuss whether the benefit of calcitonin salmon for the treatment of postmenopausal osteoporosis (thinning and weakening of bones that increase the chance of having a broken bone) outweighs a… | — |
| Mar 4, 2013 | Advisory Committee for Reproductive Health Drugs | NDA 22506, NDA 204516During the morning session, the committee will discuss new drug application (NDA) 022506, gabapentin 600 milligram (mg) tablets, submitted by Depomed, Inc., for the proposed indication of treatment of moderate to severe… | Depomed, Inc. |
| Feb 27, 2013 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccine for the 2013- 2014 influenza season. | — |
| Feb 22, 2013 | Neurological Devices Panel | The committee will discuss, make recommendations and vote on information regarding the premarket approval application (PMA) for the NeuroPace Responsive Neurostimulation (RNS) System sponsored by NeuroPace, Inc. The RNS… | — |
| Feb 14, 2013 | Medical Imaging Drugs Advisory Committee | NDA 204781The committee will discuss new drug application (NDA) 204781, proposed trade name DOTAREM (gadoterate meglumine injection), application submitted by Guerbet, LLC. The proposed indication (use) for this product is for… | Guerbet, LLC |
| Feb 12, 2013 | Blood Products Advisory Committee | The Committee will meet in open session to discuss Cangene's biologics license application for Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)-(Equine) seeking licensure under FDA's authority to approve a product… | — |
| Feb 12, 2013 | Risk Communication Advisory Committee | The Committee will discuss general factors in risk communication about FDA regulated products, including approaches to avoid message fatigue and related communication barriers such as prevention or warning fatigue or… | — |
| Jan 30, 2013 | Pulmonary-Allergy Drugs Advisory Committee | NDA 202049The committee will discuss the new drug application (NDA) 202049, for mannitol inhalation powder (proposed trade name BRONCHITOL), for oral inhalation sponsored by Pharmaxis, for the proposed indication of management of… | — |
| Jan 29, 2013 | Pulmonary-Allergy Drugs Advisory Committee | NDA 203108The committee will discuss new drug application (NDA) 203108, for olodaterol (proposed trade name Striverdi Respimat) metered dose inhaler, sponsored by Boehringer Ingelheim, for the proposed indication of long-term,… | — |
| Jan 24, 2013 | Drug Safety and Risk Management Advisory Committee | On January 24 and 25, 2013, the committee will discuss the public health benefits and risks, including the potential for abuse, of drugs containing hydrocodone either combined with other analgesics or as an antitussive.… | — |
| Jan 15, 2013 | Cellular, Tissue and Gene Therapies Advisory Committee | The committee will meet in open session to hear updates of research programs in the Laboratory of Immunology, Division of Therapeutic Proteins, Office of Biotechnology Products, Center for Drug Evaluation and Research,… | — |
| Jan 10, 2013 | Endocrinologic and Metabolic Drugs Advisory Committee | NDA 204042The committee will discuss new drug application (NDA) 204042, canagliflozin tablets, proposed trade name INVOCANA, submitted by Janssen Research and Development, LLC. Canagliflozin is a member of the sodium-glucose… | — |
| Dec 20, 2012 | Arthritis Advisory Committee | The committee will discuss new drug application (NDA) 22151, rintatolimod injection (proposed trade name AMPLIGEN), submitted by Hemispherx Biopharma, Inc., for the treatment of patients with chronic fatigue syndrome. | — |
| Dec 12, 2012 | Drug Safety and Risk Management Advisory Committee | The Food and Drug Administration Amendments Act of 2007 requires FDA to bring, at least annually, one or more drugs with Risk Evaluation and Mitigation Strategies (REMS) with Elements to Assure Safe Use (ETASU) before… | — |
| Dec 10, 2012 | Neurological Devices Panel | K023914, K090970The committee will discuss current knowledge about the safety and effectiveness of the CoAxia NeuroFlo Catheter device for the intended use of diverting cardiac output to the cerebral vasculature via partial occlusion… | — |
| Dec 7, 2012 | Anesthetic and Analgesic Drug Products Advisory Committee | NDA 202880The committee will discuss the risks and benefits of new drug application (NDA) 202880, by Zogenix Inc., for hydrocodone bitartrate extended-release capsules (proposed tradename ZOHYDRO ER), an opioid analgesic… | — |
| Dec 5, 2012 | Circulatory System Devices Panel | During session I, the committee will discuss and make recommendations regarding the 515(i) order issued by FDA on April 9, 2009 [Docket No. FDA-2009-M-0101], for the external counter-pulsating (ECP) devices, one of the… | — |
| Dec 4, 2012 | Blood Products Advisory Committee | The Committee will meet in open session to discuss labeling of Red Blood Cells with historical antigen typing results. On December 5, 2012, the Committee will meet in open session to discuss performance data… | — |
| Dec 4, 2012 | Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee | The subcommittee will receive a presentation on pediatric provisions mandated by the Food and Drug Administration Safety and Innovation Act. This will be an awareness presentation and there will not be a formal… | — |
| Nov 29, 2012 | Cellular, Tissue and Gene Therapies Advisory Committee | On November 29, 2012 the committee will meet in open session to hear updates of research programs in the Gene Transfer and Immunogenicity Branch, Office of Cellular, Tissue and Gene Therapies, Center for Biologics… | — |
| Nov 29, 2012 | Anti-Infective Drugs Advisory Committee | The committee will discuss new drug application (NDA) 22407, VIBATIV (telavancin hydrochloride) sterile powder for injection, submitted by Theravance, Inc., for the requested [[Page 58401]] indication of nosocomial… | — |
| Nov 28, 2012 | Anti-Infective Drugs Advisory Committee | NDA 204384The committee will discuss the safety and efficacy of new drug application (NDA) 204384, bedaquiline tablets, submitted by Janssen Therapeutics, Division of Janssen Products, LP. The proposed indication (use) for this… | Janssen Therapeutics, Division of Janssen Products, LP |
| Nov 14, 2012 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to discuss and make recommendations on the safety and immunogenicity of an Influenza A (H5N1) Virus Monovalent Vaccine manufactured by GlaxoSmithKline. On November 15, 2012, the… | — |
| Nov 9, 2012 | Nonprescription Drugs Advisory Committee | NDA 202211The committee will discuss data submitted by MSD Consumer Care, Inc. to support new drug application (NDA) 202211, for the partial switch from prescription to over-the-counter (OTC) of the oxybutynin transdermal system… | MSD Consumer Care, Inc. |
| Nov 8, 2012 | Endocrinologic and Metabolic Drugs Advisory Committee | The committee will discuss the safety and efficacy of new drug applications (NDAs) 203313, insulin degludec/insulin aspart [rDNA origin] injection and 203314, insulin degludec [rDNA origin] injection, manufactured by… | — |
| Nov 8, 2012 | Oncologic Drugs Advisory Committee | NDA 204026, NDA 21882During the morning session, the committee will discuss new drug application (NDA) 204026, with the established name pomalidomide, application submitted by Celgene Corporation. The proposed indication (use) for this… | Celgene Corporation |
| Nov 7, 2012 | Endocrinologic and Metabolic Drugs Advisory Committee | NDA 200677The committee will discuss the safety and efficacy of a new drug application (NDA) 200677, pasireotide injection (proposed trade name SIGNIFOR) for subcutaneous administration, submitted by Novartis Pharmaceuticals… | — |
| Nov 2, 2012 | Risk Communication Advisory Committee | The Committee will discuss general factors in risk communication about FDA regulated products, including approaches to avoid message fatigue and related communication barriers such as prevention or warning fatigue or… | — |
| Nov 2, 2012 | Anti-Infective Drugs Advisory Committee | BLA 125346The committee will discuss biologics license application (BLA) 125346, raxibacumab injection, a humanized monoclonal antibody against protective antigen of Bacillis anthracis, by Human Genome Sciences, Inc., for the… | — |
| Nov 1, 2012 | Neurological Devices Panel | K023914, K090970The committee will discuss current knowledge about the safety and effectiveness of the CoAxia NeuroFlo Catheter device for the intended use of diverting cardiac output to the cerebral vasculature via partial occlusion… | — |
| Oct 29, 2012 | Drug Safety and Risk Management Advisory Committee | On October 29 and 30, 2012, the committee will discuss the public health benefits and risks, including the potential for abuse, of drugs containing hydrocodone either combined with other analgesics or as an antitussive.… | — |
| Oct 24, 2012 | Radiological Devices Panel | The committee will discuss, make recommendations, and vote on a premarket approval application supplement to expand the indications for use of the Selenia Dimensions 3D System with C-View Software Module, sponsored by… | — |
| Oct 18, 2012 | Endocrinologic and Metabolic Drugs Advisory Committee | NDA 203568The committee will discuss new drug application (NDA) 203568, mipomersen injection, by Genzyme Corporation. The proposed indication (use) is as an adjunct to maximally tolerated lipid-lowering medications and diet to… | — |
| Oct 17, 2012 | Endocrinologic and Metabolic Drugs Advisory Committee | NDA 203858The committee will discuss new drug application (NDA) 203858, lomitapide capsules, by Aegerion Pharmaceuticals, Inc. The proposed indication (use) is as an adjunct to a low-fat diet and other lipid-lowering drugs with… | — |
| Oct 16, 2012 | Gastrointestinal Drugs Advisory Committee | NDA 203441The committee will discuss the safety and efficacy of new drug application (NDA) 203441, with the proposed trade name GATTEX (teduglutide) for subcutaneous injection, by NPS Pharmaceuticals, Inc, for the proposed… | — |
| Oct 15, 2012 | Gastrointestinal Drugs Advisory Committee | The committee will provide advice and recommendations to the Agency on the need for and design of clinical development programs necessary to support approval of parenteral lipid emulsion products as nutritional support. | — |
| Sep 28, 2012 | Ophthalmic Devices Panel | The committee will discuss, make recommendations and vote on information regarding the humanitarian device exemption (HDE) application for the Argus II Retinal Prosthesis System sponsored by Second Sight Medical… | — |
| Sep 21, 2012 | Orthopaedic and Rehabilitation Devices Panel | The committee will discuss and make recommendations regarding the classification of posterior cervical screws, including pedicle and lateral mass screws. Cervical pedicle and lateral mass screws are components of rigid,… | — |
| Sep 20, 2012 | Blood Products Advisory Committee | The committee will discuss hepatitis E virus and blood transfusion safety. In the afternoon, the committee will discuss Octapharma's biologics license application for Pooled Plasma (Human, Solvent/Detergent Treated). On… | — |
| Sep 19, 2012 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to discuss consideration of the appropriateness of cell lines derived from human tumors for vaccine manufacture. | — |
| Sep 14, 2012 | Cardiovascular and Renal Drugs Advisory Committee | NDA 203446The committee will discuss new drug application (NDA) 203446, imatinib mesylate, submitted by Novartis Pharmaceuticals Corp., as adjunctive therapy for the treatment of pulmonary arterial hypertension (WHO Diagnostic… | — |
| Sep 13, 2012 | Cardiovascular and Renal Drugs Advisory Committee | NDA 203009, NDA 203826During the morning session, the committee will discuss new drug application (NDA) 203009, lixivaptan, submitted by Cardiokine Biopharma, LLC, for the proposed indication of the treatment of symptomatic hypervolemic and… | Cardiokine Biopharma, LLC |
| Sep 11, 2012 | Pediatric Advisory Committee | The Pediatric Advisory Committee will meet to discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act (Public Law 107-109) and the Pediatric Research Equity Act (Public Law… | — |
| Sep 5, 2012 | Anti-Infective Drugs Advisory Committee | NDA 201688The committee will discuss new drug application (NDA) 201688, [[Page 40623]] tobramycin inhalation powder, application submitted by Novartis Pharmaceuticals Corporation, and the requested indication of management of… | — |
| Aug 28, 2012 | Gastrointestinal Drugs Advisory Committee | BLA 125057The committee will discuss the results from clinical trials of supplemental biologics license application (sBLA) 125057/232, for Humira (adalimumab), by Abbott Laboratories, for the proposed indication (use) for… | — |
| Aug 9, 2012 | Advisory Committee for Pharmaceutical Science and Clinical Pharmacology | During the morning session, the committee will discuss FDA's draft guidance on tablet scoring. This topic will include an overview of FDA's proposed plan to move forward and the United States Pharmacopoeia's perspective… | — |
| Aug 8, 2012 | Advisory Committee for Pharmaceutical Science and Clinical Pharmacology | During the first session, the committee will discuss the uses and limitations of in vitro dissolution testing and propose future direction for evaluation including possible research. During the second session, the… | — |
| Jul 26, 2012 | Dermatologic and Ophthalmic Drugs Advisory Committee | BLA 125156, BLA 125422During the morning session, the committee will discuss a supplement to biologics license application (BLA) 125156 for LUCENTIS (ranibizumab) injection by Genentech, Inc., for the treatment of diabetic macular edema… | — |
| Jul 25, 2012 | Oncologic Drugs Advisory Committee | The committee will discuss and provide general advice on the extent to which, if any, the pre-surgical identification of clear cell carcinoma of the kidney using an imaging test provides useful clinical information. | — |
| Jul 24, 2012 | Oncologic Drugs Advisory Committee | NDA 22059During the morning session, the committee will discuss supplemental new drug application (sNDA) 022059/014 with the trade name Tykerb (lapatinib) tablets, application submitted by SmithKline Beecham (Cork) Ltd, Ireland… | SmithKline Beecham (Cork) Ltd, Ireland d/b/a GlaxoSmithKline |
| Jun 29, 2012 | Risk Communication Advisory Committee | The Committee will discuss recent research on communicating and understanding uncertainty, and risk perception and information seeking when facing multiple risks. | — |
| Jun 21, 2012 | General and Plastic Surgery Devices Panel | The committee will discuss, make recommendations, and vote on information related to the premarket approval application, sponsored by Dune Medical Devices, Inc., for the MarginProbe System, that utilizes electromagnetic… | — |
| Jun 20, 2012 | Oncologic Drugs Advisory Committee | NDA 203213, NDA 202714During the morning session, the committee will discuss new drug application (NDA) 203213, with the established name semuloparin sodium injection, application submitted by sanofi-aventis U.S. LLC. The proposed indication… | sanofi-aventis U.S. LLC |
| Jun 13, 2012 | Circulatory System Devices Panel | The committee will discuss, make recommendations and vote on information related to the premarket approval application for the Edwards SAPIEN Transcatheter Heart Valve sponsored by Edwards Lifesciences. The Edwards… | — |
| Jun 12, 2012 | Blood Products Advisory Committee | The Committee will meet in open session to hear updates on the research programs of the Laboratory of Emerging Pathogens and the Laboratory of Bacterial and Transmissible Spongiform Encephalopathy Agents, Division of… | — |
| May 31, 2012 | Gastrointestinal Drugs Advisory Committee | The committee will discuss new drug application (NDA) 200- 436, synthetic human secretin, sponsored by Repligen Corporation, proposed for use with magnetic resonance imaging (MRI) to improve pancreatic duct… | — |
| May 24, 2012 | Peripheral and Central Nervous System Drugs Advisory Committee | NDA 202737The committee will discuss new drug application (NDA) 202737, for tafamidis meglumine capsules, proposed trade name VYNDAQEL, submitted by FoldRx Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc. The proposed… | FoldRx Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc |
| May 24, 2012 | Circulatory System Devices Panel | The committee will discuss current knowledge about the safety and effectiveness of the AMPLATZER ASO Device & Gore HELEX ASD Occluder as transcatheter Atrial Septal Defect (ASD) occluders used for the closure of… | — |
| May 23, 2012 | Cardiovascular and Renal Drugs Advisory Committee | NDA 202439The committee will discuss supplemental new drug application (sNDA) 202439/S-002, XARELTO (rivaroxaban), submitted by Janssen Pharmaceuticals, Inc., to reduce the risk of thrombotic cardiovascular events in patients… | — |
| May 15, 2012 | Blood Products Advisory Committee | The committee will discuss as a device panel the evaluation of the safety and effectiveness of the OraQuick In-Home HIV Test. On May 16, 2012, the committee will discuss the evaluation of possible new plasma products… | — |
| May 11, 2012 | Antiviral Drugs Advisory Committee | The committee will discuss new drug application (NDA) 203- 100, for a fixed-dose combination tablet of elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate, submitted by Gilead Sciences, Inc. The… | Gilead Sciences, Inc |
| May 10, 2012 | Endocrinologic and Metabolic Drugs Advisory Committee | The committee will discuss the safety and efficacy of new drug application (NDA) 22-529 (lorcaserin hydrochloride) tablets, manufactured by Arena Pharmaceuticals, Inc., as an adjunct to diet and exercise for weight… | — |
| May 10, 2012 | Antiviral Drugs Advisory Committee | The committee will discuss an efficacy supplement for new drug application (NDA) 21-572, TRUVADA (emtricitabine/tenofovir disoproxil fumarate) Tablet, submitted by Gilead Sciences, Inc. The supplemental application… | Gilead Sciences, Inc |
| May 9, 2012 | Arthritis Advisory Committee | NDA 203214The committee will discuss new drug application (NDA) 203214, tofacitinib tablets, Pfizer Inc., for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate… | — |
| May 8, 2012 | Arthritis Advisory Committee | The committee will discuss supplemental biologics license application 125249, ARCALYST (rilonacept) injection, Regeneron Pharmaceuticals, Inc., for the following proposed indication: ``ARCALYST (rilonacept) is an… | — |
| May 7, 2012 | Pediatric Advisory Committee | The Pediatric Advisory Committee will meet to discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act, for Differin Lotion (adapalene),… | — |
| Apr 11, 2012 | Radiological Devices Panel | The committee will discuss, make recommendations, and vote on information related to a premarket approval application for the Automated Breast Ultrasound (ABUS) scanning device, sponsored by U-Systems, Inc. The ABUS… | — |
| Apr 5, 2012 | Advisory Committee for Reproductive Health Drugs | NDA 202611The committee will discuss the benefits and risks of mirabegron (YM178), under new drug application (NDA) 202611, submitted by Astellas Pharma Global Development Inc., for the proposed indication of treatment of… | Astellas Pharma Global Development Inc. |
| Apr 3, 2012 | Anti-Infective Drugs Advisory Committee | During the morning session, the committee will discuss the development of an animal model of pneumonic plague (plague infection with extensive lung involvement) in African Green Monkeys and provide advice concerning the… | — |
| Apr 2, 2012 | Joint Meeting of the Anti-Infective Drugs Advisory Committee and the Nonprescription Drugs Advisory Committee | The committees will provide advice on types of consumer studies needed to assess proper use of a MedKit containing doxycycline to be taken in the event of anthrax exposure. Issues such as the feasibility of an… | — |
| Mar 27, 2012 | Cardiovascular and Renal Drugs Advisory Committee | The committee will begin with a closed session from 8 a.m. to 10:45 a.m. Following the closed session, from 11 a.m. to 5 p.m., the meeting will be open to the public. The committee will discuss biologics license… | — |
| Mar 23, 2012 | Neurological Devices Panel | The committee will discuss current knowledge about the safety and effectiveness of the Wingspan Stent System with Gateway PTA Balloon Catheter for the treatment of intracranial arterial stenosis. FDA is convening this… | — |
| Mar 21, 2012 | Oncologic Drugs Advisory Committee | NDA 202497The committee will discuss new drug application (NDA) 202497, MARQIBO (vincristine sulfate liposomes injection), application submitted by Talon Therapeutics, Inc. The proposed indication (use) for this product is for… | Talon Therapeutics, Inc |
| Mar 20, 2012 | Oncologic Drugs Advisory Committee | NDA 22465, NDA 22576During the morning session, the committee will discuss supplemental new drug [[Page 5521]] application (NDA) 022465/S-010, VOTRIENT (pazopanib hydrochloride) Tablets, application submitted by Glaxo Wellcome… | Glaxo Wellcome Manufacturing Pte Ltd. doing business as GlaxoSmithKline |
| Mar 14, 2012 | Advisory Committee for Pharmaceutical Science and Clinical Pharmacology | The committee will discuss the clinical pharmacology aspects of pediatric clinical trial design and dosing to optimize pediatric drug development. FDA will seek input on how to strategically inform pediatric clinical… | — |
| Mar 13, 2012 | Gastrointestinal Drugs Advisory Committee | The committee will discuss and provide general advice on the appropriate target populations, objectives and designs of trials intended to evaluate products for the control of hyperbilirubinemia (increased levels of… | — |
| Mar 12, 2012 | Arthritis Advisory Committee | The committee will discuss the anti-nerve growth factor (Anti-NGF) drug class that is currently under development and the safety issues possibly related to these drugs. These drugs are being developed for the treatment… | — |
| Mar 1, 2012 | Tobacco Products Scientific Advisory Committee | As part of the TPSAC's required report to the Secretary of Health and Human Services, the committee will complete their discussion of issues related to the nature and impact of the use of dissolvable tobacco products on… | — |
| Feb 29, 2012 | Blood Products Advisory Committee | The committee will discuss the evaluation of possible new plasma products manufactured following storage at room temperature for up to 24 hours, namely, plasma for transfusion prepared from whole blood held at room… | — |
| Feb 28, 2012 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to hear an overview of the research program in the Laboratory of Mycobacterial Diseases and Cellular Immunology, Division of Bacterial, Parasitic and Allergenic Products, Office… | — |
| Feb 27, 2012 | Dermatologic and Ophthalmic Drugs Advisory Committee | The committee will be asked to comment on the following topics related to the use of ophthalmic drug products (products intended for use in the eye): (1) Appropriate types of clinical evidence for developing… | — |
| Feb 23, 2012 | Pulmonary-Allergy Drugs Advisory Committee | The committee will discuss new drug application 202450, for aclidinium bromide, sponsored by Forest Laboratories, for the proposed [[Page 4567]] indication of long-term maintenance treatment of bronchospasm associated… | — |
| Feb 23, 2012 | Cardiovascular and Renal Drugs Advisory Committee | NDA 203202The committee will discuss new drug application (NDA) 203202, proposed trade name NORTHERA (droxidopa capsules), submitted by Chelsea Therapeutics, Inc., for the treatment of symptomatic neurogenic orthostatic… | — |
| Feb 22, 2012 | Endocrinologic and Metabolic Drugs Advisory Committee | The committee will discuss the safety and efficacy of new drug application (NDA) 22-580, proposed trade name QNEXA (phentermine/topiramate) Controlled-Release Capsules, manufactured by VIVUS, Inc., as an adjunct to diet… | — |
| Feb 10, 2012 | Cellular, Tissue, and Gene Therapies Advisory Committee | The committee will meet in open session to hear updates of the research programs in the Cellular and Tissue Branch, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, FDA. | — |
| Feb 10, 2012 | Neurological Devices Panel | The committee will discuss and make recommendations regarding the possible reclassification of cranial electrotherapy stimulator (CES) devices. On August 8, 2011 (76 FR 48062), FDA issued a proposed rule which, if made… | — |
| Feb 9, 2012 | Oncologic Drugs Advisory Committee | NDA 22481During the morning session, the committee will discuss supplemental new drug application (NDA) 21790/010 for DACOGEN (decitabine) for injection, application submitted by Eisai, Inc. The proposed indication (use) for… | Eisai, Inc |
| Feb 9, 2012 | Anesthetic and Analgesic Drug Products Advisory Committee | The committee will discuss the available efficacy and safety data for supplemental new drug application (sNDA) 22395/S-013, QUTENZA (capsaicin 8%) Patch, by NeurogesX, Inc., for the proposed indication of management of… | — |
| Feb 8, 2012 | Oncologic Drugs Advisory Committee | The committee will discuss supplemental biologics license application 125320/28 for XGEVA (denosumab) injection, application submitted by Amgen Inc. The proposed indication (use) for this product is for the treatment of… | Amgen Inc |
| Jan 30, 2012 | Pediatric Advisory Committee | The Pediatric Advisory Committee will meet to discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act for Prevnar 13 (Pneumococcal… | — |
| Jan 20, 2012 | Advisory Committee for Reproductive Health Drugs | The committee will discuss the benefits and risks of new drug application 22-139, progesterone gel 8%, Columbia Laboratories, Inc., for the proposed indication of ``reduction of risk of preterm birth in women with short… | — |
| Jan 18, 2012 | Tobacco Products Scientific Advisory Committee | As part of the Tobacco Products Scientific Advisory Committee's required report to the Secretary of Health and Human Services, the committee will continue discussing issues related to the nature and impact of the use of… | — |
| Jan 11, 2012 | Gastroenterology and Urology Devices Panel | The committee will discuss, make recommendations, and vote on information related to the premarket approval application, sponsored by Torax Medical, Inc., for the LINX Reflux Management System, a sterile, single use,… | — |
| Dec 14, 2011 | Antiviral Drugs Advisory Committee | On December 14 and 15, 2011, the committee will discuss pathways for the development of drugs intended to treat variola virus infection (smallpox) in the event of an outbreak, including the use of animal models of other… | — |
| Dec 12, 2011 | Psychopharmacologic Drugs Advisory Committee | NDA 22549The committee will discuss safety and efficacy issues with new drug application (NDA) 022549, ADASUVE (loxapine) inhalation powder, Alexza Pharmaceuticals, Inc., for the acute treatment of agitation associated with… | — |
| Dec 9, 2011 | Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee | The committees will discuss the benefits and risks of ORTHO EVRA (norelgestromin/ethinyl estradiol transdermal system), marketed by Janssen Pharmaceuticals, Inc., for the prevention of pregnancy. Specifically, the… | — |
| Dec 8, 2011 | Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee | The committees will discuss the benefits and risks of drospirenone-containing oral contraceptives in light of the emerging safety concern that the risk of venous thromboembolism (blood clots that can break loose and… | — |
| Dec 7, 2011 | Oncologic Drugs Advisory Committee | NDA 202324, NDA 202799During the morning session, the committee will discuss new drug application (NDA) 202324, with the proposed trade name Inlyta (axitinib) tablets, application submitted by Pfizer, Inc. The proposed indication (use) for… | Pfizer, Inc |
| Dec 7, 2011 | Circulatory System Devices Panel | P010031The committee will discuss, make recommendations, and vote on information related to a supplement to the premarket approval application (PMA) P010031, sponsored by Medtronic, Inc. Medtronic is requesting FDA approval to… | — |
| Dec 1, 2011 | Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Dermatologic and Ophthalmic Drugs Advisory Committee | The Food and Drug Administration Amendments Act of 2007 (Public Law 110-85) requires FDA to bring, at least annually, one or more drugs with Risk Evaluation and Mitigation Strategies (REMS) with Elements to Assure Safe… | — |
| Dec 1, 2011 | General and Plastic Surgery Devices Panel | The committee will discuss, make recommendations, and vote on information related to the premarket approval application, sponsored by Contura, Inc., for AQUAMID, a new material (polyacrylamide) for use as a dermal… | — |
| Nov 17, 2011 | Cellular, Tissue and Gene Therapies Advisory Committee | BLA 125400The committee will discuss Apligraf (Oral), Organogenesis, Inc., BLA 125400, for the treatment of surgically created gingival and alveolar mucosal surface defects in adults. | — |
| Nov 17, 2011 | Gastrointestinal Drugs Advisory Committee | The committee will provide recommendations to the Agency on the design and size of premarketing cardiovascular safety development programs necessary to support approval of products in the class of serotonin… | — |
| Nov 17, 2011 | Risk Communication Advisory Committee | The committee will discuss results of a literature review (as required in the Patient Protection and Affordable Care Act (Pub. L. 111-148) about communicating quantitative risk and benefit information in prescription… | — |
| Nov 16, 2011 | Gastrointestinal Drugs Advisory Committee | The committee will discuss the design of clinical trials to evaluate the safety, efficacy, and durability of response with repeat treatment cycles of XIFAXAN (rifaximin), by Salix Pharmaceuticals, Inc., for irritable… | — |
| Nov 16, 2011 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to hear an overview of the research program in the Laboratory of Method Development, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics… | — |
| Nov 4, 2011 | National Mammography Quality Assurance Advisory Committee | The committee will provide advice and recommendations on the following issues: (1) Proposed changes to the Mammography Quality Standard Act (MQSA) policies and inspection procedures; (2) accreditation body review of… | — |
| Nov 4, 2011 | Anti-Infective Drugs Advisory Committee | The committee will discuss clinical trial design issues in the development of antibacterials for the treatment of hospital-acquired bacterial pneumonia, including ventilator-associated bacterial pneumonia, and the draft… | — |
| Nov 3, 2011 | Anti-Infective Drugs Advisory Committee | The committee will discuss clinical trial design issues for the development of antibacterials for the treatment of community-acquired bacterial pneumonia and the draft document entitled ``Guidance for Industry:… | — |
| Nov 2, 2011 | Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee | The subcommittee will consider and discuss regulatory, academic, and industry perspectives regarding the development of anticoagulant products (products to suppress clotting of blood) in children. Issues for discussion… | — |
| Nov 2, 2011 | Tobacco Products Scientific Advisory Committee | The committee will continue the discussions of issues related to the nature and impact of the use of dissolvable tobacco products on the public health, including such use among children, as part of TPSAC's required… | — |
| Nov 2, 2011 | Endocrinologic and Metabolic Drugs Advisory Committee | The committee will discuss supplemental new drug applications 21-687 and 21-445, VYTORIN (ezetimibe/simvastatin) and ZETIA (ezetimibe) tablets, respectively, MSP (Merck/Schering-Plough) Singapore Company, LLC.… | — |
| Nov 1, 2011 | Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee | Information will be presented regarding pediatric development plans for four products that were either recently approved by FDA, are in late stage development for an adult oncology indication, or in late stage… | — |
| Oct 26, 2011 | Circulatory System Devices Panel | The committee will discuss, make recommendations, and vote on information related to the premarket approval application sponsored by AtriCure, Inc., for the AtriCure Synergy Ablation System to be used for the treatment… | — |
| Oct 25, 2011 | Allergenic Products Advisory Committee | The committee will meet in open session to hear and discuss CBER's review of scientific and medical literature concerning the use of non-standardized allergen extracts in the diagnosis and treatment of allergic disease.… | — |
| Oct 17, 2011 | Peripheral and Central Nervous System Drugs Advisory Committee | The committee will discuss supplemental new drug application (sNDA) 21641 (013) for AZILECT (rasagiline mesylate) Tablets, manufactured by Teva Neuroscience, Inc., for the following proposed indication: Treatment of… | — |
| Oct 14, 2011 | Immunology Devices Panel | The committee will discuss, make recommendations, and vote on a premarket approval application for the Progensa PCA3 assay sponsored by Gen-Probe, Inc. The Progensa PCA3 assay is indicated for use in conjunction with… | — |
| Oct 13, 2011 | Circulatory System Devices Panel | The committee will discuss, make recommendations, and vote on information related to the premarket approval application (PMA) for the Cook, Inc., ZILVER-PTX Drug-Eluting Stent. The ZILVER-PTX Stent is a self-expanding… | — |
| Sep 22, 2011 | Cellular, Tissue and Gene Therapies Advisory Committee | BLA 125397The committee will discuss BLA 125397, Umbilical Cord Blood, New York Blood Center, indicated for hematologic malignancies, bone marrow failure, primary immunodeficiency diseases, beta thalassemia, Hurler syndrome,… | — |
| Sep 22, 2011 | Pediatric Advisory Committee | On Thursday, September 22, 2011, the Pediatric Advisory Committee will meet to discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act (Pub. L. 107-109) and the Pediatric… | — |
| Sep 20, 2011 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to hear an overview of the research program in the Laboratory of Enteric and Sexually Transmitted Diseases, Division of Bacterial, Parasitic and Allergenic Products, Office of… | — |
| Sep 14, 2011 | Oncologic Drugs Advisory Committee | During the morning session, the committee will discuss new drug application 021825, with the proposed trade name Ferriprox (deferiprone) film-coated tablets, application submitted by ApoPharma, Inc., represented by Cato… | ApoPharma, Inc., represented by Cato Research Ltd. (authorized U.S. agent) |
| Sep 13, 2011 | Arthritis Advisory Committee | The committee will discuss the anti- nerve growth factor (Anti-NGF) drug class that is currently under development and the safety issues possibly related to these drugs. These drugs are being developed for the treatment… | — |
| Sep 9, 2011 | Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee | The committees will discuss the benefits and risks of long-term bisphosphonate use for the treatment and prevention of osteoporosis (thinning and weakening of bones that increases the chance of having a broken bone) in… | — |
| Sep 8, 2011 | Cardiovascular and Renal Drugs Advisory Committee | NDA 202439The committee will discuss new drug application (NDA) 202439, rivaroxaban tablets, submitted by Johnson & Johnson Pharmaceutical Research and Development, L.L.C., on behalf of Ortho-McNeil-Janssen-Pharmaceuticals, for… | — |
| Aug 19, 2011 | Science Board Advisory Committee | The Science Board will discuss the FDA's draft Strategic Plan for Regulatory Science. The Board will be provided with an update on the FDA's Medical Countermeasures Initiative program plans. The Board will also initiate… | — |
| Aug 15, 2011 | Risk Communication Advisory Committee | The Committee will discuss challenges of communicating about evolving methodology in the attribution of foodborne illness. Estimating the number of illnesses, hospitalizations, and deaths caused by major pathogens is… | — |
| Aug 2, 2011 | Blood Products Advisory Committee | The committee will discuss a study on the incidence of Trypanosoma cruzi infection in blood donors and its implications for selective testing of blood donors. On August 3, 2011, the committee will discuss measures to… | — |
| Aug 1, 2011 | Transmissible Spongiform Encephalopathies Advisory Committee | The committee will discuss donor deferral for time spent in Saudi Arabia to reduce the risk of variant Creutzfeldt-Jakob disease (vCJD) by blood and blood products and human cells, tissues and cellular and tissue-based… | — |
| Jul 27, 2011 | Advisory Committee for Pharmaceutical Science and Clinical Pharmacology | The committee will discuss current strategies for FDA's Office of Pharmaceutical Science implementation of quality by design principles within its review offices, incorporating an update on the International Conference… | — |
| Jul 26, 2011 | Advisory Committee for Pharmaceutical Science and Clinical Pharmacology | The committee will discuss presentations by the Office of Generic Drugs (OGD) on bioequivalence issues and quality standards relative to narrow therapeutic index (NTI) drug products as a class. In response to feedback… | — |
| Jul 21, 2011 | Tobacco Products Scientific Advisory Committee | The committee will discuss changes proposed by committee members to the Tobacco Products Scientific Advisory Committee (TPSAC) Menthol Report submitted to the Agency on March 18, 2011. The committee will consider… | — |
| Jul 21, 2011 | Gastrointestinal Drugs Advisory Committee | The committee will discuss the results from a clinical trial of supplement biologics license application 103772/5301, REMICADE (infliximab), by Centocor Ortho Biotech Inc., in the treatment of pediatric patients with… | — |
| Jul 20, 2011 | Joint Meeting of the Gastrointestinal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee | The meeting will be open to the public from 8 a.m. to 9 a.m., unless public participation does not last that long; from 9 a.m. to 1 p.m., the meeting will be closed to permit discussion and review of trade secret and/or… | — |
| Jul 20, 2011 | Circulatory System Devices Panel | The committee will discuss, make recommendations, and vote on information related to the premarket approval application for the Edwards SAPIEN Transcatheter Heart Valve sponsored by Edwards Lifesciences. The Edwards… | — |
| Jul 19, 2011 | Endocrinologic and Metabolic Drugs Advisory Committee | NDA 202293The committee will discuss new drug application (NDA) 202293 dapagliflozin, manufactured by Bristol-Myers Squibb and AstraZeneca. Dapagliflozin is the first drug in the class of sodium-glucose co-transporter 2 (SGLT2)… | — |
| Jul 14, 2011 | Oncologic Drugs Advisory Committee | BLA 125388, BLA 125399During the morning session, the committee will discuss biologics license application (BLA) 125388, with the proposed trade name ADCETRIS (brentuximab vedotin) for injection, submitted by Seattle Genetics, Inc. The… | Seattle Genetics, Inc |
| Jun 29, 2011 | Cellular, Tissue and Gene Therapies Advisory Committee | The committee will discuss cellular and gene therapy products for the treatment of retinal disorders. Topics to be considered include the following: (1) Efficacy endpoints in pediatric and adult populations, (2)… | — |
| Jun 23, 2011 | Pulmonary-Allergy Drugs Advisory Committee | The committee will discuss the new drug application (NDA) 22150, icatibant solution for injection (proposed trade name Firazyr), Shire Human Genetic Therapies, for the proposed indication of treatment of acute attacks… | — |
| Jun 21, 2011 | Arthritis Advisory Committee | The committee will discuss the supplemental biologics license application 125319, ILARIS (canakinumab), Novartis Pharmaceuticals Corp., for the following proposed indication: ``ILARIS is indicated for the treatment of… | — |
| Jun 17, 2011 | Dermatologic and Ophthalmic Drugs Advisory Committee | BLA 125387The committee will discuss biologics license application (BLA) 125387, aflibercept ophthalmic solution, proposed trade name EYLEA, sponsored by Regeneron Pharmaceuticals, Inc., indicated for the treatment of neovascular… | — |
| May 31, 2011 | Cellular, Tissue, and Gene Therapies Advisory Committee | The committee will meet in open session to hear brief overviews of research programs in the Laboratory of Biochemistry, Division of Therapeutic Proteins, Center for Drug Evaluation and Research; and the Laboratory of… | — |
| May 20, 2011 | Science Board Advisory Committee | The Science Board will discuss the report from the subcommittee's review of the Pharmacovigilance Program at the Center for Drug Evaluation and Research. The Science Board will be provided with updates on FDA's… | — |
| May 19, 2011 | Endocrinologic and Metabolic Drugs Advisory Committee | The committee will discuss the findings of the Action to Control Cardiovascular Risk in Diabetes-Lipid (ACCORD Lipid) trial as they relate to the efficacy and safety of the approved new drug application (NDA) 22224,… | — |
| May 17, 2011 | Joint Meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee | On May 17 and 18, 2011, the committees will review pertinent pharmacokinetic (how drugs are absorbed, distributed, used, and eliminated by the body), safety and efficacy data, and discuss whether new dosing information… | — |
| May 16, 2011 | Pediatric Advisory Committee | The Pediatric Advisory Committee will meet to discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act (Pub. L. 107-109) and the Pediatric Research Equity Act (Pub. L. 110-85)… | — |
| May 12, 2011 | Orthopaedic and Rehabilitation Devices Panel | The committee will discuss, make recommendations, and vote on information related to the premarket approval application (PMA) for the Augment Bone Graft, sponsored by Biomimetic Therapeutics, Inc. The intended use of… | — |
| May 12, 2011 | Allergenic Products Advisory Committee | In open session, the committee will receive updates and have discussion on the following topics: (1) Structure and Activities of the Laboratory of Immunobiochemistry (the Laboratory), Division of Bacterial, Parasitic,… | — |
| May 5, 2011 | Risk Communication Advisory Committee | The committee will hear and discuss developments in FDA's ongoing communications programs. The discussion will focus on the use of different channels for information dissemination, tracking how information is gathered… | — |
| May 2, 2011 | Joint Meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee | The committees will discuss safety considerations of ultrasound contrast agents (materials intended to improve the clarity of ultrasound imaging), particularly related to new information and developments since the prior… | — |
| May 2, 2011 | Molecular and Clinical Genetics Panel | Agenda not stated in the notice. | — |
| Apr 28, 2011 | Blood Products Advisory Committee | In the morning, the committee will discuss testing donations of Source Plasma for hepatitis B virus infection by nucleic acid testing. In the afternoon, the committee will discuss current considerations on use of plasma… | — |
| Apr 28, 2011 | Antiviral Drugs Advisory Committee | The committee will discuss a new drug application (NDA) 201-917, telaprevir (a hepatitis C virus protease inhibitor), manufactured by Vertex Pharmaceuticals, Inc., with a proposed indication for the treatment of chronic… | — |
| Apr 27, 2011 | General and Plastic Surgery Devices Panel | The committee will discuss, make recommendations, and vote on information related to the premarket approval application supplement for RESTYLANE, sponsored by Medicis Aesthetics, Inc. RESTYLANE is currently approved for… | — |
| Apr 27, 2011 | Antiviral Drugs Advisory Committee | The committee will discuss a new drug application (NDA) 202-258, boceprevir (a hepatitis C virus protease inhibitor), manufactured by Merck & Co., Inc., with a proposed indication for the treatment of chronic hepatitis… | — |
| Apr 12, 2011 | Oncologic Drugs Advisory Committee | NDA 22334, NDA 21938During the morning session, the committee will discuss supplemental new drug application (sNDA) 022334/ S-009, trade name AFINITOR (everolimus) tablets, application submitted by Novartis Pharmaceuticals Corp. The… | Novartis Pharmaceuticals Corp |
| Apr 6, 2011 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to hear updates of the research programs in the Laboratory of Bacterial Polysaccharides, Division of Bacterial, Parasitic, and Allergenic Products, Office of Vaccines Research and… | — |
| Apr 5, 2011 | Anti-Infective Drugs Advisory Committee | The committee will discuss new drug application (NDA) 20-1699, for FIDAXOMICIN tablets, submitted by Optimer Pharmaceuticals, Inc., for the requested indication of treatment of adults with Clostridium difficile… | — |
| Mar 17, 2011 | Neurological Devices Panel | The committee will discuss, make recommendations and vote on information related to the premarket approval application (PMA) for the NovoTTF-100A Treatment Kit, sponsored by Hogan Lovells US LLP for NovoCure, Ltd. The… | — |
| Mar 17, 2011 | Tobacco Products Scientific Advisory Committee | On March 17 and 18, 2011, the committee will continue to receive updates from the Menthol Report Subcommittee and discuss plans for finalizing the report regarding the impact of use of menthol in cigarettes on the… | — |
| Mar 10, 2011 | Peripheral and Central Nervous System Drugs Advisory Committee | The committee will discuss, in general, the use of historical-controlled trials for the approval of anticonvulsant monotherapy for seizures of partial origin for antiepileptic drug products that are already approved for… | — |
| Mar 10, 2011 | Anesthetic and Life Support Drugs Advisory Committee | The committee will: (1) Receive updates regarding neurodegenerative findings (findings related to degeneration in the nervous system) in juvenile animals exposed to anesthetic drugs, as well as results from human… | — |
| Mar 8, 2011 | Pulmonary-Allergy Drugs Advisory Committee | The committee will discuss new drug application (NDA) 022-383, indacaterol maleate (ARCAPTA NEOHALER), by Novartis Pharmaceuticals Corp., for the long-term once daily maintenance bronchodilator treatment of airflow… | — |
| Mar 2, 2011 | Advisory Committee for Pharmaceutical Science and Clinical Pharmacology | The committee will discuss innovative approaches to the development of drugs for orphan and rare diseases to support decisions such as dose and trial design selection. FDA will seek input and comment on how to optimally… | — |
| Feb 25, 2011 | Vaccines and Related Biological Products Advisory Committee | The committee will discuss and make recommendations on the selection of strains to be included in the influenza virus vaccine for the 2011-2012 influenza season. The committee will also hear an update on Pandemic… | — |
| Feb 11, 2011 | Menthol Report Subcommittee of the Tobacco Products Scientific Advisory Committee | The subcommittee will receive presentations and discuss the timelines and structure of the Tobacco Products Scientific Advisory Committee's required report to the Secretary of Health and Human Services regarding the… | — |
| Feb 10, 2011 | Tobacco Products Scientific Advisory Committee | The Committee will continue to do the following: (1) Receive updates from the Menthol Report Subcommittee and (2) receive and discuss presentations regarding the data requested by the Committee at the March 30 through… | — |
| Feb 9, 2011 | Oncologic Drugs Advisory Committee | BLA 125377The committee will discuss biologics license application (BLA) 125377, with the proposed trade name YERVOY (ipilimumab), submitted by Bristol-Myers Squibb Co. The proposed indication (use) for this product is for the… | Bristol-Myers Squibb Co |
| Feb 8, 2011 | Oncologic Drugs Advisory Committee | BLA 125084, BLA 125011, BLA 125147The committee will hear updates on new drug applications (NDAs) and biologics license applications (BLAs) approved under 21 CFR 314.500 and 601.40 (subpart H and subpart E, respectively, accelerated approval… | — |
| Jan 25, 2011 | Circulatory System Devices Panel | The committee will discuss and make recommendations regarding regulatory classification of Automated External Defibrillators to either reconfirm to class III (subject to premarket approval application (PMA)) or… | — |
| Jan 20, 2011 | Peripheral and Central Nervous System Drugs Advisory Committee | The committee will discuss new drug application (NDA) 202-008, florbetapir F 18 injection, sponsored by Avid Radiopharmaceuticals, Inc., proposed for use in positron emission tomography (PET) imaging of [beta]-amyloid… | — |
| Jan 12, 2011 | Gastrointestinal Drugs Advisory Committee | The committee will discuss the safety and efficacy of new drug application (NDA) 022-486, for Solpura (liprotamase) Capsules, by Alnara Pharmaceuticals, for the proposed indication (use) in the treatment of exocrine… | — |
| Dec 14, 2010 | Blood Products Advisory Committee | In the morning, the committee will discuss the risk of dengue virus infection in blood donors. In the afternoon, the committee will discuss murine leukemia virus-related human retroviruses and blood safety. On December… | — |
| Dec 14, 2010 | Cellular, Tissue and Gene Therapies Advisory Committee | The committee will meet in open session to hear updates of the research programs in the Tumor Vaccines and Biotechnology Branch, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and… | — |
| Dec 8, 2010 | Cardiovascular and Renal Drugs Advisory Committee | From 8 a.m. to 11:30 a.m., the committee will discuss and provide general advice on the appropriate clinical study design for thromboxane receptor antagonists for prevention of cardiovascular events (such as heart… | — |
| Dec 7, 2010 | Pediatric Advisory Committee | The Pediatric Advisory Committee will meet to discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act, for Prevista (darunavir… | — |
| Dec 7, 2010 | Endocrinologic and Metabolic Drugs Advisory Committee | The committee will discuss the safety and efficacy of new drug application (NDA) 20-0063, proposed tradename CONTRAVE (naltrexone HCl/bupropion HCl) extended-release tablets, manufactured by Orexigen Therapeutics, Inc.,… | — |
| Dec 6, 2010 | Pediatric Advisory Committee | The Pediatric Advisory Committee (PAC) will meet to discuss donor and banked human milk. FDA is convening the meeting to obtain and discuss information and data that will provide the Agency with a better understanding… | — |
| Dec 2, 2010 | Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee | NDA 201655The committees will begin with a closed session from 8 a.m. to 9:15 a.m. Following the closed session, from 9:15 a.m. to 4:30 p.m., the meeting will be open to the public. The committees will discuss new drug… | — |
| Dec 2, 2010 | Oncologic Drugs Advisory Committee | BLA 125377During the morning session, the committee will discuss biologics license application (BLA) 125377, with the proposed trade name Yervoy (ipilimumab), manufactured by Bristol-Myers Squibb Company. The proposed indication… | — |
| Dec 2, 2010 | Gastroenterology and Urology Devices Panel | The committee will discuss, make recommendations, and vote on information related to the premarket approval application (PMA) for SOLESTA, sponsored by Oceana Therapeutics, Inc. SOLESTA is indicated for the treatment of… | — |
| Dec 1, 2010 | Oncologic Drugs Advisory Committee | The committee will discuss supplemental new drug applications (sNDAs) 021-319/S-024, trade name AVODART (dutasteride) Soft Gelatin Capsules, [[Page 65363]] manufactured by SmithKline Beecham Corp. d/b/a (doing business… | — |
| Nov 30, 2010 | Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee | Information will be presented regarding pediatric development plans for four products that were either recently approved by FDA or, are in late stage development for an adult oncology indication. The subcommittee will… | — |
| Nov 19, 2010 | Cellular, Tissue and Gene Therapies Advisory Committee | The Committee will discuss current FDA recommendations for Testing of Replication Competent Retrovirus (RCR)/Lentivirus (RCL) in Retroviral and Lentiviral Vector Based Gene Therapy Products. | — |
| Nov 18, 2010 | Tobacco Products Scientific Advisory Committee | The committee will (1) Receive an update on the Menthol Report Subcommittee and (2) receive and discuss presentations regarding the data requested by the committee at the March 30 and 31, 2010, meeting of the Tobacco… | — |
| Nov 18, 2010 | General and Plastic Surgery Devices Panel | The committee will discuss, make recommendations, and vote on information related to the premarket approval application for MelaFind, sponsored by MELA Sciences. MelaFind is a computer-controlled multi-spectral… | — |
| Nov 16, 2010 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to review and discuss the pathway to licensure for protective antigen-based anthrax vaccines for a post-exposure prophylaxis indication using the animal rule. On November 17,… | — |
| Nov 16, 2010 | Arthritis Advisory Committee | The committee will discuss biologic license application 125370, belimumab, proposed trade name BENLYSTA, sponsored by Human Genome Sciences, for the proposed indication of reducing disease activity in adult patients… | — |
| Nov 15, 2010 | Science Board Advisory Committee | The Science Board will receive information from the ongoing review of the Pharmacovigilance Program at the Center for Drug Evaluation and Research (CDER). The Center for Food Safety and Applied Nutrition (CFSAN) will… | — |
| Nov 8, 2010 | Risk Communication Advisory Committee | On November 8 and 9, 2010, the Committee will hear and discuss developments in FDA's ongoing communications programs, such as FDA's Strategic Plan for Risk Communication, FDA's Transparency Initiative, and the… | — |
| Nov 5, 2010 | Gastrointestinal Drugs Advisory Committee | The committee will discuss the results from clinical trials of proton pump inhibitors in gastroespohageal reflux disease (GERD) in patients less than 1 year of age, performed in response to a Pediatric Written Request… | — |
| Nov 4, 2010 | Gastrointestinal Drugs Advisory Committee | The committee will discuss the adequacy of endoscopically documented gastric ulcers as an outcome measure to evaluate drugs intended to prevent gastrointestinal complications of nonsteroidal anti-inflammatory drugs… | — |
| Nov 3, 2010 | Joint Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee | The committees will discuss a number of safety concerns with intravenous administration of the anti-seizure drugs phenytoin and fosphenytoin, including the condition known as Purple Glove Syndrome, and recommend what… | — |
| Oct 28, 2010 | Transmissible Spongiform Encephalopathies Advisory Committee | The Committee will discuss: (1) FDA's risk assessment for potential exposure to the variant Creutzfeldt-Jakob disease (vCJD) agent in U.S.-licensed plasma-derived Factor VIII and (2) labeling of blood and blood… | — |
| Oct 21, 2010 | Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee | The committee will discuss considerations for the design of postmarketing studies for new drug applications (NDAs) 22-272, OxyContin (oxycodone hydrochloride controlled-release) Tablets, manufactured by Purdue Pharma,… | — |
| Oct 18, 2010 | Cardiovascular and Renal Drugs Advisory Committee | The committee will consider the results and analyses of the TREAT (Trial to Reduce Cardiovascular Events with Aranesp Therapy) study of ARANESP (darbepoetin alfa), manufactured by Amgen, Inc. This meeting is a follow-up… | — |
| Oct 8, 2010 | Neurological Devices Panel | The committee will discuss and make recommendations regarding clinical trial design issues for devices indicated for the treatment of depression. | — |
| Oct 7, 2010 | Tobacco Products Scientific Advisory Committee | On October 7 and 8, 2010, the committee will hear and discuss presentations on the publicly available industry documents as they relate to the issue of the impact of the use of menthol in cigarettes on the public… | — |
| Sep 27, 2010 | Menthol Report Subcommittee of the Tobacco Products Scientific Advisory Committee | The subcommittee will receive a presentation and discuss the timelines and structure of the Tobacco Products Scientific Advisory Committee's required report to the Secretary of Health and Human Services regarding the… | — |
| Sep 24, 2010 | Radiological Devices Panel | The committee will discuss, make recommendations, and vote on a premarket approval application for the Selenia C Digital Breast Tomosynthesis System, sponsored by Hologic, Inc. The Selenia C Digital Breast Tomosynthesis… | — |
| Sep 21, 2010 | Vaccines and Related Biological Products Advisory Committee | The committee will meet in open session to hear updates of the research programs in the Laboratory of Respiratory & Special Pathogens, Division of Bacterial, Parasitic, & Allergenic Products; Laboratory of Hepatitis… | — |
| Sep 20, 2010 | Cardiovascular and Renal Drugs Advisory Committee | The committee will discuss new drug application (NDA) 22- 512, dabigatran etexilate mesylate capsules, sponsored by Boehringer Ingelheim Pharmaceuticals, Inc., for the proposed indication of prevention of stroke in… | — |
| Sep 19, 2010 | Veterinary Medicine Advisory Committee | The committee will receive an orientation on both general scientific issues surrounding genetically engineered animals and the statutory and regulatory constraints under which the Agency must operate. On September 20,… | — |
| Sep 16, 2010 | Psychopharmacologic Drugs Advisory Committee | The committee will discuss the available safety and efficacy data for supplemental new drug application (sNDA) 21-897/015, VIVITROL (naltrexone for extended-release injectable suspension), sponsored by Alkermes, Inc.,… | — |
| Sep 15, 2010 | Endocrinologic and Metabolic Drugs Advisory Committee | The committee will discuss the results of the Sibutramine Cardiovascular Outcomes Trial (SCOUT) (M01- 392), for new drug application (NDA) 20-632, MERIDIA (sibutramine hydrochloride monohydrate) Capsules, sponsored by… | — |
| Sep 14, 2010 | Drug Safety and Risk Management Advisory Committee | The committee will discuss the abuse potential of the drug dextromethorphan and the public health benefits and risks of dextromethorphan use as a cough suppressant in prescription and nonprescription drug products. The… | — |
| Sep 7, 2010 | Anti-Infective Drugs Advisory Committee | The committee will discuss new drug application (NDA) 20-0327, for ceftaroline fosamil for injection, submitted by Cerexa, Inc., and the requested indications of: (1) Treatment of adults with community acquired… | — |
| Aug 30, 2010 | Tobacco Products Scientific Advisory Committee | The committee will receive a report from the Tobacco Product Constituents Subcommittee and discuss a proposed initial list of harmful or potentially harmful constituents, the rationale for inclusion of each constituent,… | — |
| Aug 26, 2010 | General and Plastic Surgery Devices Panel | The committee will discuss, make recommendations, and vote on premarket approval application for MelaFind, sponsored by MELA Sciences, Inc. MelaFind is a non-invasive computer vision system intended to assist in the… | — |
| Aug 20, 2010 | Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee | The committees will discuss new drug application (NDA) 22-531, sodium oxybate, 375 milligrams per milliliter (mg/ml) oral solution, sponsored by Jazz Pharmaceuticals, with a proposed indication for the treatment of… | — |
| Aug 19, 2010 | Anesthetic and Life Support Drugs Advisory Committee | The committee will discuss the available safety and efficacy data for new drug application (NDA) 22- 516, CYMBALTA (duloxetine HCL) Capsules, by Eli Lilly [[Page 39033]] and Co., as it relates to the proposed indication… | — |
| Aug 16, 2010 | Science Board Advisory Committee | The Science Board will hear about and discuss a final report from its subcommittee reviewing research at the Center for Food Safety and Applied Nutrition (CFSAN). The Science Board will hear about an interim report from… | — |
| Aug 11, 2010 | Peripheral and Central Nervous System Drugs Advisory Committee | The committee will discuss new drug application (NDA) 22-345, with the proposed trade name POTIGA (ezogabine) Tablets, by Valeant Pharmaceuticals North America. The proposed indication for this new drug product is… | — |
| Jul 30, 2010 | Ophthalmic Devices Panel | The committee will discuss, make recommendations, and vote on a premarket approval application for the Glaukos iStent Trabecular Micro-Bypass Stent, Model GTS-100 L/R, sponsored by Glaukos Corp. The device is indicated… | — |
| Jul 29, 2010 | Cardiovascular and Renal Drugs Advisory Committee | The committee will discuss Revatio (sildenafil) for the treatment of pediatric pulmonary arterial hypertension (PAH) and whether to amend the clinical trials section of the written request, issued by FDA to Pfizer, to… | — |
| Jul 28, 2010 | Cardiovascular and Renal Drugs Advisory Committee | The committee will discuss new drug application (NDA) 22-433, ticagrelor tablets, 90 milligrams, manufactured by AstraZeneca LP, for the proposed indication for use in acute coronary syndrome (including heart attacks… | — |
| Jul 27, 2010 | Orthopaedic and Rehabilitation Devices Panel | The committee will discuss, make recommendations and vote on a premarket approval application for the AMPLIFY rhBMP-2 Matrix, sponsored by Medtronic, Inc. The AMPLIFY rhBMP- 2 Matrix is used for posterolateral fusion… | — |
| Jul 26, 2010 | Blood Products Advisory Committee | In the morning session, the committee will hear updates on the following topics: June 10 and 11, 2010, meeting of the Department of Health and Human Services Advisory Committee on Blood Safety and Availability; December… | — |
| Jul 20, 2010 | Oncologic Drugs Advisory Committee | The committee will discuss supplemental biologics license applications (sBLAs) 125085/191 and 192 for AVASTIN (bevacizumab), manufactured by Genentech, Inc. The two proposed indications (uses) for this product are: (1)… | — |
| Jul 15, 2010 | Endocrinologic and Metabolic Drugs Advisory Committee | The committee will discuss the safety and efficacy of new drug application (NDA) 22-580, proposed tradename QNEXA (phentermine/topiramate) Controlled Release Capsules, by VIVUS, Inc., as an adjunct to diet and exercise… | — |
| Jul 15, 2010 | Tobacco Products Scientific Advisory Committee | The committee will (1) hear and discuss a presentation on dissolvable tobacco products in order to prepare for the Tobacco Products Scientific Advisory Committee's required report to the Secretary of Health and Human… | — |
| Jul 13, 2010 | Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee | On both days, the committees will focus primarily on the cardiovascular safety of AVANDIA (rosiglitazone maleate) Tablets, GlaxoSmithKline, a drug approved for blood glucose control in adults with type 2 diabetes… | — |
| Jul 7, 2010 | Tobacco Product Constituents Subcommittee of the Tobacco Products Scientific Advisory Committee | On July 7 and 8, 2010, the subcommittee will continue discussions, as needed, from the June 8 and 9, 2010, meeting of this subcommittee. The subcommittee will then receive presentations and discuss the analytic methods… | — |
| Jun 28, 2010 | Dermatologic and Ophthalmic Drugs Advisory Committee | The committee will discuss new drug application (NDA) 22-340, voclosporin 10-milligram capsules, by Lux Biosciences, Inc. The proposed indication for this new drug product is treatment of noninfectious uveitis involving… | — |
| Jun 21, 2010 | Pediatric Advisory Committee | On Monday, June 21, the Pediatric Advisory Committee will meet to discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act, for Kogenate FS… | — |
| Jun 18, 2010 | Advisory Committee for Reproductive Health Drugs | The committee will discuss new drug application (NDA) 22-526, flibanserin [[Page 22147]] 100 milligram (mg) tablets, by Boehringer Ingelheim Pharmaceuticals, Inc., for the proposed indication of the treatment of… | — |
| Jun 17, 2010 | Advisory Committee for Reproductive Health Drugs | The committee will discuss new drug application (NDA) 22-474, ulipristal acetate tablets, 30 milligrams (mg), by Laboratoire HRA Pharma. Ulipristal is an emergency contraceptive for the proposed indication of the… | — |
| Jun 10, 2010 | Peripheral and Central Nervous System Drugs Advisory Committee | The committee will discuss new drug application (NDA) 22-527, with the [[Page 17418]] proposed trade name GILENIA (fingolimod hydrochloride) 0.5 milligram (mg) capsules, by Novartis Pharmaceuticals Corp. The proposed… | — |
| Jun 8, 2010 | Tobacco Product Constituents Subcommittee of the Tobacco Products Scientific Advisory Committee | On June 8 and 9, 2010, the subcommittee will receive presentations and discuss the development of a list of harmful or potentially harmful constituents, including smoke constituents, in tobacco products. Topics for… | — |
| Jun 2, 2010 | Antiviral Drugs Advisory Committee | BLA 125283The committee will discuss biologics license application (BLA) 125283, motavizumab, MedImmune, LLC, proposing an indication for the prevention of serious lower respiratory tract disease caused by respiratory syncytial… | — |
| May 27, 2010 | Endocrinologic and Metabolic Drugs Advisory Committee | The committee will discuss the safety and efficacy of new drug application (NDA) 22-505, EGRIFTA (tesamorelin acetate), sterile lyophilized powder for injection, by Theratechnologies, Inc. EGRIFTA is an analogue (a… | — |
| May 12, 2010 | Joint Meeting of the Arthritis Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee | The committees will discuss new drug application (NDA) 22-478, naproxcinod0 375 milligram capsule, sponsored by NicOx S.A., a non-steroidal anti-inflammatory drug (NSAID) product indicated for the treatment of the signs… | — |
| May 7, 2010 | Vaccines and Related Biological Products Advisory Committee | In the morning, the committee will review and discuss available data regarding the unexpected finding of DNA originating from porcine circovirus type 1 (PCV 1) in Rotarix, a U.S. licensed vaccine manufactured by… | — |
| May 6, 2010 | Risk Communication Advisory Committee | On May 6 and 7, 2010, the Committee will review the state of current research in a range of fields relevant to improving risk communication at FDA, and discuss applications or gaps for strategic planning of risk… | — |
| May 6, 2010 | Peripheral and Central Nervous System Drugs Advisory Committee | The committee will discuss supplemental new drug application (sNDA) 22-432, H.P. ACTHAR Gel (repository corticotropin injection), 80 USP units per milliliter, Questcor Pharmaceuticals, proposed for the treatment of… | — |
| Apr 29, 2010 | Anti-Infective Drugs Advisory Committee | The committee will discuss the efficacy and safety of new drug application (NDA) 21-242, artesunate rectal suppositories, submitted by the World Health Organization, for the proposed use as a single dose for the initial… | — |
| Apr 22, 2010 | Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee | The committees will discuss new drug application (NDA) 22-451 ACUROX (oxycodone HCl and niacin) Tablets, Acura Pharmaceuticals, Inc., for the proposed indication of relief of moderate to severe pain where the use of an… | — |
| Apr 14, 2010 | Advisory Committee for Pharmaceutical Science and Clinical Pharmacology | The committee will: (1) Receive presentations from the Office of Generic Drugs (OGD) on a proposal for revision of the bioequivalence (BE) approaches, specifically to discuss the addition of a limitation on point… | — |
| Apr 13, 2010 | Advisory Committee for Pharmaceutical Science and Clinical Pharmacology | The committee will receive presentations from the Office of Generic Drugs and discuss two bioequivalence topics relevant to generic drug approval: (1) Revising the BE approaches for critical dose drugs and (2) the use… | — |
| Apr 12, 2010 | Blood Products Advisory Committee | The committee will meet in open session to hear updates on the research programs of the Laboratory of Cellular Hematology and the Laboratory of Biochemistry and Vascular Biology, Division of Hematology, Office of Blood… | — |
| Apr 7, 2010 | Pulmonary-Allergy Drugs Advisory Committee | The committee will discuss new drug application (NDA) 22-522, roflumilast (DAXAS), Forest Research Institute, for the maintenance treatment of chronic obstructive pulmonary disease associated with chronic bronchitis in… | — |
| Mar 30, 2010 | Tobacco Products Scientific Advisory Committee | The Tobacco Products Scientific Advisory Committee will cover the following two topics: (Topic 1) Receive presentations on the background and overview of the FDA Center for Tobacco Products, the Family Smoking… | — |
| Mar 24, 2010 | Veterinary Medicine Advisory Committee | The committee will discuss and make recommendations regarding modifications, if any, to the current risk minimization and restricted distribution program for Pfizer's PROHEART 6 (NADA 141-189), the subsequent safety… | — |
| Mar 23, 2010 | Orthopaedic and Rehabilitation Devices Panel | K082079The committee will discuss and make recommendations on issues relevant to FDA's reevaluation of the ReGen Collagen Scaffold (CS) device (marketed as the Menaflex[reg]), which FDA cleared in K082079 on December 18, 2008,… | — |
| Mar 22, 2010 | Oncologic Drugs Advisory Committee | During the morning session of March 22, 2010, the committee will discuss new drug application (NDA) 022-481, proposed trade name PIXUVRI (pixantrone dimaleate) injection, by Cell Therapeutics, Inc. The proposed… | — |
| Mar 22, 2010 | Pediatric Advisory Committee | The Pediatric Advisory Committee will meet to discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act, for: Anthelios 40, Cardiolite… | — |
| Mar 18, 2010 | Circulatory System Devices Panel | The committee will discuss, make recommendations, and vote on the premarket approval application (PMA) for the Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) sponsored by Boston Scientific. The sponsor is… | — |
| Mar 17, 2010 | Advisory Committee for Pharmaceutical Science and Clinical Pharmacology | The committee will discuss and provide comments on the following topics: (1) General scientific issues related to the application of pharmacogenomics in the early stages of drug development. Pharmacogenomics examines… | — |
| Mar 12, 2010 | The Neurological Devices Panel | The committee will discuss, make recommendations, and vote on a premarket approval application for the Deep Brain Stimulation System for Epilepsy sponsored by Medtronic, Inc. This device is indicated as adjunctive… | — |
| Mar 9, 2010 | Pulmonary-Allergy Drugs Advisory Committee | The committee will discuss new drug application (NDA) 22-535, pirfenidone, by InterMune. The proposed indication (purpose) of this drug is the treatment of patients with idiopathic pulmonary fibrosis (scarring of the… | — |
| Mar 5, 2010 | The General Hospital and Personal Use Devices Panel | The committee will discuss and make recommendations regarding clinical risks and benefits of post-market actions in response to insulin pump failures. Insulin pumps are intended for continuous delivery of insulin at set… | — |
| Mar 1, 2010 | Cardiovascular and Renal Drugs Advisory Committee | BLA 125288The committee will discuss biologics license application (BLA) 125288, for belatacept injectable, by Bristol Myers Squibb, to be used in patients with kidney transplants to prevent rejection of the transplanted kidney. | — |
| Feb 25, 2010 | Risk Communication Advisory Committee | On February 25 and 26, 2010, the committee will discuss strategies and lessons from a selection of the FDA's previously issued communications, emphasizing communications challenges. Examples, selected for illustrative… | — |
| Feb 24, 2010 | Endocrinologic and Metabolic Drugs Advisory Committee | The committee will discuss the safety and efficacy of new drug application (NDA) 22-505, for EGRIFTA (tesamorelin acetate) sterile lyophilized powder for injection, by Theratechnologies, Inc. EGRIFTA is an analogue (a… | — |
| Feb 22, 2010 | Vaccines and Related Biological Products Advisory Committee | The committee will discuss and make recommendations on the selection of strains to be included in the influenza virus vaccine for the 2010 - 2011 influenza season. | — |
| Sep 17, 2024 | Digital Health Advisory Committee | On November 20 and 21, 2024, the Committee will discuss how the use of Generative AI may impact safety and effectiveness of medical devices enabled with this technology. The Committee will discuss premarket performance… | — |
| Apr 19, 2023 | Vaccines and Related Biological Products Advisory Committee | Agenda not stated in the notice. | — |
| Jan 18, 2023 | Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Dermatologic and Ophthalmic Drugs Advisory Committee | The committees will discuss proposed changes to the iPLEDGE Risk Evaluation and Mitigation Strategy requirements to minimize burden on patients, pharmacies, and prescribers while maintaining safe use of isotretinoin… | — |
| Oct 1, 2019 | Immunology Devices Panel | On November 13 and 14, 2019, the committee will discuss the topic of immunological responses to metal-containing products regulated as medical devices. The discussion will focus on metal-containing implants as well as… | — |
| Sep 4, 2019 | General Hospital and Personal Use Panel | On November 6 and 7, 2019, the committee will discuss the topic of industrial ethylene oxide (EtO) sterilization of medical devices and its role in maintaining public health as [[Page 46548]] well as the risks of… | — |
| Jul 11, 2019 | Allergenic Products Advisory Committee | Agenda not stated in the notice. | — |
| Feb 15, 2019 | General and Plastic Surgery Devices Panel | On March 25 and 26, 2019, the committee will discuss and make recommendations regarding the benefits and risks of breast implants indicated for breast augmentation and reconstruction concerning the following topics: (1)… | — |
| Sep 18, 2018 | Endocrinologic and Metabolic Drugs Advisory Committee | On both days, the committee will discuss the ``Guidance for Industry: Diabetes Mellitus--Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes'' (<a… | — |
| Sep 17, 2018 | Anesthetic and Analgesic Drug Products Advisory Committee | Agenda not stated in the notice. | — |
| Mar 29, 2018 | Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee | The committees will be asked to discuss supplemental new drug application (sNDA) 20998, for CELEBREX (celecoxib) capsules submitted by Pfizer, Inc., which includes the results from the PRECISION (Prospective Randomized… | Pfizer, Inc. |
| Mar 9, 2018 | Peripheral and Central Nervous System Drugs Advisory Committee | Agenda not stated in the notice. | — |
| Dec 28, 2016 | Pharmaceutical Science and Clinical Pharmacology Advisory Committee | Agenda not stated in the notice. | — |
| Aug 9, 2016 | General and Plastic Surgery Devices Panel | On September 20 and 21, 2016, the Committee will discuss and make recommendations regarding the classification of certain wound care products containing antimicrobials and other drugs as part of the routine process for… | — |
| Apr 15, 2016 | Circulatory System Devices Panel | On June 2 and 3, 2016, the committee will discuss recent reports and epidemiologic investigations of nontuberculous mycobacteria (NTM) infections associated with the use of heater-cooler devices during cardiac surgical… | — |
| Jan 22, 2016 | Arthritis Advisory Committee | Agenda not stated in the notice. | — |
| Nov 9, 2015 | Food Advisory Committee | The Food Advisory Committee will meet to discuss FDA's policies related to the presence of Listeria monocytogenes in foods. | — |
| Aug 20, 2015 | Pediatric Advisory Committee | Agenda not stated in the notice. | — |
| Mar 13, 2015 | Gastroenterology and Urology Devices Panel | On May 14 and 15, 2015, the committee will discuss recent reports and epidemiologic investigations of transmission of infections associated with the use of duodenoscopes in endoscopic retrograde cholangiopancreatography… | — |
| Feb 24, 2015 | Anesthetic and Analgesic Drug Products Advisory Committee | Agenda not stated in the notice. | — |
| Aug 28, 2014 | Risk Communications Advisory Committee | On November 3 and 4, 2014, the Risk Communication Advisory Committee will discuss methods for effective risk communication with a focus on messages about the importance of eating adequate amounts of fish, while avoiding… | — |
| Aug 19, 2014 | Food Advisory Committee | The committee will discuss science issues surrounding susceptible life stages or populations and the circumstances under which FDA might decide to conduct a separate risk assessment for these populations. Also, FDA is… | — |
| Jul 17, 2014 | Food Advisory Committee | The Food Advisory Committee will discuss risk ranking and risk prioritization approaches for specific regulatory purposes. The Committee will provide input to FDA in the development of the characteristics for data… | — |
| Mar 3, 2014 | Risk Communications Advisory Committee | On May 5 and 6, 2014, the committee will meet to discuss methods for identifying the impact and increasing the reach of communications on topics of interest to consumers. The discussion will also address how FDA can… | — |
| Jan 8, 2014 | Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee | The committees will discuss data and analyses published in 2006 or later that are relevant to further understanding the relationship between nonsteroidal anti-inflammatory drugs (NSAIDs) and cardiovascular thrombotic… | — |
| Jan 3, 2014 | Risk Communications Advisory Committee | On February 3 and 4, 2014, the committee will meet to discuss methods for identifying the impact and increasing the reach of communications on topics of interest to consumers. The discussion will also address how FDA… | — |
| Jul 23, 2013 | Food Advisory Committee | On September 23 and 24, 2013, the Food Advisory Committee will meet to discuss detection signals for noteworthy chemical hazards in foods, dietary supplements, and cosmetics and consider possible sources of information,… | — |
| Apr 15, 2013 | Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee | On June 5 and 6, 2013, the committees will discuss the results of an independent readjudication of the Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycemia in Diabetes (RECORD) trial, for new… | — |
| Dec 13, 2012 | Neurological Devices Panel | Agenda not stated in the notice. | — |
| Mar 28, 2012 | Gastroenterology and Urology Devices Panel | On May 10 and 11, 2012, the committee will discuss general issues related to medical devices intended for obese patients. The committee will provide recommendations regarding trial design for clinical studies to… | — |
| Mar 19, 2012 | Circulatory System Devices Panel | Agenda not stated in the notice. | — |
| Feb 8, 2012 | Endocrinologic and Metabolic Drugs Advisory Committee | On both days, the committee will discuss the role of cardiovascular assessment in the preapproval and postapproval settings for drugs and biologics developed for the treatment of obesity. | — |
| Jul 14, 2011 | Obstetrics and Gynecology Devices Panel | On September 8 and 9, 2011, the committee will discuss and make recommendations regarding the safety and effectiveness of transvaginal surgical mesh used for repair of pelvic organ prolapse. FDA is convening this… | — |
| Jul 7, 2011 | General and Plastic Surgery Devices Panel | On August 30 and 31, 2011, the committee will discuss and make recommendations on postmarketing issues related to silicone gel- filled breast implants. This meeting is regarding the discussion of different innovative… | — |
| Feb 7, 2011 | Molecular and Clinical Genetics Panel | On March 8 and 9, 2011, the committee will discuss and make recommendations on scientific issues concerning direct to consumer (DTC) genetic tests that make medical claims. The scientific issues to be discussed include:… | — |
| Jan 26, 2011 | Tobacco Products Scientific Advisory Committee | On March 1 and 2, 2011, the Committee will continue to (1) receive updates from the Menthol Report Subcommittee and (2) receive and discuss presentations regarding the data requested by the Committee at the March 30 and… | — |
| Dec 10, 2010 | Tobacco Products Scientific Advisory Committee | On January 10 and 11, 2011, the Committee will continue to (1) receive updates from the Menthol Report Subcommittee and (2) receive and discuss presentations regarding the data requested by the Committee at the March 30… | — |
| Dec 1, 2010 | Food Advisory Committee | The Food Advisory Committee will meet to discuss whether available relevant data demonstrate a link between children's consumption of synthetic color additives in food and adverse effects on behavior. | — |
| Nov 26, 2010 | Neurological Devices Panel | On January 27 and 28, 2011, the committee will discuss and make recommendations regarding the possible reclassification of devices indicated for use in electroconvulsive therapy. | — |
| Jun 11, 2010 | Dental Products Panel | On December 14 and 15, 2010, the committee will discuss and make recommendations on scientific issues raised in petitions received by FDA concerning the final rule on the classification of dental amalgam, which… | — |
| Jun 7, 2010 | Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee | The committees will discuss Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics. As a part of the materials for the meeting, FDA anticipates presenting a proposal for… | — |
| Feb 2, 2010 | Pulmonary-Allergy Drugs Advisory Committee | On March 10 and 11, 2010, the committee will discuss the design of medical research studies (known as ``clinical trial design'') to evaluate serious asthma outcomes (such as hospitalizations, a procedure using a… | — |
FDA must notice each advisory committee meeting in the Federal Register. Applications, devices and sponsors are read from each notice's agenda paragraph; general-topic meetings name none. Votes are not in the notice. Refreshed weekly, last Nov 16, 2026. Federal Register